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Abstract 
 
Clostridium difficile is the main cause of antibiotic-associated diarrhea, leading 
to significant morbidity and mortality, and putting considerable economic 
pressure on healthcare systems. Current knowledge of the molecular basis of 
pathogenesis is limited primarily to the activities and regulation of two major 
toxins. In contrast, little is known of the mechanisms used to colonise the 
enteric system. C. difficile expresses a proteinaceous array on its cell surface 
known as the S-layer, consisting primarily of SlpA and a family of 
homologues, the cell wall protein (CWP) family. CwpV is the largest member 
of this family. CwpV is expressed in a phase-variable manner controlled by an 
invertible DNA switch, the cwpV switch. The novel mechanism controlling this 
phase variation has been charaterised using enzymatic reporter assays. A 
site-specific recombinase (RecV) catalyzing the inversion of the cwpV switch 
has been identified. Knocking out this recombinase has enabled isolation of 
cwpV switch locked ON and locked OFF strains of C. difficile, indicating that 
cwpV switch orientation is the primary determinant of CwpV expression. 
CwpV is post-translationally cleaved and expressed on the cell surface as two 
proteins that form a stable complex, with one subunit responsible for the non-
covalent cell wall anchoring of the other large repetitive subunit. Due to the 
significant heterogeneity of C. difficile strains the characteristics of CwpV 
across a panel of strains were investigated. The cwpV switch and recV are 
conserved across diverse strains and all strains tested express CwpV in a 
phase variable manner. The N-terminus of CwpV is well conserved, however 
the C-terminal repetitive domain of CwpV varies markedly. Five different types 
have been identified and shown to be antigenically distinct. All types of CwpV 
repeats promote aggregation of C. difficile cells, which may be an important 
function during infection. These findings suggest a complex evolutionary 
history for CwpV. 
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1 Introduction 
1.1 History of C. difficile infection 
The spore-forming rod-shaped bacterium that we now know as C. difficile was 
first described in 1935. It was isolated from the stool of infants and was 
named Bacillus difficilis due to the difficulties that had to be overcome to 
culture the organism (Hall & O'Toole, 1935). It was shown that this bacterium 
could produce a potent toxin (Snyder, 1937), however no consistent link with 
pathogenic infection could be found. Therefore for a number of years this 
organism was not intensively studied, but it was shown to be a member of the 
Clostridial species, renamed Clostridium difficile and some small studies were 
carried out (Smith & King, 1962, Hafiz & Oakley, 1976).  
 
Pseudomembraneous lesions in the colon, known as pseudomembranous 
colitis (PMC) were first reported in 1893 and there are a number of other 
reports of PMC in the pre-antibiotic era. PMC refers to visible changes on the 
inner surface of the lining of the colon. Characteristically, the colon has 
patches of inflammatory membrane that consist of red and white blood cells, 
fibrin and bacteria. Images of PMC visualized by endoscopy are shown in 
Figure 1.1. Once the use of antibiotics became commonplace so did the 
reports of PMC. Staphylococcus aureus was isolated from stool samples and 
became the accepted pathogen thought to be responsible for PMC on the 
basis of animal studies, consistent isolation from patients with PMC and 
already being recognized as an important nosocomial pathogen. Oral 
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vancomycin became the standard treatment for PMC and clinicians had 
substantial success with it (Bartlett, 2009a).  
 
Figure 1.1 Endoscopic visualization of pseudomembranous colitis.  
A. Image of a healthy colon. B. Image from a CDAD patient. Classic 
pseudomembranes are visible as raised yellow plaques, which range from 2-
10 mm in diameter and are scattered over the colorectal mucosa. Adapted 
from (Yassin, 2009). 
 
It was not until the early 1970s that this disease state came under closer 
scrutiny. Clindamycin introduction as a treatment for anaerobic bacterial 
infections was accompanied by a significant number of patients with severe 
diarrhoea. On behalf of the company responsible for the production of 
clindamycin an in depth study into this unfortunate side effect was carried out. 
21% of patients receiving clindamycin developed diarrhoea and when 
examined by endoscopy half of these patients had PMC. The fact that 10% of 
patients receiving clindamycin developed PMC meant that the FDA required 
this serious side effect of clindamycin to be reported to all physicians using 
the drug and PMC became known as clindamycin colitis. Importantly in this 
study S. aureus could not be isolated from stool samples, indicating that PMC 
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is not caused by this pathogen (Tedesco et al., 1974). Therefore the hunt for 
the pathogen responsible began.  
 
It was known that antibiotic use in rodents often caused a lethal complication 
characterised by diarrhoea known as wet tail followed by death a few days 
after challenge with necropsy showing a large, dilated hemorrhagic cecitis. 
This process was therefore studied as a model for clindamycin colitis in 
humans. One of the first clues that these symptoms were caused by a gram 
positive bacterial pathogen was that challenge with clindamycin followed by 
oral vancomycin provided protection (Bartlett et al., 1977a). Then it was 
shown that the symptoms were caused by a toxin, which could be transferred 
from an infected hamster to a healthy hamster causing the expected 
symptoms. This toxin could be neutralized by Clostridium sordellii antitoxin, 
implicating a member on the Clostridium family as the pathogen at work. 
Subsequent screening of Clostridial species present in these animals led to 
the identification of C. difficile as the causative agent of antibiotic-associated 
disease in hamsters (Bartlett et al., 1977b).  Following this work in the 
hamster it could be shown the PMC in humans was also caused by C. difficile 
(Bartlett et al., 1978).  
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1.2 Current understanding of C. difficile infection 
1.2.1 Nosocomial infection 
C. difficile is the main cause of infectious diarrhoea that develops in patients 
after hospitalization and antibiotic treatment. The association with antibiotic 
usage is due the interruption of the normal intestinal flora by the broad-
spectrum activity of the antibiotic. Antibiotic associated diarrhoea occurs in 5-
35% of patients who take broad-spectrum antibiotics (Wistrom et al., 2001). It 
is unclear why C. difficile is particularly effective at colonising this niche 
compared to other organisms, but what is clear is that C. difficile is the most 
common pathogen responsible and it is estimated that 20-30% of cases of 
antibiotic-associated diarrhoea are caused by C. difficile (McFarland, 2008). In 
England in 2008 there were 36,095 reported cases of C. difficile infection 
(NHS, 2010). 
 
C. difficile infection has been linked to use of almost every known antibiotic, 
with fluoroquinolones indicated as particularly predisposing (Delaney, 2007). 
The particularly high association between antibiotic usage and CDAD when 
patients are in hospital is probably due to contamination of the hospital 
environment with infectious spores. Contamination of the hands of hospital 
personnel and the ability of spores to persist for up to 20 weeks in the 
environment after seeding was first shown in 1981 (Fekety et al., 1981, Kim et 
al., 1981) and since then many studies have indicated high levels of 
contamination of the hospital environment with infectious C. difficile spores 
(Weber et al., 2010).  
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The clinical outcomes of C. difficile infection (CDI) range from asymptomatic 
colonisation to mild diarrhoea and more severe disease syndromes, including 
abdominal pain, fever and leukocytosis. Fulminant or severe complicated CDI 
is characterised by inflammatory lesions and the formation of 
pseudomembranes in the colon (PMC). In the most severe cases toxic 
megacolon or bowel perforation can then lead to septic shock and death. The 
mortality of CDI infection has recently been estimated to be approximately 6% 
within three months of diagnosis (Karas et al., 2010). In England in 2008 C. 
difficile was stated to be the underlying cause of death in 2,298 death 
certificates (Carter, 2009), equating to 6.4% of reported C. difficile cases. The 
large range of clinical symptoms caused by CDI is collectively referred to as 
C. difficile associated disease (CDAD).  
 
1.2.2 Community-acquired infection 
Although C. difficile is often referred to as a nosocomial pathogen infections 
do also occur in the community. As expected the most clearly associated risk 
factor is use of antibiotics, with other risk factors including gastrointestinal 
disorders and recent hospitalisation (Pituch, 2009). The risk factors generally 
overlap with those for nosocomial infection (Kutty et al., 2010), although there 
may be some differences in predisposing factors, for example one study 
showed that community-acquired CDI occurrs on average in younger patients 
than nosocomial infection (Naggie et al., 2010). As yet there has not been 
much work focused on community acquired CDI, and this is an area where 
future research will shed light on many of the currently unknown factors such 
as sources of infection (Otten et al., 2010, Wilcox et al., 2008). 
 18 
1.2.3  Infection of infants 
As previously mentioned C. difficile was first isolated from newborn infants 
(Hall & O'Toole, 1935) and it is now accepted that a high proportion 
(estimates of 30-40%) of infants in their first year are colonised with C. difficile 
(Jangi & Lamont, 2010, Bolton et al., 1984). Despite the presence of toxin 
produced by C. difficile infants do not develop CDAD (Kotloff et al., 1988, 
Bolton et al., 1984). The mechanisms behind this tolerance are not yet fully 
understood. Maternal antibodies acquired through breast-feeding may play a 
role in protection from toxin action (Kim et al., 1984). During months 12-24 the 
majority of infants lose C. difficile as a member of their intestinal flora and 
during this time they are developing a more adult intestinal flora composition 
(Palmer et al., 2007). Interestingly these findings of asymptomatic infant 
colonisation and subsequent clearance of infection are mimicked in hamsters 
(Rolfe & Iaconis, 1983, Kim et al., 1987) and dogs (Perrin et al., 1993a). 
Studies in rabbits have also shown neonatal tolerance of C. difficile toxin, and 
this has been linked this to low expression of toxin receptor in neonatal 
intestine compared to adult intestine (Eglow et al., 1992).  
 
It is not yet clear how the immune system of infants responds to CDI and how 
this affects their subsequent susceptibility to CDI and CDAD. It has been 
shown that the majority (60-70%) of children and adults do have antibodies to 
C. difficile toxins (Viscidi et al., 1983), which may be the result of infantile 
colonisation, and it is known that such antibodies reduce the risk of CDAD 
(Kyne et al., 2000). Therefore infantile colonisation may lead to a reduction in 
the risk of developing CDAD later in life, but this has not been shown directly.   
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1.2.4 Asymptomatic infection 
C. difficile infection is obviously a pre-requisite to the development of CDAD, 
however it has become clear that adults are commonly infected with C. 
difficile but are asymptomatic, therefore C. difficile infection alone does not 
mean that a patient will develop CDAD. As with CDAD, the prevalence of 
asymptomatic CDI has been shown to be associated with antibiotic usage 
(Walker et al., 1993, Ryan et al., 2010), although this association is not 
always seen (Rivera & Woods, 2003). Low levels of anti-toxin A IgG can 
predispose to symptomatic infection (Kyne et al., 2000) and development of 
CDAD may be linked to a reduction in IgA producing cells and macrophages 
in the gut (Johal et al., 2004), however more research in this area is required 
to fully understand why some patients develop CDAD and some do not.  
 
Asymptomatic carriers are possible sources of C. difficile infection, and there 
is evidence that in the nosocomial environment this is a major source of 
strains that are transmitted to non-colonised patients (Clabots et al., 1992). 
For this reason the feasibility of treating asymptomatic carriers with 
metranidozole or vancomycin to eliminate this source of infection has been 
investigated. However, metranidazole was ineffective and vancomycin was 
only temporally effective with a subsequent higher rate of C. difficile carriage 
than prior to vancomycin treatment (Johnson et al., 1992). This reflects the 
fact that these treatments are themselves broad-spectrum antibiotics and 
therefore show some propensity to induce CDI. In the future it may be 
possible to treat asymptomatic C. difficile carriers to eliminate these sources 
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of C. difficile from the nosocomial environment but this is not recommended 
with the treatments currently available. 
 
1.2.5 Animal infection 
As previously mentioned the link between C. difficile and antibiotic-associated 
diarrhoea was first discovered in hamsters (Bartlett et al., 1977b) and since 
this time C. difficile has been shown to cause infection in a large number of 
different animal species. Gnotobiotic mice (those without an intestinal flora) 
were shown to be susceptible to C. difficile infection in 1980, and C. difficile 
was later shown to be present in normal laboratory mouse colonies, where 
use of ampicillin increased the prevalence of C. difficile infection detected 
(Itoh et al., 1986). In 1981 antibiotic usage in guinea pigs (Rehg & Pakes, 
1981) and rabbits (Rehg & Lu, 1981) was shown to induce CDAD.  
 
Some attention therefore was turned from laboratory animals to domestic 
animals, as these are a potential source of C. difficile infection for humans. 
Dogs, cats and birds were shown to be transiently infected with both toxgenic 
and non-toxigenic C. difficile strains, and there was limited association with 
antibiotic usage (Borriello et al., 1983). Subsequent studies have confirmed 
the significant prevalence of C. difficile in cats and dogs (Berry & Levett, 1986, 
Riley et al., 1991, Lefebvre et al., 2006a, Lefebvre et al., 2006b, Lefebvre & 
Weese, 2009) and the role as a potential source for human infection has been 
highlighted although not directly shown. C. difficile also causes colitis in 
horses, and has a strong association with antibiotic usage (Perrin et al., 
1993b, Ruby et al., 2009). A diverse set of strains have also been isolated 
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from healthy horses suggesting that C. difficile is a common member of the 
gut flora in horses (Ossiprandi et al., 2009).  
 
The third major group of animals that has been assessed for C. difficile 
infection are animals used in food production, again due to the importance as 
a possible source of infection transmission to humans. C. difficile was first 
isolated from pigs in 1983 (Jones & Hunter, 1983) and has more recently 
been shown to be an important cause of diarrhoea in piglets (Yaeger et al., 
2002) and is considered to be the most important cause of diarrhoea in piglets 
that is currently uncontrolled (Songer & Anderson, 2006). Recently one 
ribotype of C. difficile (078) commonly found in pigs has emerged in humans 
and zoonotic transfer is therefore suggested, but has not been proven 
(Goorhuis et al., 2008a). 
 
Calves have been shown to be colonised with C. difficile although it appears it 
does not cause disease in calves (Rodriguez-Palacios et al., 2007). The 
majority of strains isolated from calves are also known to cause human 
disease (Rodriguez-Palacios et al., 2006) so the possibility of C. difficile 
having transferred between calves and humans is evident. Farm-raised deer 
have also been shown to have a significant level of C. difficile colonisation 
(French et al., 2010). One study has shown the presence of a diverse set of 
C. difficile strains at poultry farms (Zidaric et al., 2008). 
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Zoo animals are also at risk of developing C. difficile disease as exemplified 
by an outbreak in elephants, thought to have been triggered by diet-related 
alteration of the normal gut flora (Bojesen et al., 2006). 
 
From these studies it is clear that C. difficile can colonise a diverse set of 
mammals and birds, therefore zoonotic transfer of infection is a real 
possibility, although transfer has not yet been shown to occur directly. 
 
1.3 Clostridium difficile diagnosis 
Accurate diagnosis early in the disease course is important to the successful 
management of CDI. In the clinical setting this will ensure that patients receive 
timely, appropriate treatment and that correct infection control measures are 
put in place to reduce the chances of nosocomial transmission of infection. A 
false-positive test result may lead to unnecessary treatment and isolation, 
while the true cause of the patient’s diarrhoea may also not be further 
investigated. In hospitals where C. difficile infection patients are isolated 
together in large wards, due to lack of availability of single-room isolation 
facilities, a false-positive result could also lead to a C. difficile-free patient 
being at increased risk of acquiring infection from patients who really do have 
C. difficile infections. Conversely, false-negative results may lead to delays in 
patients receiving appropriate treatment. In many cases over-treatment with 
empirical antibiotics may occur and this can further exacerbate the CDAD. As 
these patients would not be isolated the risk of spreading infection are also 
increased.  
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Suspicion of CDI, is often based on diarrhoea that has a typical foul-smelling 
odour (Bartlett & Gerding, 2008). Odour assessment for the likelihood of CDI 
might be useful when assessing patients with diarrhoea to determine priority 
for isolation in settings where isolation capacity is limited, especially if rapid 
laboratory diagnosis is not available (Wilcox, 2007a). Laboratory testing for C. 
difficile is recommended for adults and children over 1 year of age who have 
otherwise unexplained diarrhoea associated with antibiotic use. The most 
sensitive assay available for diagnosis of CDAD is the cytotoxin assay or cell 
cytotoxicity assay (CYT), which was first described in 1978 shortly after the 
discovery of the association between C. difficile and clindamycin colitis 
(Chang et al., 1978). This assay tests the supernatants of patient faeces for 
toxic activity on cell monolayers. Toxicity attributable to C. difficile toxins is 
determined by assessing the ability of anti-C. difficile toxin antibodies to 
neutralize the cellular toxicity. C. difficile toxins can be detected at picogram 
levels using this assay. This assay is commonly used as the gold standard for 
comparing alternative toxin detection assays to. The major disadvantages of 
the CYT are that it is technically demanding and has a relatively long 
turnaround time of 24-48 hours. Both the sensitivity and specificity of CYT are 
very high (98-99%), therefore if this test is carried out additional tests provide 
little or no new information from the point of view of basic diagnosis, and are 
not usually warranted.  
 
Cytotoxigenic culture (CYTGC) is where testing is performed on supernatants 
from a bacterial culture inoculated from faeces, rather than from the faecal 
sample itself (Bouza et al., 2001). The culturing step adds further time to the 
 24 
assay, 72 hours being a typical wait for results. A further caveat to CYTGC for 
the clinician is that it is not specific for in vivo production of toxins. If a 
toxigenic C. difficile strain can be cultured it may produce detectable toxin in 
vitro even though it is not producing toxin nor causing CDAD in that particular 
patient. Therefore this assay is seldom used for routine clinical diagnosis of 
CDI. However, CYTGC is necessary for downstream determination of 
antibiotic sensitivity and molecular typing of organisms, and therefore is of 
high importance to epidemiological studies.  
 
Enzyme immunoassays (EIAs) have been developed to detect C. difficile 
toxins and in the UK there are currently six commercially available EIAs that 
detect toxins A and B. There are also three commercial lateral 
flow/immunochromatography assays that also use anti-toxin antibodies to 
detect toxins A and B (Eastwood et al., 2009). These toxin detection kits are 
attractive because they remove the need for laboratories to maintain the cell 
lines necessary for CYT testing. They are also technically easier to carry out, 
and most importantly give results much more quickly. Typically EIAs take 
around 2 hours, and immunochromatography takes less than an hour. 
Although tests were originally designed to detect either toxin A or toxin B, the 
kits currently available detect both toxins as it is now recognized that toxin A-
negative, toxin B-positive strains are virulent and therefore clinically important 
(Drudy et al., 2006a). In addition to these commercial toxin-detecting assays 
there is a PCR-based assay available that detects the presence of the toxin B 
gene. This does not give an indication of whether or not there is a high level of 
toxin being expressed in vivo, but does indicate presence of C. difficile. The 
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final test that is currently commercially available is an EIA that detects the C. 
difficile enzyme glutamate dehydrogenase (GDH). Again this indicates 
whether or not the organism is present but does not determine toxin 
expression level.  
 
A recent study was carried out to compare all these rapid tests against CYT 
and CYTGC for sensitivity and specificity (Eastwood et al., 2009). The main 
finding was that all rapid tests do not have high enough sensitivity, thereby 
generating an unacceptably high number of false negatives to allow them to 
be used as the only test for CDI with sufficient confidence. The specificity of 
these tests is much better, however some false positives are generated. As 
previously stated, both false-positive and false-negative results have serious 
implications for patient care. In this comparative study the PCR assay and 
GDH assay showed the best sensitivity, but less specificity than the rapid 
toxin detection kits. This has led to proposals that the PCR and/or GDH assay 
could be used as a first round of testing, or negative screening tool to give an 
initial indication of whether C. difficile is likely to be present. CYT or CYTGC 
could then be carried out as a second step of testing on PCR/GDH-positive 
samples to identify patients with toxins in their faeces (Eastwood et al., 2009, 
Wren et al., 2009a, Reller et al., 2010). The use of an additional test for 
lactoferrin, which is a marker of intestinal inflammation has also been 
suggested to aid identification of patients who are asymptomatically colonised 
and do not have intestinal inflammation but would test positive for C. difficile 
by PCR or GDH assay (Wren et al., 2009b). Asympotomatically colonised 
patients may then be isolated as an infection control measure but not treated 
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for CDAD.  
 
Multiple step testing is likely to increase laboratory costs, but these costs 
might be offset by reduced total healthcare costs of managing C. difficile 
infection if diagnosis is more accurate. The length of time until a final result is 
known would be longer than a single test with such a protocol, however if the 
interim results were made available and used to guide clinicians while waiting 
for CYT or CYTGC results the overall treatment and isolation outcomes may 
be improved. Further work is required to assess which assays would provide 
the optimal multi-step laboratory diagnosis of C. difficile infection, with recent 
studies reporting high levels of sensitivity and specificity for multi-step 
procedures (Sharp et al., 2009, Swindells et al., 2010). Development of new 
diagnostic kits is an area of active research and new technology and/or 
biological targets may improve the options available for diagnosis of C. difficile 
infection.  
 
1.4 Prevention of C. difficile infection  
Infection control measures to prevent CDI can be put into two groups:  
1. Those that attempt to prevent patient contact with C. difficile spores.   
2. Those that reduce the risk of patients becoming colonised with C. difficile 
upon contact with infectious spores. 
1.4.1 Preventing contact with spores 
In the hospital environment a number of measures have been tested for their 
ability to reduce C. difficile transmission. The use of gloves and gowns by 
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healthcare workers are effective methods for reducing the spread of C. difficile 
spores between patients (Johnson et al., 1990). If gloves are not used hand 
hygiene is critical to preventing the spread of spores, although alcohol hand 
rubs do not remove or kill C. difficile spores, so hand washing with soap and 
water is preferred (Jabbar et al., 2010). Studies have shown that another 
effective way to reduce transmission of C. difficile is by using disposable 
thermometers (Brooks et al., 1998, Jernigan et al., 1998). It has been shown 
that contamination of rooms is closely correlated with the C. difficile status of 
the patient. Patients with CDAD have the highest contamination rate, followed 
by asymptomatic CDI patients, and as would be expected the lowest 
contamination level is seen in rooms of patients with no CDI (McFarland et al., 
1989). Therefore isolation of patients with CDI in private rooms can reduce 
contamination of the general environment by these patients, thereby reducing 
the risk of transmission of infection to other patients. The hands of health care 
workers become contaminated in proportion to the contamination of the 
environment (Samore et al., 1996), therefore by having patients with CDI 
isolated and encouraging the changing of gloves and gowns between rooms 
and patients the risk of transmission can be reduced. Reducing contamination 
of the environment by cleaning is also important. However, traditional cleaning 
products are not sporicidal so are not the most effective means for reducing 
contamination levels. Hypochlorite solution is sporicidal and has been shown 
to significantly reduce spore contamination of the environment and therefore 
C. difficile infection rates (Mayfield et al., 2000, Wilcox et al., 2003). Ward 
overcrowding has been shown to correlate with increased CDI rates, likely 
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due to sub-optimal implementation of the infection control measures 
discussed (Kaier et al., 2010).  
 
For community associated CDI the sources of infection are less well 
understood. A recent study developed a model for transmission of infection 
outside of the hospital setting. Possible sources of infection were grouped into 
four broad categories: consumption, person-person contact, animal-person 
contact and environment-person (Otten et al., 2010).  
 
Consumption of contaminated food and water could lead to CDI. One of the 
largest studies into environmental sources of C. difficile was carried out in 
South Wales and found that 5.5% of tap water and 2.3% of raw vegetables 
tested positive for C. difficile (al Saif & Brazier, 1996). A number of more 
recent studies have found C. difficile present at a significant level (6-42% of 
samples) in commercial meat products (Songer et al., 2009, Von Abercron et 
al., 2009, Weese et al., 2009, Weese et al., 2010). One study has shown 
presence of virulent C. difficile isolates in ready to eat salads (Bakri et al., 
2009). Food and drink may therefore be a reservoir for CDI but transmission 
has not yet been directly proven. One study has shown that C. difficile spores 
can survive the heating recommendations for some meat products, and 
therefore current food preparation guidelines are not sufficient to prevent C. 
difficile  transmission (Rodriguez-Palacios et al., 2010). Contamination of food 
during preparation by the persons preparing food is also a realistic means for 
C. difficile transmission but this has not been investigated. Direct person-
person transmission of infection is likely to occur in a similar way to that in 
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which it occurs in the nosocomial environment. A couple of studies have been 
carried out to try to address transmission patterns among university students 
and employees (Ozaki et al., 2004) and in a family setting (Kim et al., 1981). 
Individuals in both settings were found to be infected with common strains but 
it is not possible to distinguish in these studies between direct person-person 
transmission and a common environmental source.  
 
Person-person transmission should also be considered as a means of C. 
difficile being transmitted from environments with high levels of C. difficile 
contamination into the community by people who work in these environments. 
Healthcare workers are the obvious example and one study showed the 19% 
of staff uniforms tested positive for C. difficile after a shift, and that these were 
taken home for laundering (Perry et al., 2001). This may be a mechanism by 
which healthcare workers act as a reservoir for community infection. 
Employees and veterinary workers on farms where animal CDI is common 
may similarly spread C. difficile spores out from their work environment.  In 
these cases the transmission from person-person would be preceeded by 
animal-person transmission.  
 
Environment-person contamination is likely to be a significant transmission 
mechanism. In one study testing the hospital environment samples from 
diseased and colonised patients’ rooms ranged from 0% to 53.3% positive 
with an average of 32.5%, while control rooms ranged from 0% to 7% with an 
average of 1.3% (Mulligan et al., 1980). In a number of similar studies the 
level of environmental contamination with C. difficile has been shown to 
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increase with proximity to colonised and diseased persons and animals. 
Therefore environmental sources of infection in the community are also likely 
to be produced by the presence of infected humans and animals. The only 
way to counteract this is by cleaning such areas with sporicidal products, as 
occurs in hospitals, but as the importance and relevance of such sources for 
infection have not yet been determined the possible benefits of this are not 
known. Environmental sources of infection less directly linked to human or 
animal infection are soil and natural water sources (lakes, rivers, sea). C. 
difficile can be isolated from such sources (al Saif & Brazier, 1996) and 
activities such as gardening and water-sports may provide a route for 
transmission.    
 
Until more is understood about the relative contributions of different sources 
of infection to community associated CDI rates little is likely to be done to 
reduce the risks of transmission. In many ways nosocomial and community 
associated infection should not be considered as completely distinct infection 
types, as the nosocomial environment is directly linked in many ways to the 
wider environment. A better understanding of the dynamics of infection 
transmisson between these environments and the relative contributions of 
different infection sources may facilitate reduction of CDI incidence in both 
nosocomial and community settings.   
1.4.2 Reducing patient susceptibility to C. difficile infection 
Altering antibiotic prescribing practice is an effective method of reducing the 
rates of CDI. This is based on the knowledge that some antibiotics are less 
likely to induce CDI than others. Therefore if high risk antibiotic prescribing 
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(for example clindamycin and cephalosporins) is reduced in favour of 
prescription of low-risk antibiotics (for example vancomycin and penicillin) the 
overall risk of inducing CDI is reduced, and infection rates have been shown 
to fall (Wilcox et al., 2004, Davey et al., 2005, Davey et al., 2006). In one 
study major changes in antibiotic prescribing were used to control a large 
outbreak of CDI in combination with optimal hygiene practices, and the 
importance of using a combination of both of these methods of CDI prevention 
is emphasized (Valiquette et al., 2007).  
1.4.3 Novel methods for preventing CDAD 
A number of studies have been carried out using probiotics to try to reduce 
CDI. The theory behind this prevention measure is that probiotics may 
partially counteract the floral disruption caused by antibiotic treatment. There 
is currently insufficient clinical evidence to support routine use of probiotics in 
prevention of CDI (Dendukuri et al., 2005, Graul et al., 2009). In the future 
improved trials with existing probiotics or new probiotic preparations may be 
shown to be efficacious in prevention of CDI (Gao et al., 2010). It should also 
be remembered that the possibility of inducing bacteraemia or fungaemia 
when using probiotics is a risk associated with this strategy for C. difficile 
prevention. 
 
A twist on the strategy of using probiotics to prevent CDI is to use non-toxic C. 
difficile colonisation to prevent infection with toxigenic strains of C. difficile. 
This strategy was suggested on the basis of evidence showing that patients 
who are colonised with C. difficile prior to hospitalization are at decreased risk 
of developing diarrhoea (Shim et al., 1998). Studies in the hamster have 
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shown colonisation with non-toxic strains to effectively prevent CDAD in 
hamsters upon challenge with toxigenic strains (Sambol et al., 2002, Merrigan 
et al., 2009). Clinical trials are currently underway (Dale Gerding, personal 
communication).  
 
Vaccination is an obvious strategy for prevention of infectious disease in 
general, and development of a vaccine to prevent C. difficile is an area of 
active research. As the C. difficile toxins are known to be the key virulence 
factors in CDAD most vaccine research so far has focused on vaccinating 
against these toxins. Existing effective toxoid vaccines for tetanus (caused by 
Clostridium tetani) and diphtheria (caused by Corynebacterium diphtheriae) 
demonstrate the potential of antitoxin immune responses in preventing toxin-
mediated disease and provide encouraging precedent for a toxoid vaccine.  
 
It has long been known that vaccination of hamsters with toxoids containing 
C. difficile toxins A and B can protect them from CDAD (Libby et al., 1982, 
Fernie et al., 1983). C. difficile culture filtrate and killed whole cells from a 
highly toxigenic strain have also been successfully used as antigens to 
prevent disease in hamsters (Torres et al., 1995). More recently a DNA 
vaccine encoding a domain of toxin A has been shown to protect mice from 
death when challenged with toxin A (Gardiner et al., 2009).  
 
High concentrations of serum antibodies against toxin A in humans have been 
shown to correlate with reduced risk of developing recurrent CDAD (Kyne et 
al., 2001) and more recent evidence suggests that concentrations of anti-toxin 
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B antibody correlate in a similar way (Leav et al., 2010). The caveat to such 
studies is that a demonstration of antibody levels against a particular antigen 
correlating with risk of CDAD does not necessarily mean that it is antibodies 
against this antigen that are directly protective. It may be that some patients 
have a generally higher immune reponse to infection than others, which 
reduces their risk of developing CDAD. If this were the case antibody levels to 
many C. difficile antigens would be higher in these patients. In the same study 
that evaluated anti-toxin A antibodies it was also shown that patients with 
recurrent CDAD has significantly lower IgM antibodies against a crude 
preparation of C. difficile non-toxin antigens (Kyne et al., 2001). From this type 
of studies alone it is not clear which of the antibodies are protective against 
colonisation or disease.   
 
Toxoid vaccination in healthy humans against toxin A can provide anti-toxin 
antibody titres exceeding that shown to correlate with protection against 
recurrent disease in CDAD patients (Aboudola et al., 2003). This means that 
testing the hypothesis that anti-toxin immunization may protect against CDAD 
is feasible with a toxoid vaccine. In a small study with 3 patients suffering from 
recurrent CDAD a toxin A and B toxoid vaccine successfully boosted levels of 
anti-toxin A and B antibodies and this was associated with resolution of 
recurrent diarrhoea (Sougioultzis et al., 2005). Larger trials are required to 
validate this vaccine strategy.  
 
In terms of desired outcome for a C. difficile vaccine the main aim is to reduce 
CDAD. However, the ideal vaccine would also prevent colonisation with C. 
 34 
difficile as this would reduce transmission of infection and herd immunity 
would be a positive outcome of vaccine usage. Anti-toxin vaccination alone 
would likely not provide protection against C. difficile colonisation, as naturally 
occurring strains without toxins can colonise. Therefore aside from anti-toxin 
vaccine strategies, the main avenue that has been pursued is use of surface 
antigens for vaccination with the aim of reducing the ability of C. difficile to 
colonise the host. Antibodies against surface proteins have been detected in 
CDAD patients (Pechine et al., 2005, Wright et al., 2008a) suggesting that 
these antigens are immunogenic and may play a role in host response to 
infection. It has been shown that high IgM antibody levels to C. difficile 
surface layer proteins are associated with a reduced risk of developing 
recurrent CDAD (Drudy et al., 2004). Passive immunization of hamsters with 
anti-surface layer protein (SLP) antibodies has been shown to prolong 
survival in the hamster model of infection (O'Brien et al., 2005). Active 
immunization of mice with surface proteins has also been shown to reduce 
colonistion levels during CDI (Pechine et al., 2007). Therefore, vaccination 
against surface antigens may have some efficacy in preventing colonisation 
but much more work is required to determine the best targets. It will also be 
important to consider strain coverage with surface antigen strategies, as the 
level of conservation of surface antigens is in general much lower than that of 
the toxins across C. difficile strains. 
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1.5 Treatment of CDAD 
1.5.1 Current standard treatment 
Current standard treatment for CDAD is to discontinue any antibiotic therapy 
that may have induced the CDI, then commence treatment with metranidazole 
or vancomycin. Metronidazole is the drug of choice for an initial episode of 
CDAD with mild-moderate symptoms, the recommended dosage being 
500mg orally 3 times a day for 10-14 days. The preference for metronidazole 
over vancomycin is largely due to recommendations that vancomycin use in 
hospitals be reduced to reduce the selection pressure for the emergence of 
vancomycin-resistant enterococci (HICPAC, 1995). There is some evidence 
that vancomycin may be generally more effective in treating CDAD than 
metronidazole (Pepin et al., 2004), however more recent data does not 
support this claim (Pepin et al., 2007). For patients with severe disease 
symptoms vancomycin has been shown to be superior to metronidazole (Zar 
et al., 2007). Therefore vancomycin treatment is recommended for severe 
symptoms, at a dosage of 125mg orally 4 times per day for 10-14 days. In 
very severe cases oral vancomycin and intravenous metronidazole can be 
administered together and at higher dosages. In the most severe, complicated 
cases surgical colectomy is required, and can be life-saving (Lamontagne et 
al., 2007). High serum lactate level and peripheral white blood cell counts can 
help guide the decision to operate, as these are markers of severe CDAD 
(Cohen et al., 2010).  
 
Vancomycin and metronidazole do both effectively kill C. difficile, but relapses 
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following withdrawal of the antibiotic are common. The relapse rate after initial 
therapy has been shown to range from 6 to 25% (Olson et al., 1994, Bartlett, 
1992). Patients who are retreated for relapse have a 40% probability of 
another relapse. Subsequent relapses occur at the alarmingly high rate of 
60% or more. Studies of relapses show that about 60% are true relapses, 
meaning the same strain of C. difficile is the causitive agent. The assumption 
in these cases is that antibiotic treatment fails to fully eradicate the pathogen. 
However, it is impossible to distinguish between this and reinfection with 
spores of the same strain from the environment, which is likely to be 
contaminated. The remaining 40% of relapses must represent new infections 
with C. difficile, because they involve a different strain (Barbut et al., 2000, 
Johnson et al., 1989).  
 
Treatment for relapses is usually determined using the same 
recommendations as for the initial episode (Cohen et al., 2010). However, for 
multiple relapses metronidazole is not recommended as there is the potential 
for cumulative neurotoxicity when using this drug long-term (Kapoor et al., 
1999). In these cases vancomycin treatment is preferred and a tapered or 
pulse dosing regimen is recommended to try to allow recovery of some of the 
native flora before full removal of the antibiotic, which is suppressing C. 
difficile.  The relapsing nature of CDAD reflects the fact that vancomycin and 
metronidazole are broad-spectrum antibiotics themselves and are therefore 
also CDI-inducing agents. Thus, the clinician is currently faced with the 
paradox that the standard drugs used to treat C. difficile infection also cause 
it. Reduction in relapse rate can be achieved in part by good infection control 
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measures, but one of the main aims of new therapy development is to prevent 
or overcome the CDAD relapses seen with vancomycin and metronidazole.  
1.5.2 Resistance to current antibiotics 
1.5.2.1  Metronidazole 
Historically resistance of C. difficile to metronidazole has rarely been seen. 
Minimal inhibitory concentrations (MICs) of nearly all strains tested have been 
less than 2 mg/L. More recently slightly higher MICs have been reported. In 
Spain 6.3% of isolates were shown to have MICs of 32 mg/L or higher (Pelaez 
et al., 2005). In the UK recent isolates of a specific ribotype (001) were shown 
to have a 6-fold increase in MIC compared to historic isolates (Baines et al., 
2008). Metronidazole does not achieve very high concentrations in the gut 
after oral administration due to >85% of the drug being absorbed. The mean 
concentration in watery stool has been shown to be 9.3 mg/L (Bolton & 
Culshaw, 1986). Therefore even a modest increase in susceptibility might 
affect clinical outcomes and continued metronidazole susceptibility monitoring 
will be necessary.   
1.5.2.2  Vancomycin 
The accepted MIC of vancomycin against C. difficile is 1-2 mg/L, with the 
highest ever reported MIC being 16 mg/L (Cohen et al., 2010). Vancomycin 
achieves very high faecal concentrations when administered orally, due to 
very limited absorption. Faecal levels of up to 880 mg/L have been measured 
(Keighley et al., 1978). Therefore development of resistance is considered 
less of a concern than with metronidazole. Concerns that vancomycin usage 
may promote the emergence of vancomycin-resistant enterococci (HICPAC, 
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1995) are more of a driving force to reduce vancomycin usage, than concerns 
of C. difficile itself becoming resistant to vancomycin.  
1.5.3 Alternative antibiotics 
Alternative antibiotics are being developed and tested with the aim of having 
agents available for use in the case of resistance emerging to metronidazole 
and/or vancomycin, but also as antibiotics with a more limited spectrum of 
activity would disturb the normal faecal flora to a lesser extent, thus reducing 
the risk of relapse.   
1.5.3.1  Rifamycins 
Rifampin, rifaximin and rifalazil are three members of the rifamycin class of 
antibiotic that have all been used to treat C. difficile (Garey et al., 2008). They 
all show good in vitro activity against C. difficile and high levels of the drug in 
the colon can be achieved. There is some evidence from pilot studies that 
there is a lower risk of relapse than with vancomycin therapy (Johnson et al., 
2007, Garey et al., 2008), but larger controlled trials are necessary to confirm 
this. The main worry with this class is natural and emerging resistance, which 
has been noted for many bacterial species, including C. difficile (Johnson et 
al., 2007, Curry et al., 2009).  
1.5.3.2  Ramoplanin 
Ramoplanin is a new lipoglycodepsipeptide, which has been shown to have 
activity comparable to vancomycin for treatment of CDAD (Bartlett, 2009b). It 
has been fast-tracked for approval by the FDA, as it does not have the same 
drawback as vancomycin with concerns about vancomycin-resistant 
enterococci (Shah et al., 2010).  
 39 
1.5.3.3  Fidaxomicin (OPT-80, PAR101, difimicin) 
Fidaxomicin is a new macrocyclic antibiotic that has potent in vitro activity 
against C. difficile. Importantly it has limited activity against normal faecal flora 
(Louie et al., 2009). It achieves high concentrations in the colon as it is 
minimally absorbed from the gut. It has been tested against oral vancomycin 
in clinical studies of CDI therapy and has demonstrated efficacy equivalent to 
vancomycin for curing acute CDI. However, fidaxomicin therapy shows an 
improvement over vancomycin therapy in that it is associated with significantly 
lower risk of CDI recurrence in the 28 days following treatment. Symptom 
resolution is also slightly quicker for some patients (Miller, 2010). Thererfore 
this treatment shows promise in becoming a routine treatment for CDAD.  
1.5.3.4  Nitazoxanide 
Nitazoxanide was developed for treatment of protozoal infections of the gut, 
but was shown to have in vitro activity against C. difficile. Testing in the 
hamster model of infection showed that it was comparable to vancomycin and 
metronidazole in preventing lethality, but importantly unlike these drugs it did 
not induce CDI. It was therefore tested in humans in a randomized, double 
blind trial of metronidazole and was shown to be equally effective (Musher et 
al., 2006). A subsequent trial tested responsiveness to nitazoxanide in 
patients who were not responding to metronidazole. 74% of patients 
responded to treatment and 27% of these relapsed (Musher et al., 2007). 
Nitazoxanide may therefore be a useful addition to the C. difficile antimicrobial 
armory.  
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1.5.3.5  Tigecycline 
Tigecycline was approved by the FDA in 2005 as the first in the glycylcyclines 
class of antibiotics. It is a ribosomal-binding protein synthesis inhibitor and 
has broad-spectrum activity. Despite this broad-spectrum activity, and 
therefore the disruption of the gut flora that tigecycline use causes, it is 
associated with low risk of CDI (Wilcox, 2007b). A large panel of C. difficile 
isolates have been shown to be susceptible to tigecycline in vitro (Nagy & 
Dowzicky, 2010) and recent case reports have shown that it is also effective 
at treating CDAD without causing relapses (Herpers et al., 2009, Lu et al., 
2010). Larger trials are therefore warranted to assess the usage of tigecyline 
to treat CDAD.   
1.5.3.6  Thuricin CD   
A recent study focusing on the concept that the native bacterial flora is in 
some way protective against C. difficile, screened gut bacteria for anti-C. 
difficile activity and isolated an antimicrobial peptide from the human gut 
bacterium Bacillus thuringiensis. Thuricin CD kills C. difficile, some other 
Clostridium sp. and Listeria monocytogenes, but has no impact on most other 
genera tested (Rea et al., 2010b). This narrow-spectrum bacteriocin was 
compared to vancomycin, metronidazole and a broad-spectrum bacteriocin in 
its propensity to affect the gut microbiota in an in vitro distal colon model. 
High-throughput pyrosequencing of 16s rRNA genes was used to determine 
the compostition of the microbiota before and after antimicrobial usage. 
Results of this 16sRNA sequencing are summarized in Figure 1.2. This 
showed that thuricin CD is as effective in killing C. difficile as the other agents 
but had no significant impact on the rest of the microbiota (Rea et al., 2010a). 
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Therefore this bacteriocin or a strain producing it could be used as a 
therapeutic, which is unlikely to lead to relapses, due to its lack of effect the 
protective native flora.  
 
 
Figure 1.2 Diversity of microbial communities in an in vitro gut model 
before and after treatment with antimicrobials. 
Determined by high-throughput 16s rRNA gene pyrosequencing. A. Phylum 
level diversity in an in vitro distal colon model. Control with no antimicrobial, is 
compared to vancomycin and metronidazole treatment. B. Family-level 
taxonomic distribution of the microbial communities present in an in vitro distal 
colon model with or without thuricin CD treatment. Values are expressed as 
percentages of total assignable sequences. Adapted from (Rea et al., 2010a). 
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It would be useful to compare all the antimicrobials discussed in this section 
for impact on the gut microbiota by 16s rRNA sequencing. It has been shown 
that different antibiotics have different effects on the gut microbial community 
(Antonopoulos et al., 2009). This information combined with their association 
with CDI relapse would determine what kind of microbiota disruption is most 
associated with predisposing to CDI and risk of relapse. This would provide a 
rationale for selection of antibiotics to treat C. difficile without causing relapse, 
and to treat other conditions without making patients susceptible to CDI. It 
may also lead to identification of the microbiota species most strongly 
associated with protection from CDI and/or relapse, and this could be used as 
a rational basis for development of therapies that specifically introduce or 
promote the growth of these species.  
1.5.4 Faecal transplant/faecal biotherapy 
Based on the rationale that disruption of the indigenous gut flora is a major 
risk for both primary infection with C. difficile and recurrence of disease, 
repopulation of the gut flora using stool from a healthy donor has been tested 
as a therapeutic strategy. A high degree of success has been reported in 
several uncontrolled case series (Gustafsson et al., 1998, Aas et al., 2003, 
Yoon & Brandt, 2010, Silverman et al., 2010). A recent systematic review of 
the literature, covering a total of 150 patients, estimated that faecal therapy 
has exhibited a 91% success rate (van Nood et al., 2009). A randomised trial 
of faecal therapy is currently underway in the Netherlands (van Nood et al., 
2009). 16S rRNA sequencing has been used to show directly how a 
recipient’s intestinal microbiota was strikingly similar to a donor’s after 14 days 
post-therapy, and it is this restoration of the microbial community that is 
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thought to be protective against C. difficile (Khoruts et al., 2010).   
 
However, the availability of this treatment is limited. For safety reasons the 
donor should be screened for transmissible agents. The logistics of the 
treatment are relatively complex. The timing, collection and processing of the 
specimen from the donor followed by preparation of the recipient, and the 
route and means of administration are all key aspects of the treatment for 
which there is as yet no standard recommendation. Despite the efficacy of 
such a treatment it seems unlikely that it will be adopted as standard practice, 
unless in the next few years no other therapies emerge to successfully 
address the problem of C. difficile recurrence. As mentioned in the previous 
section, a better understanding of the specific species responsible for 
protection against CDAD would allow more palatable, defined and logistically 
easier treatments to be developed.  
1.5.5 Passive immunotherapy 
Intravenous human immunoglobulin has been used to treat a small number of 
patients with severe disease in a few uncontrolled studies (Salcedo et al., 
1997, McPherson et al., 2006, Wilcox, 2004). Intravenous immunoglobulin 
(IVIG) is the pooled IgG extracted from the plasma of thousands of blood 
donors, which has been FDA-approved for a number of indications including 
chronic lymphocytic leukemia and pediatric HIV. The prevalence of serum 
antibodies against C. difficile toxins (and therefore likely also against other C. 
difficile antigens) in healthy populations, combined with the finding that 
recurrent disease is more likely to occur in patients with limited immune 
response to infection (Kyne et al., 2001) prompted the investigation into using 
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IVIG to treat CDAD. All studies with CDAD have demonstrated some success 
with this treatment in patients who were not responding to standard therapy. 
However, controlled studies are required to determine the true potential of this 
treatment. Unfortunately the prospects for controlled studies of intravenous 
immunoglobulin therapy are not good. Immunoglobulin manufacturers in the 
UK have not taken up any offer of being part of a comparative study (Wilcox, 
2004). IVIG is also expensive and there is limited availability, therefore the 
use of IVIG may be considered more as a proof of concept for passive 
immunotherapy. More specific passive immunotherapy strategies are being 
explored that are more likely to become standard therapy for CDAD in the 
future.  
 
Human monoclonal IgG antibodies with neutralizing activity against toxins A 
and B have been shown to be protective in the hamster model of infection 
(Babcock et al., 2006). Recently a randomized, double-blind, placebo-
controlled phase 2 study was carried out with 200 patients, who were given 
anti-toxin A/B antibodies or placebo alongside the standard treatment of 
vancomycin or metronidazole. Those patients receiving antibodies had a 
significantly lower risk of recurrence of CDI, although there was no effect on 
acute infection (severity of diarrhoeal illness, duration of hospitalization or 
time to resolution of diarrhoea) (Lowy et al., 2010). Monoclonal antibodies 
against C. difficile antigens other than the toxins may also be efficacious in 
preventing or treating CDI, but our current understanding of virulence factors 
other than the toxins is limited and therefore is holding back development of 
such antibodies.  
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An alternative passive immunotherapy strategy in development involves 
immunization of cows with formaldehyde-killed whole C. difficile cells and 
fomaldehyde-inactivated C. difficile culture filtrate (toxoid). Protein concentrate 
from their milk, which contains antibodies, can then be used as an oral 
treatment for C. difficile infection. This treatment has been shown to be safe in 
CDAD patients (Young et al., 2007) and there is some evidence that such a 
strategy has efficacy that is comparable to metronidazole (Mattila et al., 
2008). Further work is required to determine the efficacy of these treatments 
and how they compare to other passive immunotherapy strategies both in 
terms of efficacy and cost. 
1.5.6 Active immunization 
Vaccination could be used to prevent C. difficile infection, and was discussed 
previously. However, it could also be used to treat infection, as boosting the 
immune response to C. difficile may help to clear infection and prevent 
relapses. The only C. difficile vaccine trial in humans carried out so far has 
assessed the efficacy of a toxoid A and B vaccine in three patients with 
recurrent CDAD and in all cases was associated with resolution of disease 
(Sougioultzis et al., 2005). Therefore a vaccine for C. difficile could be used to 
treat patients who are not responding to standard treatments.  
 
Larger trials are required to validate this vaccine strategy, and one concern is 
that some patients may not respond well to vaccination due to reduced 
immune responses in general, which may be underpinning their disease. Only 
clinical data will resolve this issue, but patients who have limited response to 
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active immunization at a critical time in their illness could be suited to passive 
immunization instead. Having both active and passive immunotherapies 
available may provide clinicians with a much better armoury with which to fight 
C. difficile infection.  
1.5.7 Probiotics 
As discussed in the prevention of CDI section, probiotics have shown some 
efficacy in trials both to prevent CDI and reduce the risk of recurrence. 
However, current evidence is not sufficient for endorsement of probiotic use to 
treat CDI and the increased risk of bacteremia or fungemia associated with 
probiotic use may outweigh the benefits (Pillai & Nelson, 2008, Cohen et al., 
2010). The general strategy of using probiotics to promote the gut microbiota 
may prove to be efficacious for treating CDAD, but further research and 
development of treatments is required.  
1.5.8 Anion exchange resins 
C. difficile toxins A and B bind to anion exchange resins, and are therefore 
candidates for treating CDAD. Cholestyramine, a bile acid sequestrant that is 
used to treat hypercholesterolemia and to prevent diarrhoea in Crohn’s 
disease patients, was used to treat clindamycin colitis before C. difficile was 
known to be the cause, and appeared to have some efficacy (Burbige & 
Milligan, 1975). There is a strong caveat with cholestyramine, in that it binds 
vancomycin. Therefore it can interfere with vancomycin efficacy. A later study 
using a different bile acid sequestrant colestipol did not show efficacy (Mogg 
et al., 1982), and ion exchange resins lost favour as a therapeutic strategy. 
Recently tolevamer was developed specifically to treat CDAD. It is a large 
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anionic polymer that binds C. difficile toxins, but has no antibiotic activity so 
will not disrupt the native flora (Barker et al., 2006). It has been tested against 
vancomycin and metronidazole in two large phase III studies and was shown 
to be inferior to both antibiotics in curing acute disease, although the relapse 
rate was lower (Weiss, 2009). Therefore development was halted. It seems 
unlikely that such a treatment with no direct antibiotic activity will be used 
alone to treat CDAD, although perhaps it could be useful in combination with 
antibiotic therapy or immunization strategies. 
1.6 Economics of C. difficile infection 
Determining the cost of C. difficile infection to healthcare systems is complex 
and likely to differ between different healthcare settings, different patient 
groups and different countries. A number of studies have been carried out to 
try to estimate the economic burden that C. difficile is responsible for. The 
conclusions of economical studies have important implications for the 
strategies behind developing and improving current preventative, diagnostic 
and therapeutic options. 
 
There have been two excellent systematic reviews carried out in the past two 
years that have aimed to summarise and critically examine the available 
literature on the economic impact of CDI (Dubberke & Wertheimer, 2009, 
Ghantoji et al., 2010). These reviews analysed studies carried out from 1983-
2008 and converted currencies and costs to 2008 USD equivalents to allow 
for comparisons between studies. These converted costs are used in this 
section to allow for ease of comparison. 
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Costs attributed to CDI can be broadly grouped into three categories; costs of 
medication, laboratory costs for diagnosis and general hospital costs 
associated with length of stay. In a UK-based study carried out by Wilcox et al 
in 1996 CDI patients had an average increase in length of stay of 21.3 days 
over control patients. The overall cost per patient attributable to CDI was 
calculated to be $8995, and 94% of this cost was due to the increased length 
of stay, with only 6% due to medicine and diagnostic costs (Wilcox et al., 
1996). A study in Northern Ireland in 2000 also calculated the major cost of 
CDI to be increased length of stay, accounting for 93.8% of the total 
attributable cost (Al-Eidan et al., 2000).  
 
Two US-based studies have aimed to estimate the total cost to the US 
healthcare system attributable to CDI. In 2002 a prospective study on patients 
from a single hospital receiving antibiotic treatment and found that those who 
developed CDAD cost an extra $4486 per patient, of which most was 
accounted for by an increased length of stay of 3.6 days (Kyne et al., 2002). 
Assuming 239,000 cases per year in the US this cost could be extrapolated to 
costing the US healthcare system a total of $1.3 billion per year. This study 
did not take into account subsequent relapses of infection. One study has 
estimated the cost of recurrences of disease, and shown that each episode is 
associated with an average 8.8 day length of stay, translating to a cost per 
episode of $4,096 (McFarland et al., 1999). Give the high rate of relapse seen 
with current therapies, this would add a significant amount to the total cost 
estimated by Kyne et al. In 2007 O’Brien et al. used retrospective data from 
the whole of Massachusetts to estimate the costs of CDI in the US (O'Brien et 
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al., 2007). Their total cost estimate was $3.4 billion per year, and this 
significantly higher estimate than Kyne et al. was due to increased estimates 
of cost per patient of $10,000 for a patient admitted for CDI and $14,507 for a 
patient with underlying disease with the secondary problem of CDI. Again 
these costs could be primarily attributed to increased length of stay.  
 
Some studies have addressed specific patient populations. It has been 
estimated that CDI infection in inflammatory bowel disease patients costs 
$11,346 per patient, primarily due to an average increased length of stay of 3 
days (Ananthakrishnan et al., 2008). A similar 3-day length of stay increase 
has been shown to occur in the intensive care unit (ICU) for patients with 
CDAD (Lawrence et al., 2007). In surgical inpatients length of stay has been 
shown to increase by an average of 16 days due to CDI, and this leads to an 
average increased cost of $90,664 per patient attributable to CDI (Zerey et al., 
2007). This estimate shows how much the cost consequence of increased 
length of stay can vary between patient groups.  
 
Important gaps in knowledge exist that should be highlighted. There is a lack 
of studies addressing the economic cost of CDI in non-hospital settings, such 
as long-term care facilities. Also studies so far ignore indirect costs associated 
with CDI such as missed work, reduced productivity and increased childcare 
costs due to increased length of hospital stay of patients. Recent changes in 
the epidemiology of C. difficile (discussed in the next section) appear to have 
altered infection rates, risk of relapse and severity of symptoms, and therefore 
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new studies are required to assess the impact of these changes on the 
economics of C. difficile infection.  
 
Given the significant costs associated with CDI, it is clear that investment in 
improving prevention and treatment of CDAD makes economical sense, as 
well as improving the quality of life of patients and reducing morbidity and 
mortality. An example of spending money on prevention leading to overall 
cost saving is a study carried out in the US in 1998, where hospital-wide 
clindamycin usage restriction cost on average $269 per patient due to 
enforced usage of more expensive antibiotics. However, this led to a 
reduction of cases of CDI from 11.5 to 3.3 per month translating to an overall 
cost saving for the hospital (Climo et al., 1998). This exemplifies how cost-
effective infection prevention measures can be, and in the more costly patient 
groups such as surgical inpatients prevention measures have the potential to 
save even more money, and therefore increased spending on prevention 
measures is justified.  
 
A recent study used an economic computer simulation model to determine the 
potential economic value of a C. difficile vaccine (Lee et al., 2010). Using 
inputs for costs based on studies similar to those discussed so far, and 
probabilities of patients developing CDI and subsequent grades of CDAD 
symptoms based on clinical studies, the cost effectiveness of a vaccine could 
be simulated. Use of a vaccine to prevent initial CDI or to prevent recurrence 
of disease in CDAD patients were considered. A number of realistic scenarios 
with respect to vaccine cost, vaccine efficacy and risk of infection were shown 
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to be cost-effective. This suggests that as well as preventing morbidity and 
mortality a C. difficile vaccine could in fact save healthcare systems money, 
due to the substantial cost associated with CDAD management. Interestingly, 
using a vaccine to prevent recurrence of CDAD was shown to be likely to be 
more cost effective than a vaccine used to prevent initial episodes of CDAD, 
as the vaccine would only be administered to the target population and would 
prevent the high costs associated with recurrence. However, this model did 
not incorporate effects that a vaccine could have on C. difficile transmission. If 
a vaccine reduced colonisation rates this would lead to lower levels of 
contamination of the nosocomial environment and thus a lower risk of 
infection. This would make a vaccine strategy aimed at preventing initial CDI 
more cost-effective than this model suggests. From a strategic perspective, it 
is important to consider this aspect of vaccination, as the design of the 
vaccine (antigens used) would determine whether or not it is likely to reduce 
colonisation or just prevent CDAD symptoms. It would be interesting to 
compare by modelling the cost-effectiveness of a vaccine that only prevents 
CDAD symptoms (toxin-targeted) to a vaccine that also prevents colonisation, 
as this would help to guide vaccine development strategies.  
 
1.7 C. difficile evolution and population biology 
1.7.1 Typing strains 
Since the discovery of C. difficile as a human pathogen a number of typing 
methods have been used to allow epidemiological studies of C. difficile to be 
carried out. Early methods relied on testing phenotypes such as antibiotic 
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resistance or serotype, but were quickly superceded by genotype-based 
methods once the technology became available. A brief description of the 
main typing methods currently in use, and their various merits are discussed 
in this section.  
1.7.1.1  PCR-ribotyping 
This method exploits the differences in length of the spacer regions of the 16S 
and 23S ribosomal RNA genes that occur in different strains. Specific primers 
are used that amplify a small number of fragments of DNA from this region 
and the banding pattern visualized by gel electrophoresis corresponds to a 
particular ribotype (Stubbs et al., 1999, Bidet et al., 1999). This has become a 
well-accepted typing system for C. difficile, particularly in Europe, exhibiting a 
useful level of discrimination for studying the macroevolution of C. difficile. 
1.7.1.2  Restriction endonuclease analysis (REA) 
Restriction enzymes are used to cut the bacterial genome at a relatively high 
frequency resulting in a large number of small DNA fragments that are 
separated on an agarose gel (Clabots et al., 1993). The complex banding 
patterns produced allow a high degree of discrimination between strains, but 
can be difficult to interpret and reproduce. REA is not widely used, therefore 
its interlaboratory reproducibility is not known.  
1.7.1.3 Pulse-field gel electrophoresis (PFGE) 
Restriction enzymes are used to cut the bacterial genome at a low frequency 
to yield large DNA fragments. These fragments are slowly separated in a 
polyacrylamide gel using repeatedly switching voltage. This enables the large 
DNA fragments to migrate through the gel, and the banding pattern visualized 
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by staining indicates the strain type sometimes referred to as a pulsovar 
(Killgore et al., 2008).  
1.7.1.4  Amplified fragment length polymorphism (AFLP) 
This technique is carried out by digesting the genomic DNA with restriction 
enzymes, followed by ligation of DNA adapters to the end of the digested 
fragments. Primers specific to these adapters are used to amplify fragments 
by PCR, and some degree of selectivity is included in the primers to limit the 
number of fragments amplified. AFLP types can be distinguished by the 
degree of similarity of the fragments amplified, usually a cut-off is determined 
and in the case of C. difficile different AFLP types are defined as having <86% 
similarity (Killgore et al., 2008).  
1.7.1.5  Multilocus variable number tandem repeat analysis (MLVA) 
MLVA is used to count the numbers of repeat alleles present at predefined, 
conserved repetitive loci in the genome by PCR amplification (van den Berg et 
al., 2007). This method produces a numerical result (code) for each strain. 
Much of the technology of this technique has been developed for forensic 
science, as it is the basis of human DNA fingerprinting. MLVA requires 
expensive equipment but is highly discriminatory and facilitates cross-
laboratory comparisons.   
1.7.1.6  Multilocus sequence typing (MLST) 
This technique relies on the sequencing of a specified number of genes 
amplified by PCR. For each gene a strain will have an allele type based on 
point mutations. The combination of the different allele types for each gene 
defines the sequence type. As the data produced is sequence data this 
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technique is ideal for data-sharing and comparison between laboratories. For 
C. difficile an MLST protocol was developed analyzing seven housekeeping 
genes (aroE, ddl, dutA, tpi, recA, gmk, and sodA) (Lemee et al., 2004). 
However, this protocol has not been widely used to type C. difficile strains. 
This may be partly due to the discovery that the ddl gene does not amplify 
from all stains, compromising the usefulness of this protocol. Also a curated 
online database was not developed for this protocol. More recently a 
reportedly more robust MLST protocol has been developed with an online 
database to facilitate comparison of data between laboratories (Griffiths et al., 
2010). Seven loci were chosen based on information available from C. difficile 
genome sequences. These genes (adk, atpA, dxr, glyA, recA, sodA, and tpi) 
were chosen as they show a significant degree of divergence across the 500 
bp, but no gaps were present and according to the 630 genome annotation 
they span housekeeping genes. This MLST typing system correlates well with 
ribotyping and it remains to be seen whether it will be widely adopted. 
1.7.1.7  slpA sequence typing (slpAST) 
slpAST relies on the sequencing of a PCR product amplified from the variable 
region of the major surface layer gene (slpA). The amino acid sequence can 
be deduced from the DNA sequence and a new type is defined as differing 
from existing types by more than 20 amino acid residues. Groups differing by 
less than 20 amino acid residues are referred to as subtypes (Kato et al., 
2005). As for MLST, sharing and comparing of sequence data makes this 
technique well suited to comparisons of strains typed in different laboratories. 
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1.7.1.8  Toxinotyping 
This method focuses on the 19kb long pathogenicity locus (PaLoc), which 
encodes tcdA and tcdB genes for the C. difficile toxins A and B along with 
three regulatory genes tcdC, R and E. In order to toxinotype two PCR 
products (one from tcdA and one from tcdB) are amplified and subjected to 
restriction digest (an RFLP-PCR method) (Rupnik et al., 1998). By reference 
to characterised strains the test strain can then be identified as belonging to a 
certain toxinotype, or if a new toxinotype is identified further analysis of the 
PaLoc is carried out. There are currently 27 defined toxinotypes. Some C. 
difficile strains produce a third toxin CDT, a clostridial binary toxin, which is 
not encoded in the PaLoC. This can be tested for by carrying out a PCR to 
amplify one of the binary toxin genes cdtB (Stubbs et al., 2000).  
1.7.2 Comparison of Typing Methods 
A study carried out in 2008 by all the main C. difficile typing laboratories 
worldwide compared these techniques in their ability to type and discriminate 
between 42 isolates of C. difficile (Killgore et al., 2008). The isolates were 
selected to include strains known to be of different subtypes by a given 
method but also closely related strains, to allow the discriminatory power of 
the techniques to be tested. All techniques were successfully able to type all 
the isolates and showed a high degree of concordance of groupings by all 
methods. The discrimination index was calculated for each technique, which 
is a mathematical description of the ability of the technique to discriminate 
between strains. The closer the value is to 1 the higher degree of 
discrimination it exhibits. The discrimination indices for the techniques tested 
ranged from 0.964 to 0.631 in the following order: MLVA, REA, PFGE, 
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slpAST, PCR-ribotyping, MLST, and AFLP. This meant that MLVA, REA, 
PFGE and slpAST could identify subtypes amongst the types determined by 
the less discriminatory techniques. All types were sufficiently discriminatory to 
detect a strain that is causing an outbreak within an institution. However, if 
intratypic discrimination is required to study the relationship between isolates 
of the same type that are temporally or geographically distinct MLVA or REA 
should be used. The final conclusion of this study was that all of these 
methods, if carried out in a laboratory with appropriate technology and 
expertise, are sufficient for detection of an outbreak strain within an institution. 
However, there is currently no method in use for strain tracking across 
institutions that exhibits intratypic discrimination with proven reproducibility 
between laboratories.  
 
It should be noted that as the cost of genome sequencing continues to fall it is 
likely that many in-depth evolution studies will employ genome sequencing 
rather than any of these typing methods. The first of such studies on C. 
difficile has been recently published (He et al., 2010), and provides 
phylogenetic information that agrees with the results of typing studies. As 
more diverse genomes are sequenced, and we improve our understanding of 
the diversity of the species it is likely that sequence-based typing methods 
(eg. MLST, slpAST) can be developed or improved to provide the optimum 
level of discrimination for typing studies. Provided these sequence-based 
typing methods are sufficiently validated they would provide a much more 
transferable and inter-lab reproducible typing method than the other methods. 
This would facilitate worldwide study of C. difficile epidemiology.  
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1.7.3 Patterns of disease transmission 
Many studies have used typing to characterise the strains present during 
outbreaks of C. difficile in hospitals (Kato et al., 2001, Muto et al., 2007). 
These studies provide information about transmission of strains within this 
environment and evidence for the need to improve or increase infection 
control measures in order to get the outbreak under control.  
 
Large-scale typing studies across regions or countries are also carried out 
with the aim of monitoring the general prevalence of different C. difficile types. 
These studies provide information about the transmission of C. difficile over 
larger geographical areas. Some studies include data from community-
acquired cases and animal isolates. Temporal information about the types 
causing disease can be ascertained if samples are collected over a long 
period of time. In the past 10 years these studies have highlighted that the 
prevalence of different C. difficile types causing disease has changed and is 
continuing to change. This has been accompanied by an increase in C. 
difficile incidence and changing clinical aspects of CDI, and therefore studies 
are also trying to address possible associations between C. difficile types and 
these changes.  
 
The most significant recent change is the emergence of outbreak-causing 
ribotype 027 strains. It was reported in 2005 that outbreaks that occurred 
between 2000 and 2003 in eight different health care facilities in the United 
States were all associated with this type of strain (REA group B1, PFGE type 
NAP1, ribotype 027), and for five of the facilities the majority of strains were 
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027 (McDonald et al., 2005). This finding was of significance because 
historically 027 was a rare type. Since the original reported ribotype 027 
strains have been isolated from outbreaks in 40 US states, Canada, most of 
Europe, Hong Kong and Japan (Kato et al., 2007, Smith, 2005, Cheng et al., 
2009, Kuijper et al., 2007, Loo et al., 2005, O'Connor et al., 2009). In English 
hospitals this ribotype became the most common type of C. difficile strains 
associated with hospital outbreaks, accounting for 41.3% of isolates collected 
nationwide in 2007-2008 (Brazier et al., 2008). A number of studies have 
found evidence that cases caused by 027 strains are associated with more 
severe disease than cases caused by other ribotypes, although not all studies 
have been able to show this (Freeman et al., 2010). There are many possible 
confounding factors such as unrecognized independent risks, temporal 
changes in the patient population, and infection control measures that make 
studies of this nature very hard to compare with confidence. It is clear that 
ribotype 027 C. difficile has spread quickly around the globe causing 
outbreaks of CDAD, but the evidence for its role in increased severity of 
CDAD is still under scrutiny.  
 
Cases of CDAD caused by ribotype 078 C. difficile strains also seem to be on 
the increase. In the Netherlands between 2005 and 2007 the proportion of 
cases associated with 078 ribotypes increased from 3 to 13% (Goorhuis et al., 
2008a). Disease severity was reported to be similar to the 027 ribotype, but 
interestingly 078 cases were more likely to be community-acquired and 
affected younger patients. As this ribotype is commonly found in pigs and 
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calves, the possible zoonotic transmission of this type of C. difficile has been 
recognized and is under investigation (Goorhuis et al., 2008b). 
 
Another ribotype, which has emerged causing outbreaks of CDAD in the past 
10 years is ribotype 017 (Drudy et al., 2007b, Kim et al., 2008). These strains 
are of particular interest as they are toxin A-negative, toxin B-positive strains. 
The prevalence of these strains had immediate significance to diagnostic 
practices, as toxin A-specific assays were common, but would obviously not 
detect these strain types. Any therapeutic strategies targeting toxin A alone 
are therefore also undesirable.   
 
Despite the presence of C. difficile types that are associated with outbreaks of 
C. difficile and the intriguing changing patterns of incidence and disease 
severity that may be associated with the evolution of particular types, a clear 
and underemphasized conclusion from C. difficile typing studies is that the 
types of strains causing CDAD at any one time and in any one place are 
remarkably diverse. A recent large study typed samples (REA and ribotype) 
from 1,111 CDAD cases from 187 sites in 16 countries that were acquired 
during a clinical trial for tolevamer (Cheknis et al., 2009). Isolates were REA-
typed and compared to 7 REA types known to have caused hospital 
outbreaks. In North America the most common type was REA B1 (ribotype 
027), accounting for around 40% of isolates. Of the other 60% of isolates, half 
were one of the other 6 types known to cause outbreaks and half were a non-
specific REA type. In Europe the most common REA type was type J 
(ribotype 001), accounting for 19% of isolates, 37% fell into the other 6 
 60 
common REA groups and 44% were a non-specific REA type. 24 samples 
were from Australia and the majority of these types were not of the well-
known outbreak types, indicating differences in the geographical distribution 
of C. difficile types. Therefore the overall diversity of C. difficile strains 
responsible for CDAD is remarkably high, and the prevalence of known 
outbreak types and emerging types is not as high as may be suggested by the 
number of studies focusing on these emerging types. The results of this study 
are summarized in Figure 1.3 
 
 
Figure 1.3 REA types of C. difficile isolates recovered from a worldwide 
clinical trial.  
Data taken from (Cheknis et al., 2009). The diversity of REA types is clear, 
with a large number of isolates (Other) not falling into any of the outbreak 
types. Geographical differences between incidences of REA types are also 
clear.  
 
1.7.4 Genomic studies 
The first C. difficile genome sequence was published in 2006 (Sebaihia et al., 
2006). This strain is known as 630, is a PCR-ribotype 012 strain with multi-
drug resistance and was isolated from a patient with severe 
pseudomembranous colitis in Zurich. It has a circular 4.29 Mb chromosome 
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and a 7.9 kb plasmid, together encoding 3679 predicted protein sequences. A 
large proportion (11%) of the genome consists of mobile genetic elements. 
The presence of these elements implies that C. difficile may have acquired an 
extensive array of its genes involved in antimicrobial resistance, virulence and 
host interaction by horizontal gene transfer.  
 
Having this reference C. difficile genome sequence enabled a PCR spotted 
microarray to be constructed, including probes for all the known genes from 
this strain 630. A broad range of 75 strains from widespread geographical 
locations isolated at different times was then tested using this microarray to 
determine levels of gene conservation across the C. difficile strain population 
and to give information about the phylogeny of strains (Stabler et al., 2006b). 
This comparative phylogenomics study revealed four distinct clades. PCR 
ribotype 027 strains fall into one clade, toxin A-negative toxin B-positive 
ribotype 017 strains fall into another clade, and there were two further clades 
containing a mixture of animal and human isolates. Ribotype 078 strains were 
all shown to fall into one of these clades, with both animal and human isolates 
clustering together, further suggesting the possibility of zoonotic transfer. 
Closely related ribotype 027 and 017 strains were from diverse geographical 
origins, providing further evidence for the transcontinental spread of these 
lineages.  
 
This microarray study also provided evidence of evolution within the 027 
strains, providing clues as to why this lineage suddenly became such a 
common CDAD-associated isolate and spread globally (Stabler et al., 2006b). 
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To follow up this finding two ribotype 027 strains were sequenced, a historic 
isolate and an isolate from a recent 027 outbreak. Three way genomic 
comparisons were carried out between these two strains and 630. Genes 
were therefore identified that were specific to the 027 lineage and that were 
specific to the recent 027 isolate, suggesting that they have been recently 
acquired and may have contributed to the increased incidence of human 
CDAD caused by this lineage (Stabler et al., 2009). Future work will aim to 
experimentally determine the impact of these identified differences on the 
virulence of C. difficile isolates.  
 
From this original microarray study only 19.7% of genes were highly 
conserved by all 75 strains, highlighting how diverse the C. difficile species is 
(Stabler et al., 2006b). A later similar comparative microarray study was 
carried out using 73 isolates from humans and animals (Janvilisri et al., 2009). 
Again the isolates could be grouped into 4 clades, with 3 of the 4 groups 
containing both human and animal isolates. From this study 16% of 630 
genes were highly conserved among all strains. This study also contained 
probes for genes from a sequenced 027 strain, to define a core gene set for 
this clade. Interestingly this study showed that some divergent genomic 
regions were conserved between strains isolated from the same host species. 
These regions may be associated with host adaptation. In both studies the 
genes common to all isolates tested (core genes) were not only house-
keeping genes, some appeared to have more complex functions and may 
represent genes that are key for infectivity and virulence of C. difficile.  
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A very recent comparative array study using in situ inkjet oligonucelotide 
synthesis to generate the probes allowed a more comprehensive set of 
probes to be used in an array (Marsden et al., 2010). This microarray 
consisted of over 41,000 probes (~10-fold more probes than previous arrays, 
which had approximately one probe per gene), mostly based on the 630 
genome sequence with an extra 631 probes covering genes present in 
sequenced 027 strains and not in 630. 94 strains were chosen for 
comparative hybridization based on selection of the most prevalent ribotypes 
from clinical isolates in the UK and Europe. This array found that 32% of the 
630 probes were conserved, higher than the previous two array studies. The 
variety of strains tested was wider, but as the density of probes used was 
much higher, variable genes such as slpA could be detected by probes 
located in their conserved regions. Therefore it seems likely that the 32% level 
of conservation estimated from this denser array is a more accurate estimate 
of conservation of genes across C. difficile strains than estimated by the PCR-
arrays. One of the aims of the study was to see if any sequence markers 
could be found that are in the 027 strains and no others. No such markers 
were found, in fact no single probe was found to be representative of just one 
ribotype. However, some genes appear to be most conserved amongst known 
outbreak-causing ribotypes (027, 001, 020, 106 and 078) and therefore may 
be associated with increased transmission and/or virulence (Marsden et al., 
2010).  
 
Further detail regarding the evolutionary relationship between different C. 
difficile isolates has come from new genome sequencing projects. A recent 
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study reported comparing the genome sequences of thirty C. difficile isolates 
(He et al., 2010). There were two aims of this study, to investigate the 
macroevolution of C. difficile as a diverse species and to investigate the 
microevolution of the ribotype 027 clade. Therefore 8 diverse isolates from 
human and animal origin were sequenced and 21 isolates from the 027 clade. 
The genome sequences of the diverse isolates were used to construct a 
phylogenetic tree (containing 630, and ribotypes 027, 001, 017, 078). Each 
ribotype was confirmed to be a distinct lineage, indicating that ribotyping is a 
good reflection of C. difficile genetic diversity. Interestingly the 078 lineage 
appeared to be highly divergent from the other lineages. Given the significant 
diversity of the C. difficile species this study concluded that it is an ancient 
bacterial species, with an estimated age of 1.1-85 million years.  
 
The phylogentic trees constructed from all these studies have confirmed that 
outbreak-causing strains have emerged independently from multiple lineages, 
suggesting that virulent strains can emerge from across the diversity of the 
species, rather than being confined to a specific pathogenic lineage. This 
suggests that certain genetic elements common to all C. difficile strains 
underlie virulence. Given our current knowledge it is likely that the incidences 
of different lineages causing disease are dynamic, and we cannot predict 
which lineages may cause future outbreaks. Therefore it may make more 
sense to try to understand the common features (core genes) of C. difficile as 
an ancient species, and how these underpin virulence, rather than focusing on 
the differences between current strains. In order for intervention strategies to 
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be successful in the long-term they must target the diversity of C. difficile 
strains, rather than specific lineages.  
 
1.8 Studying the molecular basis of C. difficile pathogenesis 
From typing and sequencing studies of different naturally occurring C. difficile 
strains, and correlations with various phenotypic assays or clinical outcomes it 
has been possible to make hypotheses as to the molecular bases of C. 
difficile virulence. However, definitive studies of the molecular basis of 
bacterial virulence rely on the ability to manipulate the pathogen at the genetic 
level and test the resulting isogenic strains for virulence. In this section the 
tools currently available for genetic manipulation and experimental models of 
C. difficile infection are discussed.  
 
1.8.1 Tools for the genetic manipulation of C. difficile 
A system for clostridial gene knock-out utilising the mechanism of group II 
intron insertion has been developed. The rules governing integration site 
specificity of mobile group II introns have been elucidated (largely base-
pairing between intron RNA and target site DNA) therefore the intron can be 
retargeted to disrupt genes of interest (Mohr et al., 2000). These constructs 
are referred to as Targetrons (Perutka et al., 2004, Karberg et al., 2001, 
Zhong et al., 2003).  A retrotranscription activiated marker (RAM) is used for 
positive selection of genomic integrants:  a resistance gene is carried by the 
group II intron, but before transfer it is interrupted by a self-splicing group I 
intron.  The process of chromosomal integration of the group II intron leads to 
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excision of the group I intron, generating a functional selectable marker in the 
group II intron integrated into the genome.  This system has been adapted to 
incorporate a promoter and selectable markers that function in the clostridia: 
resulting in the ClosTron system (Heap et al., 2010, Heap et al., 2007).  In 
proof of principle studies, ClosTron constructs were used to knock out pyrF 
and spo0A genes in C. difficile, C. acetobutylicum and C. sporogenes.   
 
The ClosTron system generates stable mutants as there are no homologous 
sequences flanking the insertion site created using this technique. Therefore 
the insertion cannot be lost by homologous recombination to revert to the 
original genotype. The only other reported method for making site-specific C. 
difficile knock-outs is the use of an unstable plasmid with a targeting region of 
homology to the gene of interest to generate single homologous crossover 
insertions in the C. difficile chromosome (O'Connor et al., 2006). The 
drawback of this method is that the recombination event that generates the 
site-specific insertion is reversible, making mutants generated by this method 
inherently unstable.  
 
An alternative to the reverse-genetics approach of making site-specific 
mutants is the forward-genetics approach of generating a library of random 
mutants and screening these for phenotypes of interest, then determining the 
mutations responsible. The advantage of the forward-genetics approach is 
that the genetic basis of a phenotype of interest can be elucidated without a 
prior assumption as to the genes involved. This year the first report of a 
system for creating a suitable library of random mutants in C. difficile was 
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published (Cartman & Minton, 2010). This system relies on the mariner-
transposon to insert randomly at TA target sites, ideal for C. difficile with its 
low G-C content. The transposon and its transposase are introduced to C. 
difficile on a unstable shuttle plasmid, such that once the transposon has 
inserted the plasmid is lost, losing the transposase from the cell, thus 
immobilizing the transposon at its insertion site. This new tool for creating 
libraries of C. difficile mutants is likely to facilitate identification of genes 
associated with phenotypes important for virulence 
 
Introducing genetic material to C. difficile via stable replicative plasmids has 
also only been possible in recent years. Stable plasmids based on the 
plasmid replicon isolated from an indigenous C. difficile plasmid pCD6 have 
been developed (Heap et al., 2009). These autonomously replicating vectors 
are transferred to C. difficile through oriT-based conjugation from E. coli donor 
strains, as there is no established method for direct transformation of C. 
difficile. These replicative plasmids allow expression of exogenous genes in 
C. difficile, over-expression of C. difficile genes and complementation of site-
specific mutants. There is currently no reported method available for 
introducing genes of interest to the chromosome of C. difficile.  
 
1.8.2 Experimental models of C. difficile infection 
Now that it is possible to make isogenic mutants and random mutant libraries 
of C. difficile experimental models of infection are required to test these 
mutants to allow the molecular basis of C. difficile virulence to be determined.  
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1.8.2.1 Hamsters  
It has long been known that hamsters are susceptible to C. difficile infection, 
exhibiting many of the symptoms observed in man, including diarrhoea, 
histological damage, colonisation of the large bowel and sporulation of the 
organism at the terminal stage of the disease (Fekety et al., 1979), and the 
antibiotic-compromised golden Syrian hamster C. difficile infection is the 
established model for acute CDAD. Hamsters are given a dose of clindamycin 
(or another antibiotic) to perturb the normal protective gut flora and 
subsequently challenged with C. difficile. Typically toxigenic C. difficile 
infection is lethal within a few days and time to death is commonly used as a 
measure of virulence (Razaq et al., 2007, Sambol et al., 2001). Recent 
refinement of the model uses telemetry chips to monitor movement and body 
temperature of the hamsters, allowing the animals to be culled prior to death, 
giving the experiments a more humane endpoint whilst also providing extra 
scientific data regarding the course of infection (Douce & Goulding, 2010).  
The lethality is due to hamsters being very sensitive to the C. difficile toxins. 
Non-toxic C. difficile strains asymptomatically colonise hamsters, and have in 
fact been used to protect against colonisation with toxic C. difficile strains, 
indicating that the symptoms observed are primarily toxin-mediated (Borriello 
& Barclay, 1985, Merrigan et al., 2009, Wilson & Sheagren, 1983). Therefore 
this model has been extensively used to model the acute phase of C. difficile 
infection where toxins are key virulence determinants.  
 
The large number of reported studies using the hamster model can be 
grouped into three main categories; studies evaluating preventative or 
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therapeutic interventions, studies comparing different C. difficile isolates, and 
studies comparing isogenic C. difficile mutants to determine the role of C. 
difficile genes in virulence. This first category includes pre-clinical vaccination 
experiments (Torres et al., 1995, Giannasca et al., 1999), evaluation of 
antibiotics in the induction (Merrigan et al., 2003b, Larson & Borriello, 1990) 
and treatment of CDAD (Anton et al., 2004, Ochsner et al., 2009), evaluation 
of probiotics and passive immunization strategies (Kink & Williams, 1998, van 
Dissel et al., 2005). Studies comparing naturally occurring C. difficile isolates 
have shown that there are significant differences in the virulence and 
pathology caused by different isolates, these sometimes correlate with clinical 
virulence trends, however from these studies alone it is not clear what the 
molecular basis are for the differences between isolates (Delmee & Avesani, 
1990, Sambol et al., 2001, Razaq et al., 2007, Goulding et al., 2009). Given 
the recent development of C. difficile genetic manipulation techniques there 
only three reported studies using the hamster model to compare isogenic 
mutants of interest. (Lyras et al., 2009), (Kirby et al., 2009, Kuehne et al., 
2010), findings of these studies are discussed in the relevant virulence factor 
sections below.  
 
The hamster model has proved very useful in studying the acute toxin-
mediated stage of disease. However it is desirable to have animal models, 
which can be used to study other types of C. difficile infection such as chronic 
infection, asymptomatic carriage and transmission of infection. These non-
acute, non-fulminant types of infection are very relevant to human infection 
and improving our understanding of these processes is important for 
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improving our ability to manage C. difficile infection. Additionally, there are 
limited resources available to study host-aspects of hamster infections such a 
knock-out animals and cell lines. Therefore, other animal models are being 
pursued.  
1.8.2.2 Mouse models 
It has long been known that C. difficile can be isolated from mice, suggesting 
that mice can be colonised by C. difficile (Itoh et al., 1986). Models of acute 
infection in mice have been developed either using gnotobiotic (germ-free) 
mice or by antibiotic treatment of conventional mice prior to C. difficile 
exposure (Wilson et al., 1986, Chen et al., 2008). Such models can be used in 
a similar way to the acute hamster model of infection. In a recently described 
model five different antibiotics were used to treat mice prior to C. difficile 
exposure. Disease severity was shown to vary from minimal symptoms to 
fulminant disease, associated with the dose of C. difficile used to infect the 
animals (Chen et al., 2008). This spectrum of disease more closely mimics 
human disease and may therefore be an improvement on the fulminant-only 
models of infection.  
 
Another recent study showed that mice can be asymptomatically colonised 
with C. difficile establishing a carrier state that persists for months. Antibiotic 
treatment with clindamycin leads to a high number of spores being shed in the 
faeces, referred to as a super-shedder state. Although no overt symptoms are 
seen in these animals, they do exhibit mild inflammation of the intestine, 
accompanied by disruption of the tight junctions, microvillus effacement and 
the transient production of an inflammatory exudates in the faeces. After 
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cessation of antibiotic treatment the number of C. difficile spores in the faeces 
decreases, but if a subsequent dose of clindamycin is administered animals 
return to the super-shedder state (Lawley et al., 2009a). This is reminiscent of 
relapsing infection in humans. This model demonstrates active colonisation of 
mice by C. difficile without acute symptoms, and is therefore a valuable model 
for studying the molecular mechanisms underpinning colonisation. The power 
of using a mouse model was further demonstrated in this study by the use of 
a knock-out mouse line. Myd88(-/-) mice with impaired innate immune 
function were shown to develop severe intestinal disease upon challenge with 
C. difficile that was often fatal (Lawley et al., 2009a). The availability of knock-
out mice will allow investigation into the role of host factors in the response to 
C. difficile infection.  
1.8.2.3 Piglet model 
A recent study investigated the use of piglet models of infection, as piglets are 
known to be susceptible to C. difficile infection (Steele et al., 2010). Using 
gnotobiotic piglets C. difficile was shown to cause a range of symptoms from 
chronic diarrhoea to acute lethal diarrhoea, dependent of the age of the 
piglets and the dose of C. difficile given. This model of infection therefore also 
allows investigation of colonisation, providing a useful alternative to the acute 
hamster model. 
1.8.3 In vitro gut model 
Study of C. difficile based on in vitro growth in faecal emulsions was first used 
in the mid-1980s to demonstrate inhibition of C. difficile growth by faecal 
emulsions. A continuous flow culture system (Freter et al., 1983) was also 
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used to demonstrate the suppression of pathogens including C. difficile by 
normal hamster flora (Wilson & Freter, 1986). This system has been further 
developed into a three stage compound continuous flow model, with the 
transit time, pH, and metabolic composition of each stage mimicking the 
human gut (Macfarlane et al., 1998). This model has been used to investigate 
the effects of dietary input such as prebiotic non-digestible oligosaccharides 
(Hopkins & Macfarlane, 2003); the elimination of spores by antibiotic 
administration (Baines et al., 2005); and the effects of antibiotic administration 
on gut microflora composition and on C. difficile proliferation and toxin 
production (Freeman et al., 2003, Baines et al., 2005, Freeman et al., 2005) 
including C. difficile strain comparisons (Baines et al., 2006, Freeman et al., 
2007).  Overall this in vitro model system allows designed experimentation 
into the interactions of complex ecosystems under a controlled environment. 
However, in this model there is obviously no interaction between bacteria and 
host cells or the immune system.  
1.9 C. difficile virulence factors 
As previously discussed, genetic manipulation of C. difficile has only been 
possible in the last few years, and therefore most of our knowledge of C. 
difficile virulence factors does not come from definitive studies of isogenic 
mutants tested in animal models. However, other types of studies have 
yielded information about C. difficile virulence factors, and our current 
understanding of the molecular basis of C. difficile virulence is summarized in 
this section.  
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1.9.1 Toxins 
It has been known for some time that some strains of C. difficile produce two 
related UDP-glycosylating toxins, known as toxin A and toxin B (TcdA and 
TcdB) (von Eichel-Streiber et al., 1992). These two toxins are encoded in a 
pathogenicity locus (PaLoc) typically 19.6kb in size, which also encodes 
protein regulators of their expression (Braun et al., 1996). A diagram of the 
prototypical PaLoc is shown in Figure 1.4. As mentioned previously, the 
PaLoc varies between strains, with some strains not having a PaLoc at all 
(non-toxic strains), others having only tcdB, as well as many other variable 
regions of the PaLoc (Rupnik, 2010). Given that non-toxic strains do not 
cause symptomatic disease and are generally regarded as being non-
pathogenic, these toxins are key C. difficile virulence factors, and have 
therefore been extensively studied.   
 
Figure 1.4 Diagrammatic representation of the C. difficile pathogenicity 
locus (PaLoc).  
The five proteins encoded are the two major toxins TcdA and TcdB, the 
positive regulator (alternative sigma factor) TcdR, the negative regulator TcdC 
and the putative holin TcdE. Diagram taken from (Rupnik et al., 2005). 
 
1.9.1.1 Toxin structure and function 
TcdA and TcdB are members of the large clostridial glucosylating toxin family, 
which includes toxins from many other clostridial species. For example, the 
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hemorrhagic and lethal toxins from Clostridium sordellii and the alpha toxin 
from Clostridium novyi. Toxins in this family are very large, 250-308 kDa in 
size and have a high degree of sequence identity (ranging from 36% tp 90%). 
A four-domain structure of these toxins, known as the ABCD model has been 
suggested based on many structural and biochemical studies (Jank & 
Aktories, 2008). In this model the A (activity) domain at the N-terminus 
confers glucosyl transferase activity. Adjacent to this is the C (cutting) domain, 
which is a cysteine protease domain that mediates auto-cleavage of the toxin. 
In the middle of the protein is the D (delivery) domain, which contains a 
hydrophobic region and is thought to mediate translocation of the toxin across 
host cell membranes. At the C-terminus the B (binding) domain consists of 
polypeptide repeats, which mediate binding of toxin to host cells. For TcdA 
this binding region has been shown to bind to a trisaccharide (Krivan et al., 
1986, Greco et al., 2006), and it is therefore thought that TcdA binds to host 
cells via interactions with glycosylated ligands. TcdA and TcdB act in the 
cytosol of host cells, glucosylating small GTPases including Rho, Rac and 
Cdc42. The GTPases are glucosylated at a specific threonine residue, which 
prevents them adopting their active GTP-bound conformation thus causing 
inactivation of the GTPases and blocking of signal transduction pathways. 
This leads to actin condensation, cell rounding and eventually cell death. In 
the gut this leads to impairment of tight junctions, resulting in fluid 
accumulation and extensive damage to the integrity of the epithelium (Voth & 
Ballard, 2005).  
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1.9.1.2 Regulation of toxin expression 
Toxin production is under transcriptional regulation. Early studies showed that 
toxins are not produced during exponential growth phase, nor in the presence 
of glucose, but are expressed in stationary phase (Dupuy & Sonenshein, 
1998). The TcdR protein encoded upstream of tcdB in the PaLoc is an 
alternative RNA-polymerase sigma-factor, which is required for the expression 
of TcdA and TcdB from their own promoters (Mani & Dupuy, 2001). 
Homologous proteins are found to regulate toxin expression in a number of 
other Clostridia, and these sigma-factors constitute their own subgroup of 
sigma-factors (Dupuy & Matamouros, 2006). Some of these sigma factors are 
conserved to a high enough level that they are functionally interchangeable 
(Dupuy et al., 2006). TcdR expression is responsive to the cellular growth 
phase and constituents of the growth medium, and it stimulates its own 
synthesis. It is therefore thought that toxin expression level is regulated 
indirectly by the regulation of TcdR expression level in response to 
environmental signals (Mani et al., 2002). Growth temperature has also been 
found to control the expression of TcdA and TcdB, dependent on TcdR 
(Karlsson et al., 2003). One study reported that quorum sensing may play a 
role in regulation of toxin production (Lee & Song, 2005), but the mechanistic 
basis of this regulation has not been investigated. There is evidence that the 
upregulation of toxin production is accompanied by the upregulation of 
proteins involved in alternative energy metabolism and sporulation (Karlsson 
et al., 2008), and it is therefore possible that TcdR plays roles in regulation of 
other proteins as well as the toxins. The TcdC protein encoded downstream of 
the toxin genes is a negative regulator of toxin expression, which destabilizes 
 76 
the TcdR-containing RNA-polymerase holoenzyme, inhibiting transcription of 
the toxin genes (Matamouros et al., 2007). TcdC is expressed during 
exponential phase, ensuring toxins are not expressed during this growth 
phase (Dupuy et al., 2008). The presence of a positive and negative regultor 
of TcdA and TcdB transcription in the PaLoc is likely to allow tight regulation 
of toxin production during infection. It will be interesting to see the effects of 
mutations in these genes on virulence in animal models of infection now that 
the genetic technology for production of isogenic mutants is available.  
1.9.1.3 Contributions of toxins to C. difficile virulence 
Two recent studies have reported testing toxin A and toxin B negative 
isogenic mutants of C. difficile 630 in the hamster model of infection. One 
study showed that toxin B is essential for virulence, but toxin A is not (Lyras et 
al., 2009). The other study showed that either toxin A or toxin B alone can 
cause fulminant disease in the hamster model, with only a toxin A and toxin B 
double-mutant strain being avirulent (Kuehne et al., 2010). In earlier studies 
utilizing purified toxin preparations to challenge hamsters toxin A alone was 
shown to elicit all the symptoms of CDAD, and toxin B did not cause any 
symptoms unless there was prior intestinal damage or toxin A was co-
administered (Lyerly et al., 1985). A number of possible explanations for these 
differences have been suggested (Carter et al., 2010). The isolation of natural 
isolates expressing only toxin B that cause the same spectrum of disease as 
toxin A and B expressing strains provides some evidence that toxin B is also 
key to virulence in humans (Drudy et al., 2007a). The relative contribution of 
these two toxins to virulence has obvious implications for diagnostic and 
vaccine design. It is now standard diagnostic practice to detect toxin B, as 
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toxin A is lacking in some virulent strains. Further work using current genetic 
manipulation technology with diverse C. difficile strains in a variety of animal 
models is required to resolve the relative importance of these two toxins in 
disease.  
1.9.1.4 Binary toxin 
Some C. difficile strains produce an actin-specific ADP-ribosylating binary 
toxin encoded by cdtA and cdtB, which are not found in the PaLoc (Perelle et 
al., 1997). These binary toxin genes are tightly regulated by CdtR, which is 
encoded next to cdtA/B in a locus named CdtLoc, which is found inserted into 
the same position in all strains analysed so far (Carter et al., 2007). Binary 
toxin ADP-ribosylates G-actin and inhibits actin polymerization, which induces 
a redistribution of microtubules. It has been shown that this can increase the 
adherence of C. difficile to human cells in vitro (Schwan et al., 2009). The 
contribution of binary toxin to the overall virulence of C. difficile strains 
remains to be determined.  
1.9.2 Sporulation factors 
C. difficile produces spores, which can survive outside the colonic 
environment for long periods of time and are therefore responsible for long-
term contamination of the environment with viable C. difficile organisms. 
Sporulation is therefore key to transmission of C. difficile infection, and factors 
important to the sporulation process can be considered virulence factors. 
Comparative genomics of the well-characterised sporulation processes of 
Bacillus subtilis and other Clostridial sp. (Paredes et al., 2005) allows 
identification of putative factors in the C. difficile sporulation process.  
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The master regulator of sporulation SpoOA is well conserved across spore 
forming species and the C. difficile gene has been shown to be essential for 
sporulation in knock-out studies (Heap et al., 2007, Underwood et al., 2009). 
ClosTron knock-out technology has also been used to confirm the role of a 
histidine kinase (CD2492) in sporulation that was identified as playing a 
putative role by bioinformatic analysis (Underwood et al., 2009). Interference 
of the sporulation initiation pathway by gene knock-out has been shown to 
reduce toxin production, indicating that these two processes are linked in the 
C. difficile cellular regulation networks (Underwood et al., 2009). Such 
interlinking of sporulation and virulence signaling networks has been observed 
in other spore-forming bacterial species (Perego & Hoch, 2008). Now that it is 
possible to genetically manipulate C. difficile, future studies are likely to 
further unravel the role of factors involved in sporulation that can be identified 
by bioinformatic comparisons. Sporulation-deficient members of random 
mutant libraries are likely to throw up other genes involved. Such knowledge 
may facilitate development of therapeutics that can inhibit sporulation and 
perhaps also toxin production, thereby reducing the virulence of C. difficile.  
 
The spore proteome has recently been described (Lawley et al., 2009b). This 
information will allow the role of proteins known to be present in the spores to 
be investigated by genetic studies. As well as signaling molecules such as 
SpoOA, there will be other classes of proteins that are key to the production 
and integrity of spores. Identification of these proteins will facilitate the rational 
development of therapies and disinfectants.  
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1.9.3 Germination factors 
Ingestion of C. difficile spores leads to germination of spores and subsequent 
vegetative proliferation of C. difficile to establish a C. difficile infection. 
Germination is therefore a pre-requisite of colonisation and factors required 
for germination can therefore be considered as virulence factors. Preventing 
germination in the host is an attractive strategy for intervention as it 
represents a natural bottleneck in the infection process (Nakamura et al., 
1985). Also, inducing germination in the environment can aid 
decontamination, as it makes the organism much more susceptible to 
antimicrobials (Wheeldon et al., 2008b), therefore germination induction could 
improve the efficacy of cleaning procedures.  
 
It has long been known that bile salts sodium taurocholate and sodium 
cholate stimulate spore germination (Wilson et al., 1982, Wilson, 1983). More 
recently glycine was shown to act as a co-germinant with these cholate 
derivatives (Wheeldon et al., 2008a, Sorg & Sonenshein, 2008), and kinetic 
studies suggest that there are distinct germination receptors for taurocholate 
and glycine (Ramirez et al., 2010) although the identity of germination 
receptors is not yet known. Interestingly, it has also been shown that 
deoxycholate, a metabolite of cholate produced by the normal intestinal flora 
induces germination of C. difficile spores but inhibits growth of vegetative cells 
(Sorg & Sonenshein, 2008). This generated the hypothesis that the 
metabolism of bile salts by the normal gut flora is one mechanism by which 
the normal flora protects against C. difficile infection, and experiments with 
antibiotic-treated and untreated mice cecal extracts support this hypothesis 
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(Giel et al., 2010). Future studies using C. difficile mutants aim to identify the 
germination receptors, and characterise how germinants interact with them.  
 
After germination has been triggered the spore cortex must be broken down, 
and spore cortex lytic enzymes responsible for this have been identified in B. 
subtilis and C. perfringens. Homologues of these lytic enzymes are present in 
the C. difficile genome and by using ClosTron mutagenesis a C. difficile 
enzyme SleC has been shown to be essential for germination of spores in 
response to taurocholate (Burns et al., 2010). SleC inhibition is therefore a 
strategy that could prove efficacious in preventing C. difficile infection, whilst 
SleC activation could aid disinfection of spore-contaminated environments. 
The only other germination factor that has been experimentally identified is 
cspBA, which is a homolog of a germination-specific protease known to be 
essential for spore germination in C. perfringens. The importance of this gene 
was determined by screening a random mutant library for 
sporulation/germination deficient mutants (Cartman & Minton, 2010). Many 
other genes of importance to sporulation and germination are likely to be 
identified this way now that the technology for making libraries is available, 
providing new targets for therapeutic intervention.  
1.9.4 Colonisation factors 
Successful colonisation of the gut requires interactions between C. difficile, 
the host, and the intestinal flora including functions such as adhesion to the 
epithelium, micro-colony formation, immune evasion, immune manipulation, 
inhibition of other bacterial species and antibiotic resistance. Therefore it is 
postulated that a wide variety of factors can be classified as colonisation 
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factors. The factors required for successful colonisation of the gut by C. 
difficile are as yet largely uncharacterised, but I will summarize in this section 
factors that have been characterised that are likely to play a role in this 
process.  
1.9.4.1 Antibiotic resistance 
The fact that C. difficile is resistant to a large number of antibiotics (Delaney, 
2007) provides it with a competitive advantage over susceptible organisms 
when colonising a host undergoing antibiotic therapy. Therefore factors 
conferring resistance to antibiotics can be considered virulence factors. In 
many cases these virulence factors are transposon-mediated, such as ermB-
conferred erythromycin resistance carried on Tn5398 (Sebaihia et al., 2006) 
and chloramphenicol resistance carried on Tn4453 (Lyras et al., 2004). 
However, sometimes antibiotic resistance is conferred by point mutation, such 
as mutations in gyrB conferring resistance to fluoroquinolones (Drudy et al., 
2006b). Fluoroquinolone resistance is spreading at an alarming rate, having 
been found in a large number of ribotypes (Spigaglia et al., 2008). In general it 
is important to monitor antibiotic resistance in C. difficile, as changes in 
resistance will need to be accompanied by appropriate changes in clinical 
practice to reduce the effects of antibiotic resistance on increasing C. difficile 
virulence.  
1.9.4.2 Para-cresol production  
It has been shown that C. difficile can produce para-cresol, which is a 
phenolic compound with bacteriostatic properties (Dawson et al., 2008). It has 
been suggested that following antibiotic treatment and C. difficile infection of 
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the gut, para-cresol production by C. difficile inhibits re-colonisation of the gut 
by other bacteria (Dawson et al., 2008). The importance of para-cresol 
production to C. difficile virulence remains to be tested by genetic studies.  
1.9.4.3 The C. difficile S-layer 
C. difficile produces an S-layer, a paracrystalline proteinaceous array that 
completely coats the bacterial cell wall.  The S-layer is primarily composed of 
two proteins, the high molecular weight S-layer protein (HMW SLP) and the 
low molecular weight (LMW) SLP, which are cleavage products of the SlpA 
precursor (Calabi et al., 2001b). Cleavage of the SlpA precursor is carried out 
by the cysteine protease Cwp84 (Kirby et al., 2009, Dang et al., 2010). Cwp84 
is essential for cleavage of SlpA, and C. difficile exhibits a marked growth 
defect in vitro upon knock-out of cwp84 (Kirby et al., 2009). Interestingly, this 
growth defect can be compensated for by addition of trypsin to the growth 
medium as trypsin can cleave the SlpA precursor. Despite its clear in vitro 
phenotype the cwp84 knock-out was found to exhibit the same level of 
virulence as the wild-type strain in the hamster model of infection, but the role 
of host proteases in compensating for the lack of cwp84 in vivo was not 
investigated (Kirby et al., 2009). Therefore it is not clear whether SlpA 
cleavage is essential for C. difficile virulence, although in the hamster model 
of infection Cwp84 is not essential for virulence.   
 
The LMW and HMW SLP form a stable non-covalently associated complex, 
the low-resolution structure of which was recently solved by small-angle X-ray 
scattering (Fagan et al., 2009). The HMW SLP is thought to attach to the 
underlying cell wall via three copies of a putative cell wall binding domain 
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(Pfam domain PF04122).  The LMW SLP is highly immunogenic and exposed 
to the environment.  It is extremely variable between strains, with over 20 
distinct sequences identified to date (Calabi & Fairweather, 2002b, Kato et al., 
2005, Karjalainen et al., 2002a, Eidhin et al., 2006). A high-resolution 
structure of the LMW SLP shows that the residues conserved across strains 
form a core, likely reflecting functional conservation, with the variable regions 
mostly confined to loops, allowing for immune evasion (Fagan et al., 2009). 
Based on this knowledge of SlpA a model of C. difficile cell wall organization 
has been proposed and is illustrated in Figure 1.5. 
 
Figure 1.5 Model of the cell wall of C. difficile.  
A. The HMW SLP (light grey) LMW SLP (dark grey) complex is shown as a 
layer above the peptidoglycan. Other minor cell wall proteins (CWPs) are 
shown as white two-lobed structures. Cell wall polymers are shown as black 
bars.  B. SlpA undergoes post-translational processing to cleave off the signal 
peptide (black triangle) and is cleaved by Cwp84 at a specific site (open 
triangle) to generate the mature LMW and HMW SLP proteins.  Figure taken 
from (Fagan et al., 2009). 
 
Purified HMW SLP protein has been shown to bind to human and mouse 
intestinal epithelium and anti-HMW SLP antibodies block adherence to HEp2 
cells (Calabi et al., 2002). However, our current understanding of the 
arrangement of the S-layer proteins suggests that the HMW SLP may not be 
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directly exposed to the host epithelium (Fagan et al., 2009), making the 
relevance of these binding studies unclear. SLPs have also been shown to 
induce inflammatory and regulatory cytokines in human monocytes and 
dendritic cells, suggesting that during infection they may interact with the 
immune system (Ausiello et al., 2006). The role(s) of SlpA in virulence has not 
yet been definitively addressed by knock-out studies, and this may be 
particularly challenging if SlpA is essential for C. difficile growth. Therefore, 
although it appears likely that SlpA will play key roles as a virulence factor, 
these roles are yet to be definitively elucidated.  
1.9.4.4 The C. difficile CWP family 
In the genome of 630, 28 paralogs of the HMW SLP have been identified 
(Sebaihia et al., 2006). This family is known as the C. difficile cell wall protein 
(CWP) family. All the members contain two or three copies of the putative cell 
wall binding domain (PF04122) in addition to a second unique domain that is 
proposed to specify function. The C. difficile CWP family is illustrated in Figure 
1.6. Given their homology to the HMW SLP the CWPs may contribute to the 
S-layer two-dimensional packing interactions, however the interactions 
between these proteins on the cell surface have not been investigated. 
Transcriptomic and proteomic studies have shown several of these proteins to 
be expressed in vitro (Wright et al., 2005, Emerson et al., 2008). Antibodies 
against some of these proteins are found in serum of infected patients (Wright 
et al., 2008b) implying at least some of the CWPs are expressed in vivo 
during infection and exposed to the host immune system.   
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The cysteine protease Cwp84 responsible for the cleavage of SlpA (as 
discussed above) is a member of this CWP family. Biochemical studies using 
purified recombinant Cwp84 suggested a role for Cwp84 in the degradation of 
host extracellular matrix proteins, and proposed this as a virulence factor that 
may degrade host tissue integrity (Janoir et al., 2007). However, as 
mentioned above a recent study using a Cwp84 knock out strain did not show 
a key role for Cwp84 in virulence in the hamster model of infection (Kirby et 
al., 2009). More insight into the role of Cwp84 may come from studying these 
mutants in different models of infection as the acute nature of the standard 
hamster model of infection may not be very sensitive in detecting colonisation 
phenotypes. 
 
Cwp66 is another member of the CWP family whose function has been 
investigated. It has been shown to be expressed on the cell surface and the 
C-terminus of the protein is variable between strains (Waligora et al., 2001b). 
Antibodies raised against recombinant Cwp66 were shown to inhibit adhesion 
of C. difficile to a mammalian cell line, and therefore it was suggested that 
Cwp66 is an adhesive virulence factor (Waligora et al., 2001a). Given the 
recent advances in genetic technology this work needs to be followed up with 
knock-out studies to determine whether or not Cwp66 does pay an important 
role in C. difficile adhesion to host cells and overall virulence.  
 
There is no other published work on the CWP family, other than on CwpV 
(Emerson et al., 2009), which has been the focus of my PhD. CwpV will be 
introduced in the next section.  
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Figure 1.6 Diagrammatic representation of the C. difficile CWP family.  
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1.9.4.5 Other cell surface colonisation factors 
A 68 kDa protein expressed on the surface of C. difficile, but not part of the 
CWP family has been named a fibronectin binding protein (Fbp68) based on 
biochemical detection of interactions between this protein and fibronectin 
(Hennequin et al., 2003). The relevance of this finding to C. difficile virulence 
has yet to be determined with targeted knock-out studies.   
 
C. difficile has been shown to be motile in swimming assays due to the 
presence of flagella (Tasteyre et al., 2000a). The flagellin gene fliC has been 
shown to be variable across C. difficile strains (Tasteyre et al., 2000b). The 
flagellin proteins have been shown to be glycosylated, and across strains 
there also appears to be diversity in the flagellar biosynthetic locus with 
respect to glycan biosynthesis (Twine et al., 2009). The fliD gene encoding 
the flagellar cap has however been shown to be well conserved across C. 
difficile strains (Tasteyre et al., 2001b). Flagella from a wide range of bacteria 
have been shown to be important as colonisation and virulence factors. 
Recombinant C. difficile flagellar subunits FliC and FliD, and crude flagellar 
preparations have been shown to bind to mouse mucus. Recombinant FliD 
was also shown to bind to a mammalian cell line. Flagellated strains have 
been shown to exhibit increased adherence to mouse tissue than non-
flagellated strains, although there is no clear difference in the overall 
colonisation of germ-free mice between flagellated and non-flagellated strains 
(Tasteyre et al., 2001a). These comparisons were carried out using strains of 
the same serogroup that did or did not express flagella. The role of flagella in 
C. difficile colonisation and virulence could now be further investigated using 
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isogenic mutants, as this may provide a clearer picture. Testing such mutants 
in animal models with a gut flora, rather than germ-free mice, may also 
provide more relevant information as to the role of flagella in C. difficile 
virulence.  
 
A complete set of genes encoding putative type IV pili is present in the 
genomes of 630 and the ribotype 027 strain R20291. In many pathogens, type 
IV pili are involved in aspects of pathogenesis such as motility and adhesion 
(Mattick, 2002). Using antibodies against recombinant PilA proteins pili-like 
structures on the surface of C. difficile in close association with host tissues 
have been visualised in the hamster model of infection using immuno-gold 
electron microscopy (Goulding et al., 2009). This suggests that type IV pili are 
expressed in vivo and may be important colonisation factors, but further work 
is required to determine the role of type IV pili in C. difficile infection.  
 
1.10  The C. difficile cell wall protein CwpV  
For my PhD I have studied a member of the CWP family, CwpV. This is the 
largest member of the CWP family encoded in the 630 genome (see Figure 
1.6). Initial characterisation of CwpV had been carried out prior to the start of 
my project, which identified this protein as an interesting candidate for further 
study. Here I summarise the preliminary findings that led into my project.  
1.10.1 The cwpV gene in C. difficile 630 
CwpV (CD0514, Cwp15) is a paralogue of the HMW-SLP. The cwpV gene is 
not situated in the slpA gene cluster, where many of the other CWPs are 
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situated (Calabi et al., 2001b).  An N-terminal signal sequence is predicted by 
SignalP 3.0 (Bendtsen et al., 2004).  In 630 the cwpV gene encodes a 
predicted protein of 167 kDa consisting of three distinct domains:  
(1) An N-terminal HMW-SLP homology region incorporating three copies of 
the PF04122 motif (putative cell wall binding domain); (2) A region of 
unknown function terminating in a serine-glycine-rich flexible linker;  (3) Nine 
repeats of 120 amino acids These repeats are almost perfect copies of one 
another with the exception of the first repeat, which is more divergent. A 
cartoon representation of the 630 CwpV protein is shown in Figure 1.7. 
 
Figure 1.7 The CwpV protein in C. difficile strain 630.  
Cartoon representation of the CwpV protein from 630. The predicted signal 
peptide is shaded black. The three Pfam04122 domains are shaded grey. The 
domain of unknown function is white. The serine-glycine-rich linker is pink. 
The nine repeats are shown in blue.  
 
The CwpV protein has been previously detected in the cell wall of 630 (Wright 
et al., 2005), and is annotated as a cell surface putative 
haemagglutinin/adhesin protein (Sebaihia et al., 2006). This is due to some 
weak homology of the repetitive domain to proteins exhibiting these functions. 
No Pfam domains are detected in the region of unknown function or the 
repeat domains. 
1.10.2 CwpV C-terminal variability across strains 
All 75 strains so far tested by microarray contain one copy of the N-terminal 
cell wall binding domain of CwpV, but the C-terminal repeat region is not well-
conserved (Stabler et al., 2006b). The cwpV genes from a number of different 
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strains have been sequenced. All cwpV genes characterised encode 4-9 
repeating units of between 79-120 amino acids at the C-terminus of the 
protein. These repeating units can be grouped into 5 “types” based on 
differences in amino acid sequences of the repeating units. Some strains 
examined exhibit a mosaic-like repeat structure containing two different types 
of repeat. A diagrammatic representation of these five types is shown in 
Figure 1.8.  
 
 
Figure 1.8 Sequence variation of CwpV across C. difficile strains.  
The N-terminus up to the end of the serine-glycine-rich linker is conserved 
across diverse C. difficile strains. Different CwpV C-terminal repeat types are 
shown in different colours (type I – blue; type II - yellow; type III – green; type 
IV – red; type V – purple).  
 
Therefore cwpV is a highly variable gene between C. difficile strains, encoding 
CwpV with a conserved N-terminus and a variable C-terminus. The 
significance of this C-terminal variation to CwpV antigenicity and function had 
not been investigated when I started this study. 
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1.10.3 CwpV is expressed in a phase variable manner in 630 
CwpV is expressed on the bacterial surface in a phase variable manner. 
Antibodies raised against the Type I repeats (anti-CwpVrptI), which are those 
found in 630, were used to show that expression of CwpV within a clonal 
population of lab-cultured 630 is only detectable in a small proportion of cells. 
Evidence for the phase variable expression of CwpV in 630 is shown in Figure 
1.9. 
 
Figure 1.9 Detection of CwpV phase variable expression.  
A. A clonal population of C. difficile 630 was labelled with anti-CwpV (green) 
and anti-HMW SLP (red) antibodies for fluorescent microscopy. Only a 
minority of cells labelled with the anti-CwpV antibody, indicative of phase 
variable expression of CwpV. B. Flow cytometry analysis of 630 stained with 
anti-CwpV antibody. 7.62% of cells are labelled, representing the CwpV-
expression population. C. Analysis of gold-labelled anti-CwpV stained cells by 
electron microscopy. This confirms that only some cells are labelled and that 
in those cells CwpV is surface expressed.  
 
1.10.4 Mechanism of CwpV phase variation 
This phase variation has been shown to be mediated by inversion of 195 bp 
flanked by imperfect 21 bp inverted repeats (IRs). The inversion region, 
referred to as the cwpV switch, is located approximately 60 bp upstream of 
the translational start codon. The organization of this region in 630 and PCR 
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evidence of the inversion of the cwpV switch in a number of C. difficile strains 
is shown in Figure 1.10. The repeat sequence has not been found at any 
other location in the C. difficile genome sequences available. Therefore it 
appears that this switch only controls the expression of CwpV. 
 
The mechanism by which one orientation results in expression of CwpV (ON) 
and one orientation precludes expression of CwpV (OFF) had not been 
determined at the start of my project. The IRs flanking the inversion region are 
characteristic of substrates for site-specific recombinases. The identity of the 
recombinase(s) responsible for catalysis of the inversion was not known at the 
start of my project. In previously studied systems where phase variation is 
mediated by site-specific recombination the inversion region either contains 
the promoter or is present in the coding region of the gene (van der Woude & 
Baumler, 2004). In cwpV the inversion region is upstream of the coding region 
and therefore inversion must mediate phase variation either by inverting the 
promoter or by a novel mechanism.  
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Figure 1.10 The cwpV switch.  
A. Diagram of the location of the cwpV switch upstream of the cwpV gene in 
630. The sequences of the IRs (LIR and RIR) are shown, with the perfectly 
repeated sequence underlined. The locations of the ribosome binding site 
(RBS) and ATG start codon are also shown. B. Orientation-specific PCR 
using primers NF823 and NF825 (ON) or NF826 (OFF) allows detection and 
distinction between the two orientations of the cwpV switch. C. Orientation 
PCR analysis of a panel of C. difficile strains detects both orientations of the 
cwpV switch in all strains tested, with the exception R8366, which carries a 
2bp deletion in the LIR.  
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1.10.5 Function of CwpV 
Despite discovery of the unusual regulation of CwpV expression, previous 
work had given little insight into CwpV function. The 630 cwpV gene is 
annotated as a cell surface putative haemagglutinin/adhesin protein (Sebaihia 
et al., 2006). In general bacterial pathogens are well known for expressing 
surface localised and secreted proteins containing repetitive sequences. S. 
aureus expresses fibronectin binding proteins (FnBPA) (Jonsson et al., 1991), 
clumping factor (ClfA) (McDevitt & Foster, 1995) and Protein A (Sjodahl, 
1977), which all contain repetitive sequences that are involved in binding to 
host cellular components. Streptococcus pyogenes M protein contains 
repeats that mediate binding to fibronectin (Hollingshead et al., 1986). The 
family of large clostridial toxins (von Eichel-Streiber et al., 1996) also contain 
repetitive sequences in their C-terminal domains that mediate binding to host 
cell receptors. The presence of multiple repeats in these proteins increases 
the avidity of binding to the host receptor (Ingham et al., 2004). Given the 
repetitive nature of CwpV it was postulated that it may have a ligand-binding 
function, however no experimental evidence supporting this hypothesis had 
been obtained at the start of my project.  
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1.11  Project Aims  
The current understanding of the molecular basis for C. difficile pathogenesis 
is limited. A better understanding of C. difficile surface proteins and the roles 
they play during host colonisation may aid development of interventions that 
aim to reduce or prevent colonisation of hosts by C. difficile. 
 
Observation of phase variable expression of CwpV, the finding that this 
regulatory mechanism appears to be conserved across a diverse set of C. 
difficile strains, and the variation of CwpV repeat domains exhibited by 
different strains of C. difficile prompted a detailed molecular study into CwpV 
regulation, expression, strain-strain variation and function.  
 
The major aims for this project were: 
1. To characterise the molecular mechanism responsible for CwpV phase 
variation 
2. To identify the site-specific recombinase(s) required for inversion of the 
cwpV DNA switch 
3. To study CwpV protein processing and expression in the S-layer 
4. To assess the level of conservation of the regulation and processing of 
CwpV across strains of different CwpV types 
5. To determine whether different CwpV repeat types are antigenically distinct 
6. To investigate the function of CwpV   
 
In the subsequent chapters results are presented addressing these aims.  
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2 Materials and Methods 
2.1 Bacterial strains and culture 
2.1.1 C. difficile strains 
C. difficile 630 was provided by Dr Peter Mullany, Eastman Dental Institute, 
London, and has been fully sequenced by the Wellcome Trust Sanger 
Institute. R20352 was obtained from Prof. Brendan Wren and was isolated 
from patients from an outbreak in Quebec (Canada). CDKK167 was provided 
by Professor C. P. Kelly, Harvard Medical School, Boston, USA and was 
isolated from a patient with a single episode of diarrhoea that responded well 
to metronidazole treatment. M9 was obtained from Dr. Denise Drudy, Dublin, 
Ireland and was isolated from a symptomatic patient in a TcdA–B+ outbreak. 
AY1 was provided by Dr Dale Gerding, it is a non-toxic strain isolated in 
Minnesota, USA. An erythromycin sensitive derivative of 630 (630∆erm) 
(Hussain et al., 2005) was used for creation of mutants using ClosTron and 
therefore as a wild-type strain when carrying out phenotypic assays with 
mutant strains.   
2.1.2 C. difficile culture conditions 
C. difficile was routinely cultured either on blood agar base II (Oxoid) 
supplemented with 7% horse blood (TCS Biosciences); on brain-heart 
infusion (BHI) agar plates (Oxoid) or in BHI broth (Oxoid).  Culture was 
undertaken in an anaerobic cabinet (Don Whitley Scientific) at 37ºC in an 
anaerobic atmosphere (10% CO2, 10% H2, 80% N2).  Long-term C. difficile 
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stocks were samples of overnight BHI cultures frozen at -80ºC in 15% 
glycerol.   
2.1.3 E. coli strains 
Commercial chemically competent TOP10 cells (Invitrogen) were used for 
initial transformation after cloning and were used for plasmid maintenance.  
Protein expression was carried out in either BL21(DE3) or Rosetta (Novagen) 
cells.  Rosetta are BL21(DE3) cells carrying a plasmid encoding tRNAs 
specific to codons that are rare in E. coli but common in other organisms, 
dramatically enhancing protein expression from Clostridial genes. 
2.1.4 E. coli culture conditions 
E. coli strains were routinely grown at 37ºC on LB-agar plates or in LB liquid 
culture in the presence of selective antibiotics where appropriate to any 
transformed plasmid (50 µg/ml ampicillin, 50 µg/ml kanamycin, 30 µg/ml 
chloramphenicol). For long term storage, E. coli strains were grown overnight 
in LB, then made up to 15% glycerol and frozen at –80ºC. 
2.1.5 Chemical transformation of E. coli 
Purified plasmid DNA or an entire ligation reaction was mixed with a freshly 
thawed aliquot of chemically competent cells and incubated on ice for 30 min.  
The transformation tubes were then transferred into a 42ºC water bath for 30 
s before returning to ice for 2 min.  250 µl SOC medium (Invitrogen) was then 
added to the cells and the tubes incubated with shaking at 37ºC for 1 h before 
spreading onto selective LB-agar plates.  
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2.1.6 Production of chemically competent E. coli 
An overnight culture of E. coli in LB media was sub-cultured with shaking at 
37°C and its optical density at 600nm (OD600) monitored using an Ultrospec 
cell density meter (Amersham). When the cultures were in the exponential 
growth phase (OD600 0.4-0.6) they were centrifuged at 3,400 x g for 10 min at 
4°C and the pellet re-suspended in 5ml ice-cold 100mM CaCl2. After 15 min 
on ice the sample was centrifuged at 3,400 x g for 10 min at 4°C and re-
suspended in ice-cold 1 ml CaCl2 containing 15% glycerol. The cells were 
incubated on ice for 2 h before freezing at -80°C. All steps except 
centrifugation were performed in a 4°C cold room. 
2.1.7 Clostridium perfringens strain and culture conditions 
Clostridium perfringens strain SM101 was kindly provided by Bruno Dupuy 
and was routinely cultured either on blood agar base II (Oxoid) supplemented 
with 7% defibrinated horse blood (TCS Biosciences), BHI agar (Oxoid) or in 
BHI broth (Oxoid). Cultures were grown in an anaerobic cabinet (Don Whitley 
Scientific) at 37°C in an anaerobic atmosphere (10% CO2, 10% H2, 80% N2).  
2.1.8 E. coli-Clostridium conjugation 
1ml of an LB 30µg/ml chloramphenicol overnight culture of E. coli CA434 
containing a pMTL960-derived plasmid was pelleted at 1700 x g for 10 min at 
4 °C.  The pellet was washed gently with 1 ml LB.  Cells were pelleted again, 
the supernatant discarded and the pellet transferred to an anaerobic cabinet.  
200 µl of an overnight Clostridium culture was used to resuspend the CA434 
cell pellet.  The resulting mixed bacterial suspension was spotted out onto a 
BHI agar plate and incubated at 37 °C in the anaerobic cabinet for 8 h to allow 
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conjugation to proceed. Then 1 ml of BHI was used to resuspend bacteria 
from the agar plate. Appropriate dilutions (typically neat, 1:5, 1:25) of this 
suspension were plated onto BHI plates supplemented with 15 µg/ml 
thiamphenicol to select for pMTL960-based plasmids and 250 µg/ml 
cycloserine to inhibit E. coli growth.  Plates were incubated overnight at 37°C, 
in anaerobic conditions. Transconjugants were picked and streaked onto fresh 
selective plates (15 µg/ml thiamphenicol 250 µg/ml cycloserine) to single 
colony purify transconjugants and ensure no carry over of E. coli from the 
conjugation.  
2.2 Bioinformatics and computer programs  
2.2.1 Genome visualization 
The genome sequence of 630 and its annotation were obtained from The 
Wellcome Sanger Institute website (Sebaihia et al., 2006) (Sebaihia et al., 
2006, http://www.sanger.ac.uk/Projects/C_difficile/). The software Artemis 
(The Sanger Institute, http://www.sanger.ac.uk/Software/Artemis/) was used 
to visualise the genome sequences and annotation. 
2.2.2 DNA sequencing and alignments  
DNA sequencing chromatograms were visualized using Bioedit (Ibis 
biosciences).  The Vector NTI suite of programs (Invitrogen) was used to 
create plasmid maps, construct contigs from multiple sequencing reactions 
and carry out alignment analysis after cloning.  
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2.2.3 Primer design 
Annealing temperature and secondary structure of primers were predicted 
using OligoCalc (http://www.basic.northwestern.edu/biotools/oligocalc.html).  
2.2.4 Nucleic Acid Folding and Hybridization prediction 
Predictions of free energy of RNA folding were carried out using the Mfold 
web server (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-
form1.cgi). 
2.2.5 Homology Searches 
Homology searches were carried out using BLAST (basic local alignment 
search tool).  Searches against all known protein or nucleotide sequences 
were carried out using BLASTP and BLASTN respectively 
(http://www.ncbi.nlm.nih.gov/BLAST/).  Searches against C. difficile 630 
sequences were carried out on the website of The Sanger Institute 
(http://www.sanger.ac.uk/cgi-bin/blast/submitblast/c_difficile). 
2.2.6 Gene and protein property predictions 
Softberry BPROM (prediction of bacterial promoters) was used to predict the 
site of initiation of transcription (http://www.softberry.com). Basic properties of 
proteins, such as molecular weight and pI were calculated using tools from 
the ExPASy website (http://www.expasy.ch/tools). Searching for presence of 
repeats in proteins was carried out using RADAR 
(http://www.ebi.ac.uk/Tools/Radar/index.html).   
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2.3 DNA manipulation 
Full details of recombinant plasmid production are given in Chapter 3. All 
recombinant plasmids used in this study are detailed in Table 2.3. 
2.3.1 C. difficile genomic DNA preparation 
Genomic DNA was isolated from 10 ml BHI C. difficile overnight liquid 
cultures. The Gentra Puregene Yeast/Bact. Kit (Qiagen) was used according 
to manufacturers instructions. 
2.3.2 Chelex preparations  
As an alternative to genomic DNA for PCR template, colonies of C. difficile 
grown on agar plates were subjected to chelex preparation. Chelex 100 resin 
(Bio-Rad) was prepared at 0.05g/ml in water. C. difficile colonies were 
resuspended in 100µl prepared chelex or 10µl of overnight liquid culture was 
added to 90µl prepared chelex.  Samples were boiled for 10 min at 100°C 
then centrifuged at 20,000 x g for 10 min at 4°C.  Supernatants were 
recovered and either used as PCR template immediately or stored at  -20°C. 
2.3.3 Polymerase chain reaction (PCR) primers 
Primers used in this study were ordered for synthesis by Eurofins MWG 
Biotech and are described in Table 2.2.  
2.3.4 Diagnostic PCR 
For purposes where fidelity of the DNA polymerase was not critical, for 
example colony PCR to determine presence of vector inserts after ligation, 
Taq DNA polymerase was used. Redtaq polymerase kit (Sigma) was used 
containing a master mix of MgCl2, dNTPs, Taq polymerase and loading buffer. 
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Primers were used at 10 pmol/µl. 1 µl of forward primer, 1 µl of reverse 
primer, 1 µl template and 7 µl RNase free water were added to 10 µl of 
Redtaq solution to make a final volume of 20 µl. Thermal cycler parameters 
were 95ºC, 5 minutes; thirty cycles of denaturation (95ºC, 30 s), annealing 
(25 s) and extension (72ºC, 1 minute per kb of the desired PCR product); and 
a final 10 min 72ºC incubation. Annealing temperature was generally 5ºC 
lower than the predicted melting temperature (Tm) of the primers used. If initial 
PCR was unsuccessful a set of PCRs with a gradient of annealing 
temperatures was set up to identify the optimum annealing temperature.  
2.3.5 High fidelity PCR 
For cloning reactions, where fidelity is of high importance a proofreading 
polymerase KOD Hot-start DNA polymerase (Novagen) was used. Thermal 
cycler parameters were 95ºC, 2 min; 25-35 cycles of: Denaturation (95ºC, 
15 s); Annealing (temperature appropriate for primers, 30 s) and Extension 
(68-72ºC, 20-30s per kb of the desired PCR product). Annealing temperature 
was generally 5ºC lower than the predicted melting temperature (Tm) of the 
primers PCR, or optimized as described above. 
2.3.6 PCR product purification 
If a single band was visualized on an agarose gel the product was purified 
using a QIAquick PCR purification spin kit (Qiagen). If there were multiple 
bands present and a particular band was desired for purification it was purified 
from the gel. The band was excised using a scalpel and QIAquick Gel 
Extraction Kit (Qiagen) was used according to the manufacturer’s instructions. 
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2.3.7 Agarose gels 
PCR reactions were run on 0.8 - 2.0% TAE-agarose gels (TAE: 40mM Tris, 
20mM acetic acid, 1mM EDTA) containing SYBR Safe DNA gel stain 
(Invitrogen). DNA was visualized using a Gel Doc system (Bio-Rad).    
2.3.8 TOPO Cloning  
A TOPO TA Cloning Kit (Invitrogen), which clones the insert using 
topoisomerase bound to the ends of the open vector, was used for primary 
cloning and also cloning for sequencing. Briefly, after PCR amplification of 
DNA fragment of interest with a proofreading polymerase, 0.2µl Taq (Sigma) 
was added and the reaction incubated at 72ºC for 10 min to add A-overhangs 
at the end of PCR products. The required PCR product was then subjected to 
either QIAquick PCR Purification or QIAquick Gel Extraction. 2µl cleaned 
amplification product was then mixed with 0.5µl TOPO kit salt solution and 
0.5µl pCR4-TOPO vector (Invitrogen) and incubated at room temperature for 
10 min before immediate transformation into TOP10 E. coli (Invitrogen). 
2.3.9 Restriction enzyme digestion 
For subcloning or cloning of PCR products into a specific vector DNA was 
digested with restriction endonucleases. All restriction enzymes were obtained 
from NEB and digestion conditions set up as recommended by the 
manufacturer.  
2.3.10 Purification and Quantification of digested DNA 
For digested PCR products the QIAquick PCR purification spin kit (Qiagen) 
was used to purify the DNA for ligation. For digested vectors where there 
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were two or more products produced from digestion the desired fragment was 
purified from an agarose gel. The band was excised using a scalpel and 
QIAquick Gel Extraction Kit (Qiagen) was used according to the 
manufacturer’s instructions. DNA concentration was quantified using a 
NanoDrop Spectrophotometer (Thermo Scientific). 
2.3.11 DNA Ligation 
Following digestion, purification and quantification of the two fragments of 
DNA required for ligation 50ng of digested DNA vector was mixed with the 
insert at a molar ratio of 1:1 - 1:10. Freshly thawed DNA ligase buffer 
containing ATP was mixed with the DNA and Quick Stick ligase (Bioline). The 
reaction was incubated at room temperature for 15 min and then transformed 
into chemically competent TOP10 E. coli (Invitrogen).  
2.3.12 Colony PCR 
Colonies containing inserts in the vector were selected via colony PCR, using 
standard Taq PCR conditions, with an additional 10 min boil step at the start 
to promote lysis of the bacterial cells. Colonies were subjected to PCR with 
primers annealing either side of the insertion site, to allow distinction by size 
between empty vector and vector containing inserts.  
2.3.13 Plasmid purification 
Plasmids were purified from an overnight culture of E. coli grown in LB with 
the appropriate antibiotics to maintain the plasmid. Plasmids were purified 
using a QIAprep Spin Miniprep Kit (Qiagen) according to manufacturers 
instructions.  
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2.3.14 DNA Sequencing 
Sequencing of purified plasmid DNA at a concentration of 50-100ng/µl was 
carried out by GATC Biotech (Konstanz, Germany) using dideoxy chain 
terminator DNA sequencing. Sequencing primers are provided at 10pmol/µl or 
ordered for synthesis by GATC.  
2.4 Protein manipulation 
2.4.1 Recombinant protein expression in E. coli 
Vectors (pET28a or pACYCY-Duet-1) containing the genes of interest under 
the control of a lactose inducible promoter were used for recombinant protein 
expression. LB cultures of BL21(DE3) or Rosetta E. coli containing these 
plasmids were grown for 6 h with the appropriate antibiotic selection to 
maintain the plasmids. These cultures were then used to inoculate Overnight 
Express Autoinduction medium (Novagen). The cultures were grown 
overnight at 37°C with shaking to saturation of the medium. The cells were 
harvested by centrifugation and the pellet resuspended in lysis solution 
(50mM NaH2PO4 , 300mM NaCl, 10mM imidazole containing 10% BugBuster 
Protein Extraction Reagent (Novagen), 1% DNase and 1% lysozyme). Lysis 
was allowed to proceed for 30 min at room temperature with constant gentle 
mixing. Following lysis the suspension was centrifuged at 14,000rpm in a 
tabletop centrifuge for 5 min. The supernatant was harvested as it contains 
the soluble fraction of protein for purification.  
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2.4.2 Purification of His-tagged proteins 
The pH of the supernatant from cell lysis was measured and if necessary 
adjusted to pH8. This supernatant containing the His-tagged protein was then 
applied to a gravity flow column containing Nickel-NTA agarose (Qiagen). The 
supernatant was incubated with the column for 1 h at 4°C. The solution was 
then allowed to flow through the column and the flow through was collected. 
The column was then washed with 5 column volumes of wash buffer (50mM 
NaH2PO4, 300mM NaCl, 10mM imidazole). Wash fractions were collected and 
A280nm monitored to determine when washes have removed most 
contaminating protein. Finally 5 column volumes of elution buffer (50mM 
NaH2PO4, 300mM NaCl, 250mM imidazole) were applied to the column and 
fractions collected. A280nm was used to monitor elution and if necessary more 
elution buffer was added to elute all protein from the column. Fractions of 
interest were then run on SDS-PAGE gel to determine which fractions 
contained purified protein and allow estimation of purity.  
2.4.3 Dialysis of Purified Protein 
In order to transfer purified protein from elution buffer following purification to 
a buffer more suitable for long-term storage dialysis was carried out. Fractions 
containing purified protein were pooled and protein transferred to a Slide-A-
Lyzer Dialysis Cassette (Thermo Scientific). In general the dialysis buffer was 
10mM HEPES, 150mM NaCl. The dialysis cassette was floated in 2 litres of 
pre-cooled dialysis buffer at 4°C for 2 h with stirring. The buffer was then 
changed and the dialysis left overnight with stirring at 4°C. The buffer was 
changed once more and left for a further 6 h before protein was retrieved from 
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the cassette. Recovery of proteins was confirmed by SDS-PAGE prior to 
determination of protein concentration.  
2.4.4 Determination of protein concentration  
Protein concentration was accurately determined using a BCA assay (Pierce) 
carried out according to the manufacturer’s instructions.  Briefly, standards of 
BSA of known concentration and samples were serially diluted in PBS.  
Reagents A and B were mixed in a 50:1 ratio, then 180µl reagent was added 
to 20µl sample.  The reaction was incubated for 30 min at 37ºC, then the 
absorbance at 595nm determined using a Benchmark microplate reader (Bio-
Rad).  
2.4.5 C. difficile surface layer preparation 
C. difficile cells from 50ml overnight cultures were harvested after OD600 
measurement by centrifugation at 6000 x g for 10 min.  Pellets were washed 
with 5ml sterile PBS and cells harvested again. Pellets were resuspended in 
500µl 0.2M glycine–HCl pH 2.2 and incubated at room temperature with 
rotation for 30 minutes.  Preparations were then centrifuged at 20,000 x g in a 
microcentrifuge for 15 minutes at 4°C.  Supernatants were recovered and pH 
adjusted to pH 6–8 with 2M Tris, adding 10 µl at a time and monitoring pH 
with pH strips (Whatman).   
2.4.6 Expression of Strep-tagged proteins in C. difficile and 
StrepTactin purification  
C. difficile strains containing pMTL960-based expression plasmids were 
grown in static BHI culture overnight with 15 µg/ml thiamphenicol to ensure 
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maintainance of the plasmids. Surface layer preparations from the overnight 
culture were carried out as described above. Surface layer preparations were 
mixed 1:1 with StrepTactin wash buffer (150mM NaCl, 100mM Tris-HCl, 1 mM 
EDTA, pH 8.0). 100 µl of StrepTactin resin (50 µl bed volume) (Novagen) was 
washed twice with 0.5 ml dH2O, then twice with 0.5 ml of wash buffer. The S-
layer preparation/wash buffer mixture was then incubated with the resin 
overnight at 4°C with rotation. The next day, the mixture was centrifuged for 
10 s at 20,000 x g to pellet the resin. The resin was washed with 1 ml wash 
buffer to remove non-specifically bound proteins. In order to determine the 
total number of washes, washes were monitored by A280nm to determine when 
protein concentration of washes had returned to a baseline, and therefore 
most contaminating protein had been washed off. Elutions were carried out by 
addition of 50µl of elution buffer (150mM NaCl, 100mM Tris-HCl, 1 mM EDTA, 
2.5mM desthiobiotin, pH 8.0) followed by centrifugation to pellet the resin and 
removal of the supernatant. In order to determine the total number of elutions, 
elutions were monitored by A280nm to determine when protein concentration of 
elutions had returned to a baseline, and therefore most protein had been 
eluted. All fractions were collected for analysis via SDS-PAGE.  
2.4.7 SDS-PAGE 
SDS-PAGE gels a fixed concentration of acrylamide (8 – 15%) were prepared 
using mini-protean kits (Bio-Rad). The resolving gel (8 – 15% 39:1 
acrylamide:bisacrylamide, 375mM Tris pH 8.8, 0.1% SDS, 0.5% APS, 0.07% 
TEMED) was poured and a layer of isopropanol was gently poured on top.  
Once the gel was set, the isopropanol was discarded. The stacking gel (5% 
39:1 acrylamide:bisacrylamide, 62.5mM Tris pH 6.8, 0.1% SDS, 0.1% APS, 
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0.24% TEMED) was poured on top of the resolving gel and the comb put in 
place to form the wells.  Once set, the comb was removed and the gel was 
immersed in electrophoresis buffer (25mM Tris, 192mM glycine, 0.1% SDS).  
Protein samples were diluted in sample buffer (final concentration 45mM Tris 
pH 6.8, 0.7% SDS, 0.7mg/ml sucrose, 3.5% β-mercaptoethanol, trace 
bromophenol blue).  These, along with a 10µl aliquot of Broad Range Protein 
Marker (NEB), were heated to 100ºC for 5 minutes and then briefly 
centrifuged.  Samples were loaded into the wells of the gel and a constant 
voltage of 200V applied for 40-50 min. Gels were then either Coomassie 
stained or transferred to PVDF membranes for immunoblotting. 
2.4.8 Coomassie staining 
For visualisation of proteins following SDS-PAGE, gels were stained in 
Coomassie blue  (45% methanol, 10% acetic acid, 1mg/ml Coomassie blue 
stain) for 4 - 16 h, followed by destaining using 45% methanol, 10% acetic 
acid. A final destain in 10% acetic acid was carried out prior to scanning of 
gels for documentation.  
2.4.9 N-terminal Sequencing 
S-layer extracts were separated on 10% SDS-PAGE gel and transferred onto 
a PVDF membrane (see Western immunoblotting for transfer protocol). After 
protein transfer the membrane was washed in water for 10 min, and stained in 
0.1% Coomassie Blue R in 50% MeOH for 5 min. After destaining in 50% 
MeOH, 10% acetic acid (3x 5 min with rocking) and washing in water (3x 5 
min with rocking) the membrane was allowed to dry thoroughly. Bands 
requested for sequencing were indicated and the membrane sent to the 
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Protein and Nucleic Acid Chemistry Facility, Department of Biochemistry, 
University of Cambridge. Edman degradation was carried out to determine the 
first 5 amino acids of protein bands excised from the PVDF membrane.  
2.4.10 Production of antibodies 
Anti-CwpVNter and anti-CwpVrptI were produced prior to this study as 
reported (Emerson et al., 2009). For raising anti-CwpVrptII-V antibodies 
recombinant CwpV repeat domains were purified from E. coli and dialysed 
into 10mM HEPES, 150mM NaCl for use as antigens. Samples were sent to 
Covalab for immunization of rabbits according to their standard protocols. For 
each antigen two rabbits were immunized. Pre-immunisation serum and post-
immunisation serum from all rabbits were analysed to confirm successful 
production of specific antibodies. The characteristics of the antigens used for 
production of these anti-CwpV antibodies is described in Table 2.1. 
Table 2.1 Description of recombinant antigens used to raise antibodies  
Antibody C. difficile 
strain 
No. of 
repeats 
Size (bp) MW 
(kDa) 
Amplification 
primers 
CwpVNter* CD630 n/a 1365 50 664/5 
rptI* CD630 1 207 7.6 345/6 
rptII R20352 2 506 18.5 1021/22 
rptIII CD167 2 560 20.5 1023/4 
rptIV M9 1 318 11.5 1025/6 
rptV AY1 1 280 10 1027/8 
 
*These antibodies had been raised previously in our laboratory – information 
provided for completeness 
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2.5 Immunodetection  
2.5.1 ELISA 
96-well MaxiSorp PS Immuno F96 plates (Nunc, Roskilde, Denmark) were 
coated overnight at 4ºC with 50µl protein of interest at 10ug/ml.  After three 
washes with PBS + 0.1% Tween-20 (PBS-T) the plates were blocked with 
100µl PBS-T + 3% dried skimmed milk (milk) per well at 37ºC for 2 h.  Plates 
were washed three times with PBS-T.  Subsequent incubation steps with 
protein of interest or antibody were carried out at the appropriate 
concentration made up in PBS-T + 3% milk at room temperature for 1 h. 
Three PBS-T wash steps were carried out between each incubation.  After 
final incubation with HRP-conjugated antibody and three washes with PBS-T, 
50µl OPD substrate (5ml 0.1M citric acid, 5ml 0.2M Na2HPO4, 10ml H20, 1 
OPD tablet (Sigma), 8µl H202) was added to each well and incubated on the 
plate at room temperature for up to 1 h.  The reaction was stopped using 20µl 
3M H2SO4 per well and the A492nm was determined using a microplate reader.  
2.5.2 Western immunoblotting 
SDS-polyacrylamide gels were transferred to PVDF Immobilon-P Transfer 
membrane (Millipore) using a semi-dry protocol. SDS-PAGE gel and filter 
paper were pre-soaked in transfer buffer (25mM Tris, 192mM glycine, 20% 
methanol).  Immobilon-P membrane was prepared for transfer by incubation 
sequentially in methanol, H20 and transfer buffer according to manufacturer’s 
protocol. The filter paper, membrane and gel were stacked in Trans-blot SD 
semi-dry transfer cell (Bio-Rad) and run at 25V for 15-30 min. Transferred 
proteins were visualised by staining with Ponceau S solution (Sigma) for 1 
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min and destained using H2O. Locations of protein marker bands were 
marked in pencil. The membrane was then transferred to methanol for 1 min 
then allowed to dry completely. Antibody used for detection was then 
incubated with the membrane with shaking for 1 h at an appropriate dilution in 
3% milk PBS-T. For His-tag detection anti-His antibody HRP Conjugate 
(Abcam) was used for detection. For strep-tag detection mouse anti-Strep-tag 
II (Novagen) was used. For non-conjugated antibodies a secondary HRP-
conjugated antibody was required (goat anti-rabbit HRP (Dako) or goat anti-
mouse HRP (Dako)). Between antibody incubation steps three washes in 
PBS-T were carried out. After final antibody incubation the blot was washed in 
PBS-T and then freshly prepared SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) was added to the membrane and allowed to 
develop for up to 5 min at room temperature. Chemiluminescence was 
detected using a LAS-3000 Image Reader (Fujifilm) and a white picture also 
taken to allow protein markers to be visualised. 
2.5.3 Immunofluorescence microscopy 
C. difficile cells from 800µl of a culture were harvested by centrifugation at 
8000 rpm for 1 min.  The supernatant was discarded and the pellet washed 
twice with 1 ml PBS.  For fixation, pellets were then resuspended in 8% 
formaldehyde (made fresh from 36% stock solution (Sigma) diluted in PBS) 
and incubated for 15 min at room temperature.  Fixed cells were pelleted and 
washed twice in 1 ml PBS by centrifuging at 8000 rpm for 2 min.  After the 
final wash pellets were resuspended in 500µl 20 mM NH4Cl2 and incubated 
for 15 min at room temperature.  Cells were pelleted at 8000 rpm for 2 min 
then washed twice with 1 ml PBS.  The final wash supernatant was discarded 
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and pellets were resuspended in 40 µl 1% BSA in PBS and left for 10 min. 
Primary antibody was added to make the appropriate dilution (for anti-CwpV 
antibodies 1:20) and incubated with the cells for 45 min. Cells were then 
washed twice with PBS and once with 1% BSA in PBS. Again the pellet was 
resuspended in 40µl 1% BSA in PBS and fluorescent secondary antibodies 
added to the appropriate dilution (anti-rat and anti-rabbit Cy2/rhodamine redX 
conjugated antibodies from Jackson Immunoresearch, used at 1:200 dilution 
as recommended). Tubes were incubated in the dark for 45 min. Cells were 
washed twice with PBS, then twice with dH20 before resuspending in 40µl 
dH20. Stained cell suspension was then spotted onto a SuperFrost (Thermo 
Scientific) microscope slide and allowed to air dry in the dark. Once dry 
coverslips were mounted on top of the spot of cells using prolong gold anti-
fade reagent (Invitrogen). Bacteria were visualized using a Nikon Eclipse 
E600 microscope fitted with a Nikon DMX1200 camera.  
2.6 Reporter Assays 
2.6.1 FbFP reporter assays 
Cells from C. difficile cultures were harvested and washed with PBS, then 
resuspended in PBS to an OD600 of 1.0. Samples were transferred to black 
FluoroNunc 96-well plates (Nunc) then fluorescence of each well measured 
with a spectrophotometer (Cary Eclipse), using an excitation wavelength of 
450nm and an emission wavelength of 495nm.  
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2.6.2 GusA reporter assays - C. difficile 
The OD600 values of growing C. difficile cultures were monitored and from 
mid-logarithmic growth phase cultures 10ml samples were taken, bacterial 
cells were harvested by centrifugation and the pellet frozen at -80ºC. The 
pellet was then thawed and resuspended in 0.8ml Z buffer (60 mM NaH2PO4, 
60 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50mM 2-mercaptoethanol, pH7). 
The cell suspensions were transferred to tubes containing 150-212µm 
diameter unwashed glass beads (Sigma) and the tubes treated in a BIO101 
Fast Prep FP120 bead beater (BIO101 Savant) at setting 6 for 45s. Lysed 
suspensions were cooled on ice then spun at 14,000rpm in a bench top 
centrifuge for 10 minutes at 4ºC to pellet beads. 0.4ml lysis supernatant was 
mixed with 0.4 ml fresh Z buffer and incubated at 37ºC for 5 minutes. 0.16ml 
of 6mM p-nitrophenyl-β-D-glucuronide (Sigma) was then added to each tube 
and incubated at 37ºC for a defined length of time. The reaction was stopped 
by addition of 0.4ml of 1M Na2CO3. Tubes were centrifuged at 14,000rpm in a 
bench top centrifuge for 10 min to remove cell debris. The A405nm of 
supernatant was measured and GusA activity calculated using the formula: 
(A405nm x 1000)/(OD600 x reaction time (min) x 1.25 x vol of culture (ml)). 
2.6.3 GusA reporter assays - Clostridium perfringens 
The OD600 values of growing C. perfringens cultures were monitored and from 
mid-logarithmic growth phase cultures 1ml samples were taken, pelleted and 
frozen at -80ºC. The pellet was then thawed and resuspended in 0.8ml Z 
buffer (as above). To lyze the cells 8µl of toluene (Sigma) was added to the 
cell suspension. Tubes were capped and mixed vigorously for 1 min. Tubes 
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were then incubated on ice for 10 min then at 37ºC for 30 minutes. To start 
the enzymatic reaction 0.16ml of 6mM p-nitrophenyl-β-D-glucuronide (Sigma) 
was added to each tube. Tubes were incubated at 37ºC for a defined length of 
time. The reaction was stopped by addition of 0.4ml of 1M Na2CO3. Tubes 
were centrifuged at 14,000rpm in a bench top centrifuge for 10 min to remove 
cell debris. The A405nm of supernatent was measured and GusA activity 
calculated using the formula: (A405nm x 1000)/(OD600 x reaction time (min) x 
1.25 x vol of culture (ml)). 
2.7 Phenotypic assays 
2.7.1 Colony morphology 
For macroscopic visualization of C. difficile colony morphology strains were 
grown on BHI agar (Oxoid) for 5 days from an appropriate C. difficile inoculum 
such that isolated colonies grew on the plate. Plates were then scanned using 
a transmissive flat-bed scanner (Epson) to record images of the colonies or 
photographed.  For microscopic visualization of C. difficile colony morphology 
glass-bottomed dishes (MatTek corporation) were inoculated directly on the 
glass with C. difficile taken with a sterile pipette tip from a 24 h-old C. difficile 
colony grown under standard conditions. Anaerobic BHI 0.7% agar at 40ºC 
was then carefully poured over the glass to cover the dish and allowed to set. 
C. difficile was grown between the glass and the agar for 3 days. Dishes were 
removed and images taken using a Zeiss Axiovert 200 widefield microscope 
at FILM, Imperial College London. Microscope images were analysed using 
Volocity 5.3.2 software (Improvision).  
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2.7.2 Flagella Expression Assay 
C. difficile cultures were analysed for flagella expression based on a 
published protocol (Twine et al., 2009). BHI plates were inoculated with C. 
difficile from an overnight culture and grown for 24 hours to produce a lawn of 
bacterial growth. 500µl of distilled water was then added to the plate and 
bacteria harvested by scraping with an L-shaped spreader. Samples were 
normalized to an OD600 of 50. Samples in eppendorf tubes were subjected to 
3 min of vortexing, following by centrifugation at 14,000rpm for 5 min. The 
supernatant was taken and concentrated 5-fold (200µl to 40µl). This 
concentrated supernatant was then analysed for flagella expression by SDS-
PAGE and Coomassie staining, with 630 FliC running at ~33kDa.  
2.7.3 Swimming Motility Assay 
BHI 0.175% agar was poured into sterile FACS tubes and allowed to cool to 
room temperature. Tubes were then transferred to the anaerobic cabinet and 
left for 4 hours to equilibrate under anaerobic conditions. Tubes were 
inoculated to a defined depth with the straight end of sterile inoculation loops 
that had been dipped into C. difficile overnight liquid cultures. Tubes were 
incubated overnight then photographed to document motility exhibited.  
2.7.4 C. difficile fibronectin ELISA 
96-well MaxiSorp PS Immuno F96 plates (Nunc) were coated overnight at 4ºC 
with 50µl cellular fibronectin (Sigma) at 10ug/ml.  After three washes with PBS 
+ 0.1% Tween-20 (PBS-T) the plates were blocked with 100µl PBS-T + 3% 
dried skimmed milk (milk) per well at 37ºC for 2 hours.  Plates were washed 
three times with PBS-T. C. difficile overnight cultures were harvested by 
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centrifugation then resuspended to an OD600 of 10. A two-fold dilution series 
of the bacterial suspension was carried out in PBS. 50µl samples of bacterial 
suspensions of the appropriate OD600 were then added to fibronectin-coated 
wells and incubated for 1 h at 37ºC. Following incubation wells were washed 
three times with PBS-T. Then anti-HMW SLP (1:15,000 dilution) and anti-
LMW SLP (1:30,000 dilution) antibodies in milk were applied to each well and 
incubated for 1 h at 37ºC. Wells were washed three times with PBS-T then 
anti-rabbit HRP in milk (1:2000 dilution) added to each well, and incubated for 
1 h at 37ºC. Wells were washed three times in PBS-T then 50µl OPD 
substrate (5ml 0.1M citric acid, 5ml 0.2M Na2HPO4, 10ml H20, 1 OPD tablet 
(Sigma), 8µl H202) was added to each well and incubated on the plate at room 
temperature for up to 1 h.  The reaction was stopped using 20µl 3M H2SO4 
per well and the optical density at 450nm was determined using a microplate 
reader.  
2.7.5 C. difficile Caco-2 cell binding Assay 
Caco-2 BBE1 cells (ATCC) were cultured under the conditions recommended 
by ATCC. Briefly, cells were propagated in high glucose (4.5g/L) DMEM 
(Gibco, Invitrogen) supplemented with 20% heat-inactivated fetal calf serum, 
100µM MEM non-essential amino acids (Gibco, Invitrogen) and GlutaMAX 
(Invitrogen). In order to subculture cells trypsin-EDTA solution (Sigma) was 
used to remove cells from the flask. Cells were subcultured prior to confluency 
(maximum ~80% confluent) for routine propagation. For binding assays cells 
were grown in 12-well plates and 5 days after confluency differentiated cells 
were used for C. difficile binding assays. The 12-well plate containing cells 
was transferred to the anaerobic cabinet and 100µl of overnight C. difficile 
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culture was added directly into the cell culture medium. To allow comparison 
between strains overnight cultures were normalized to the same OD600 prior to 
addition to Caco-2 cells. Cells were incubated with the bacteria for 4 h in the 
anaerobic cabinet. The medium was carefully removed from cells and 1ml BHI 
added to each well, and gently shaken for 1 min to wash the cells. This gentle 
wash step was repeated twice more. Finally 100µl of BHI was added to the 
well, and the cells scraped and resuspended in this volume. This neat sample 
was diluted in BHI (10-1, 10-2, 10-3 dilutions), and plated out on BHI plates to 
determine the number of adherent bacteria per well.  
2.7.6 C. difficile Caco-2 cell infection immunofluorescence  
After infection of Caco-2 BBE1 cells grown on coverslips with C. difficile 
(same infection conditions as described for binding assay) cells were washed 
gently twice with PBS. Cells were then fixed with 3% formaldehyde in PBS for 
20 minutes at room temperature. Cells were washed twice with PBS, then 
twice with 50mM NH4Cl in PBS, then twice more with PBS. One wash was 
carried out with 1% BSA in PBS then all liquid removed from the cells. A 40µl 
drop of 1% BSA in PBS, containing anti-HMW SLP (1:100) was then added to 
the cells, and incubated for 45 min. Two PBS washes and one 1% BSA in 
PBS wash were carried out prior to addition of a 40µl drop of 1% BSA in PBS, 
containing Hoechst (1:500) and anti-rabbit rhodamine red-X (1:200) to the 
cells. Two PBS washes and one dH2O wash of coverslips were carried out 
then excess liquid drained prior to mounting on a microscope slide with 
prolong gold antifade mount (Invitrogen). Cells were visualized using a Nikon 
Eclipse E600 microscope fitted with a Nikon DMX1200 camera.  
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2.7.7 Induction of C. difficile sporulation  
C. difficile strains were streaked onto BHIS agar (For 1 litre: 37g BHI (Oxoid), 
5g Yeast Extract (BD Bacto), 1g L-Cysteine (Sigma), 15g Agar (BD Bacto) 
and grown overnight anaerobically at 37ºC. A single colony was used to 
inoculate 15 ml of TGY broth (For 1 litre: 30g Tryptic Soy Broth (BD Bacto), 
2% Glucose (VWR), 10g Yeast Extract (BD Bacto) 1g L-Cysteine (Sigma). 
Following overnight growth to stationary phase in TGY broth under standard 
culture conditions, bacteria were subcultured at a dilution of 1 in 10 in SMC 
medium (For 1 litre: 90g Bacto Peptone (BD Bacto), 5g Proteose Peptone 
(Sigma), 1g Ammonium Sulphate (Sigma), 1.5g TRIS (VWR). When the OD600 
of the SMC culture reached 0.4, 100 µL of the culture was spread on SMC 
agar (SMC broth with 1.5% agar (BD) and incubated anaerobically at 37°C for 
5 days. Addition of 2ml of dH2O followed by mixing with an L-shaped spreader 
allowed harvesting of the crude spore preparation. Samples were taken for 
analysis by phase microscopy.  
2.7.8 Quantification of sporulation efficiency 
Spores were purified using HistoDenz (Sigma) based on a published protocol 
(Sorg & Dineen, 2009). Crude spore preparations harvested from SMC plates 
(see above) were washed five times in 1ml ice-cold dH20 by centrifugation 
and resuspension/vortex steps. The OD600 of this washed spore preparation 
was measured to reflect the amount of material present prior to purification, a 
sample for microscopy was also taken. The washed spore preparation was 
then pelleted by centrifugation and resuspended in 500 µL 20% (w/v) 
HistoDenz. This was carefully layered onto 1 ml 50% (w/v) HistoDenz in an 
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eppendorf tube to form a density gradient. This gradient was then centrifuged 
at 14,000 x g for 15 minutes. Cell debris and any remaining vegetative cells 
collected at the boundary between 20% and 50% HistoDenz, and was 
discarded. The pellet containing spores was washed five times in ice-cold 
dH2O to remove HistoDenz and yield the purified spore preparation of which 
OD600 measurements and samples for microscopy were taken. Purified 
spores were stored in water at 4°C, or frozen at -80ºC for long-term storage. 
Sporulation yield was calculated as OD600 purified spores (post-
HistoDenz)/OD600 washed spore preparation (pre-HistoDenz). 
2.7.9 Germination Efficiency Assay 
Purified spores were normalized to an OD600 of 1.0 in dH2O. A ten-fold dilution 
series of this purified spore preparation was carried out in PBS 0.05% Tween-
80 (Sigma). Samples (typically of 10-4, 10-5, 10-6 and 10-7 dilutions) were 
spread onto BHI plates containing 0.1% sodium taurocholate (Sigma) in 
triplicate. Plates were then incubated overnight anaerobically at 37ºC. 
Colonies were counted to determine the number of spores germinating from 
the samples. Germination efficiency was calculated as the number of colony 
forming units (cfu) per ml of an OD600=1.0 purified spore preparation.  
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Table 2.2 Primers used in this study 
Name Sequence (5’ to 3’) Characteristic or use 
NF812 GGTAAATAAGGAAAAAATAATAAGAATTCGAATTTTTTAGGGGGAAAATACCATG 
Site-directed mutagenesis to introduce EcoRI site 10 bp upstream of 
RBS in pCBR001, creating pCBR003 
NF813 CATGGTATTTTCCCCCTAAAAAATTCGAATTCTTATTATTTTTTCCTTATTTACC 
Site-directed mutagenesis to introduce EcoRI site 10 bp upstream of 
RBS in pCBR001, creating pCBR003 
NF883 CTTTAACTATGCCGGGATACATCGCAGCGTAATGC Site-directed mutagenesis to remove BamHI site from gusA 
NF884 GCATTACGCTGCGATGTATCCCGGCATAGTTAAAG Site-directed mutagenesis to remove BamHI site from gusA 
NF885 CCGGAATTCCTGCAGTAAAGGAGAAAATTTTATGTTACG Amplification of gusA 
NF886 CGCGGATCCGGTGCGCCAGGAGAGTTGTTGATTC Amplification of gusA 
NF814 GGTACCAATATCTAATTTTAAAGAGGTTTCTAACTATAATG Amplification of short ON from CD630 gDNA 
NF815 GAATTCACTTAATTTTTTAACTTTGTTCCCGTTCTAATTCT Amplification of short ON/OFF from CD630 gDNA 
NF816 GGTACCTTTTTATACAAAACCCTATTTTTTATAACAATTC Amplification of short OFF from CD630 gDNA 
NF855 CCGCCGGGTACCGTAATTTGAATTAAAATGTAAATATAAAGAATAATTAAAAAAATATCGC Amplification of ON/OFF from CD630 gDNA 
NF856 CCGCCGGAATTCACTTAATTTTTTAACTTTGTTCCCGTTCTAATTCT Amplification of ON/OFF from CD630 gDNA 
NF864 AAAGTGCTACTCTTTTTACAAATAAATTTTATTATTTATACTTG Inverse PCR to delete 2 bp from IR 
NF865 ATTCTAAAGGATACTTAATATCTAATTTTAAAGAGGTTTC Inverse PCR to delete 2 bp from IR 
NF866 ATTCTAAAGGCTACTTTTTTTATACAAAACCCTATTTTTTATAAC Inverse PCR to delete 2 bp from IR 
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Name Sequence (5’ to 3’) Characteristic or use 
NF867 GAACGGGAACAAAGTTAAAAAATTAAGTGAATTCGAATTTTTTAG Inverse PCR to delete 2 bp from IR 
NF894 GTGCTACTCTTTTTACAAATAAATTTTATTATTTATACTTG Inverse PCR deletion of whole region of inversion, or parts of region of inversion 
NF895 CGGGAACAAAGTTAAAAAATTAAGTGAATTCGAATTTTTTAG Inverse PCR deletion of whole region of inversion 
NF952 CT TAA AAT ATA AAT TTA CAA ATT TTT CAA TCA ATA AGA AAA TTT C Inverse PCR to create ∆1 deletion in inversion region 
NF953 GTA AGT TTG ATT TTT ATG TTA ATG AAT TGT TAT AAA AAA TAG G Inverse PCR to create ∆2 and ∆4 deletions in inversion region 
NF954 CAA TGT AAC AAA ATA ATT ACA AAT TAA TTA TGA AAT CAT TAT AG Inverse PCR to create ∆2 and ∆5 deletions in inversion region 
NF956 CGG GAA CAA AGT TAA AAA ATT AAG TGA ATT CCT G Inverse PCR to create ∆4 deletion in inversion region 
NF909 ATT CTA AAG GAT ACT TAA TAT CTA CAA AAC CCT ATT TTT TAT AAC AAT TC 
For mutation of 5bp in the OFF orientation of the cwpV switch 
(OFF>ON) 
NF910 GAA TTG TTA TAA AAA ATA GGG TTT TGT AGA TAT TAA GTA TCC TTT AGA AT 
For mutation of 5bp in the OFF orientation of the cwpV switch 
(OFF>ON) 
NF911 TT CTA AAG GCT ACT TTT TTT ATA ATT TTA AAG AGG TTT CTA ACT ATA ATG 
For mutation of 5bp in the OFF orientation of the cwpV switch 
(ON>OFF) 
NF912 CAT TAT AGT TAG AAA CCT CTT TAA AAT TAT AAA AAA AGT AGC CTT TAG AA 
For mutation of 5bp in the OFF orientation of the cwpV switch 
(ON>OFF) 
NF913 CGCGGATCCAAATAATGATAAGAAAATTATAAAAGTACATAA Amplification of recombinase CD1932 for cloning into pACYCDuet-1 
NF914 ATAAGAATGCGGCCGCTTAATCGTCCTCAATCCATTCAA Amplification of recombinase CD1932 for cloning into pACYCDuet-1 
NF915 CGCGGATCCAAAAGCTGCAATTTATTCAAGA Amplification of recombinase CD1905 for cloning into pACYCDuet-1 
NF916 ATAAGAATGCGGCCGCCTAATTGCTTAAAGAAACAGAATTATC Amplification of recombinase CD1905 for cloning into pACYCDuet-1 
 123 
Name Sequence (5’ to 3’) Characteristic or use 
NF917 CGCGGATCCAAATGCATTTATTAGAAAAAGAAATAA Amplification of recombinase CD2066 for cloning into pACYCDuet-1 
NF918 ATAAGAATGCGGCCGCTTAATTAGCATTAAATAAACTTTCAGA Amplification of recombinase CD2066 for cloning into pACYCDuet-1 
NF919 CGCGGATCCAAATGTGGCAATTTATTTACGCAAAA Amplification of recombinase CD1882 for cloning into pACYCDuet-1 
NF920 ATAAGAATGCGGCCGCTTAATCTCTTGGGATATTAGGGTAA Amplification of recombinase CD1882 for cloning into pACYCDuet-1 
NF921 CGCGGATCCAAAAATGGCAACAAGACCTATAGAAA Amplification of recombinase CD1167 for cloning into pACYCDuet-1 
NF922 ATAAGAATGCGGCCGCTTAACCAATAAAGAAATTTTCACTAGC Amplification of recombinase CD1167 for cloning into pACYCDuet-1 
NF1043 CGCGGATCCAATGATTATTATATATGGATATTGCCGTG Amplification of recombinase CD3578 for cloning into pACYCDuet-1 
NF1044 ATAAGAATGCGGCCGCCTAAATTGATTTTTTAGCACGAATAAGTGTGC Amplification of recombinase CD3578 for cloning into pACYCDuet-1 
NF1045 CGCGGATCCAATGGATATTATAGAGGGATATATAG Amplification of recombinase CD1222 for cloning into pACYCDuet-1 
NF1046 ATAAGAATGCGGCCGCCTATTTAGCTTCTGCTTTTTGTAATTCTAC Amplification of recombinase CD1222 for cloning into pACYCDuet-1 
NF823 GCATTTTTCCATCCATCTTG For cwpV switch orientation PCR, anneals outside region of inversion 
NF825 TTTAAGGTAAGTTTGATTTTTATGTTAATGAAT For cwpV switch orientation PCR, anneals in region of inversion 
NF826 ATTCATTAACATAAAAATCAAACTTACCTTAAA For cwpV switch orientation PCR, anneals in region of inversion 
NF793 CACCTCCTTTTTGACTTTAAGCCTACGAATACC For cwpV switch orientation PCR, anneals in pMTL960 backbone  
NF1215 CTTAATCACATATATCACACTTGTATAAGTTTACTGG Analysis of recV ClosTron insertion site 
NF1356 CATTAATAGCTTGCTGAGTTACCCTTATATATCGC Analysis of recV ClosTron insertion site 
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Name Sequence (5’ to 3’) Characteristic or use 
NF1357 AGA GCT CAA TCA AAC TAA GAG GAG TGG TTG AAA ATG GC For amplification of recV for cloning into pRPF146 with a C-terminal strep tag 
NF1359 GTG GAT GAC TCC ACT CGA GAC CAA TAA AGA AAT TTT CAC TAG CTT C 
For amplification of recV for cloning into pRPF146 with a C-terminal 
strep tag 
NF1360 TGG ATC CTT ATT TTT CAA ATT GTG GAT GAC TCC ACT CGA GAC C For amplification of recV for cloning into pRPF146 with a C-terminal strep tag 
NF1411 GAT TTA TAA GGG TAA CTC AGC AAG C To create Y176F mutation in recV  
NF1412 GCT GTG TAG TGG CTA CAG AGC To create Y176F mutation in recV 
NF1019 GAT ATA CCA TGG GCT CTT CAT CAA AGG TAG GTC AAA TAA AAT TTA G Amplify two and nine 630 type I repeats for pET28a cloning 
NF1020 GTG GTG CTC GAG ACC TAC TGC TGG CGC TGC CAC ATA TTT TTT AAC Amplify two 630 type I repeats for pET28a cloning 
NF1021 GATATACCATGGGCTCATCAAAAGTAGATAAAGTAGTTTTG Amplify two R20352 type II repeats for pET28a cloning 
NF1022 GTGGTGCTCGAGTACTACTTTTCCTGCTTCAAATGTCTC   Amplify two R20352 type II repeats for pET28a cloning 
NF1023 GATATACCATGGGCGTGGCAAAAATAACAAGCGTTCCTGC  Amplify two CDKK167 type III repeats for pET28a cloning 
NF1024 GTGGTGCTCGAGTATAGCTGTTCTGGCTGG  Amplify two CDKK167 type III repeats for pET28a cloning 
NF1025 GATATACCATGGGCACACCAACAGTAGACCCAGTTGAAGG  Amplify one M9 type IV repeat for pET28a cloning 
NF1026 GTGGTGCTCGAGTGTTGGTGTTTTATCTAATACTATTG Amplify one M9 type IV repeat for pET28a cloning 
NF1027 GATATACCATGGGCCCAGCCAAATCAACAAAAGTAATAATAGG Amplify one AY1 type IV repeat for pET28a cloning 
NF1028 GTGGTGCTCGAGTCCTGCTGTTGCTCCTGATAC Amplify one AY1 type IV repeat for pET28a cloning 
NF1095 CTA ATT TTT ATT CAT ATT TCA TCT CGA GTT TTA ATA TAT TAA ATA AAC Amplify nine 630 type I repeats for pET28a cloning 
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Name Sequence (5’ to 3’) Characteristic or use 
NF1096 CCGGAATTCAAATGGACAAGGGGGAAGAAAATAAAATG 
Amplification of cwpV gene from CD630 gDNA for cloning into 
pCBR023 to produce pCBR044, and for amplification of all other 
types of cwpV gene 
NF1097 CGCGGATCCCCAATACTAGTATTATCAAGAAAATTTACATC Amplification of cwpV gene from CD630 gDNA for cloning into pCBR023 to produce pCBR044 
NF1123 CCA CGG CGC GCT GAT GAA GAA CTT CCT CCA CTA C For deletion of the cwpV repeat region to produce truncated cwpV  
NF1124 GAG TGG GCT CGA GTA AAT AAT GAA ATA TGA ATA AAA ATT AG For deletion of the cwpV repeat region to produce truncated cwpV 
NF1296 CACAATTTGAAAAATAAATAATGAAATATGAATAAAAATTAG To add strep tag to cwpV in pCBR044 
NF1297 GATGACTCCACTCGAGTTTTAATATATTAAATAAACTTGATAGC To add strep tag to cwpV in pCBR044 
NF1298 CGCCTCGAGTTTCATAAATCCTAGTATTCTTGATAACATTAATGC Amplification of R20352 cwpV gene for cloning into C. difficile expression vector, pairs with NF1096 
NF1299 CGCCTCGAGTTTATTAAAATTAAAAATATTTACTGCTATTCTACCC Amplification of CDKK167 cwpV gene for cloning into C. difficile expression vector, pairs with NF1096 
NF1300 CGCCTCGAGATTAATTACAGATTTTGCTACATTTGTAAGATTTG Amplification of M9 cwpV gene for cloning into C. difficile expression vector, pairs with NF1096 
NF1301 CGCCTCGAGTTTAACCAGATTAGTAAACTTAAGCATTAGTC Amplification of AY1 cwpV gene for cloning into C. difficile expression vector, pairs with NF1096 
NF1308 GCC AAG ATA GAA AAT AAT TCT AAA GG CwpV cleavage domain mutagenesis, primer F1 
NF1309 ACT AAC TTA AAG GTT AAT GAT AAA AAT GG CwpV cleavage domain mutagenesis, primer F2 
NF1310 GAT GGA ACT TTT GTT AAC TAT GG CwpV cleavage domain mutagenesis, primer F3 
NF1311 GTG GAT GAT GTA GTT ATA GAT GAT GTA AAA GAT GG CwpV cleavage domain mutagenesis, primer F4 
NF1312 CCT AAT GGT GAT GTA AAT AAC TAT GC CwpV cleavage domain mutagenesis, primer F5 
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Name Sequence (5’ to 3’) Characteristic or use 
NF1313 TAT TTT TCC ATA GTT AAC AAA AGT TCC CwpV cleavage domain mutagenesis, primer R1 
NF1314 TTT TAC ATC ATC TAT AAC TAC ATC ATC C CwpV cleavage domain mutagenesis, primer R2 
NF1315 TTT TGC ATA GTT ATT TAC ATC ACC ATT AGG CwpV cleavage domain mutagenesis, primer R3 
NF1316 CAT GTT GAT AGT CAC AGT CTT TGT ATA TG CwpV cleavage domain mutagenesis, primer R4 
NF1317 ACC ATT TAA GTT TAC TGT TAC TGC CwpV cleavage domain mutagenesis, primer R5 
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Table 2.3 Plasmids used in this study 
Name Relevant characteristics Source/ reference 
pTUM177 Contains promoterless gusA gene with C. difficile tcdB RBS. 
Mani and Dupuy 
(2001) 
pMTL960 E. coli – C. difficile shuttle vector. 
Purdy et al., 
(2002) 
pCBR001 Contains synthetic gene for FbFP; pUC19 backbone. 
This study and 
Drepper et al., 
(2007b) 
pCBR003 pCBR001 modified by introduction of EcoRI site upstream of RBS. This study. 
pCBR012 Derived from pCBR001; contains fbfp gene under control of cwp2 promoter; pMTL960 backbone. This study. 
pCBR023 Contains modified gusA gene under control of cwp2 promoter; pUC19 backbone. This study. 
pCBR024 pUC19 containing gusA and short upstream sequence. cwpV switch in ON orientation. (short ON) This study. 
pCBR025 pUC19 containing gusA and short upstream sequence. cwpV switch in OFF orientation. (short OFF) This study. 
pCBR026 pUC19 containing gusA and long upstream sequence of cwpV with switch in ON orientation. (ON) This study. 
pCBR027 pUC19 containing gusA and long upstream sequence of cwpV with switch in OFF orientation. (OFF) This study. 
pCBR028 Derivative of pCBR026 containing 2 bp deletion in LIR of cwpV switch. (ON LIR*) This study. 
pCBR029 Derivative of pCBR027 containing 2 bp deletion in LIR of cwpV switch. (OFF LIR*) This study. 
pCBR030 Derivative of pCBR026 containing 2 bp deletion in RIR of cwpV switch. (ON RIR*) This study. 
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pCBR031 Derivative of pCBR027 containing 2 bp deletion in RIR of cwpV switch. (OFF RIR*) This study. 
pCBR032 Derivative of pCBR027 with entire switch region deleted (∆IR) This study. 
pCBR033 pUC19 containing the full-length cwpV gene from 630 under the control of the cwp2 promoter This study. 
pCBR034 Insert from pCBR023 cloned into pMTL960. (Pcwp2-gusA) This study. 
pCBR035 Insert from pCBR024 cloned into pMTL960. (short ON-gusA) This study. 
pCBR036 Insert from pCBR025 cloned into pMTL960. (short OFF- gusA) This study. 
pCBR037 Insert from pCBR026 cloned into pMTL960. (ON- gusA) This study. 
pCBR038 Insert from pCBR027 cloned into pMTL960. (OFF- gusA) This study. 
pCBR039 Insert from pCBR028 cloned into pMTL960. (ON LIR*- gusA) This study. 
pCBR040 Insert from pCBR029 cloned into pMTL960. (OFF LIR*- gusA) This study. 
pCBR041 Insert from pCBR030 cloned into pMTL960. (ON RIR*- gusA) This study. 
pCBR042 Insert from pCBR031 cloned into pMTL960. (OFF RIR*- gusA) This study. 
pCBR043 Insert from pCBR032 cloned into pMTL960. (∆IR- gusA) This study. 
pCBR044 pMTL960 containing the full-length cwpV gene from CD630 under the control of cwp2 promoter (pOECwpV) This study. 
pCBR045 pACYC-Duet1 containing CD1932 This study. 
pCBR046 pACYC-Duet1 containing CD1905 This study. 
pCBR047 pACYC-Duet1 containing CD2066 This study. 
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pCBR048 pACYC-Duet1 containing CD1882 This study. 
pCBR049 pACYC-Duet1 containing CD1167 (recV) This study. 
pCBR050 pACYC-Duet1 containing CD3578 This study. 
pCBR051 pACYC-Duet1 containing CD1222 This study. 
pCBR059 Derivative of pCBR038 with section of cwpV switch deleted - ∆1 This study. 
pCBR060 Derivative of pCBR038 with section of cwpV switch deleted - ∆2 This study. 
pCBR061 Derivative of pCBR038 with section of cwpV switch deleted - ∆4 This study. 
pCBR062 Derivative of pCBR038 with section of cwpV switch deleted - ∆5 This study. 
pCBR063 Derivative of pCBR037 with 5bp in predicted stem loop mutated (ON>OFF) This study. 
pCBR064 Derivative of pCBR038 with 5bp in predicted stem loop mutated (OFF>ON) This study. 
pCBR065 Derivative of pCBR033 with truncated cwpV gene This study. 
pCBR066 Insert from pCBR065 cloned into pMTL960 (pOE Nter) This study. 
pCBR068 pET28a for expression of two CwpV Type I repeats (630)  This study. 
pCBR069 pET28a for expression of two CwpV Type II repeats (20352)  This study. 
pCBR070 pET28a for expression of two CwpV Type III repeats (CDKK167) This study. 
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pCBR071 pET28a for expression of one CwpV Type IV repeat (M9)  This study. 
pCBR072 pET28a for expression of one CwpV Type V repeat (AY1)  This study. 
pCBR073 pET28a for expression of nine type I repeats (630) This study. 
pCBR079 Derivative of pCBR034 encoding CwpV with a C-terminal strep-tag  This study. 
pCBR080 Insert from pCBR079 cloned into pMTL960 (pOE I) This study. 
pCBR081 Derivative of pCBR080 with CwpV cleavage domain deletion – CDM1 This study. 
pCBR082 Derivative of pCBR080 with CwpV cleavage domain deletion – CDM2 This study. 
pCBR083 Derivative of pCBR080 with CwpV cleavage domain deletion – CDM3 This study. 
pCBR084 Derivative of pCBR080 with CwpV cleavage domain deletion – CDM4 This study. 
pCBR085 Derivative of pCBR080 with CwpV cleavage domain deletion – CDM5 This study. 
pCBR086 Derivative of pCBR080 with CwpV cleavage domain deletion – CDM6 This study. 
pCBR100 Derivative of pCBR079 encoding 20352 CwpV  This study. 
pCBR101 Derivative of pCBR079 encoding CDKK167 CwpV This study. 
pCBR102 Derivative of pCBR079 encoding M9 CwpV  This study. 
pCBR104 Derivative of pCBR079 encoding AY1 CwpV  This study. 
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pCBR105 Insert from pCBR079 cloned into pMTL960 (pOE II) This study. 
pCBR106 Insert from pCBR079 cloned into pMTL960 (pOE III) This study. 
pCBR107 Insert from pCBR079 cloned into pMTL960 (pOE IV) This study. 
pCBR109 Insert from pCBR079 cloned into pMTL960 (pOE V) This study. 
pCBR113 Derivative of pRPF146 encoding RecV with a C-terminal strep-tag under the control of a tetracylcine-inducible promoter This study. 
pCBR115 Derivative of pCBR113 with a mutation to encode RecV Y176F This study. 
pRPF146 pMTL960 with gusA under the control of a tetracylcine-inducible promoter  Dr. Robert Fagan 
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3 Production of recombinant plasmids  
3.1 Reporter Plasmids 
Plasmid pCBR001 was constructed (Codon Devices, USA) carrying a synthetic 
gene for the blue light photoreceptor FbFP (Drepper et al., 2007b) under the 
control of the constitutive cell wall protein Cwp2 promoter (Pcwp2) and its ribosome 
binding site (RBS) with a pUC19 backbone. pCBR001 was digested with BamHI 
and Acc65I and the BamHI-Acc65I fragment containing the Pcwp2 sequence and 
the FbFP gene were subcloned into the E.coli-C. difficile shuttle plasmid pMTL960 
(Purdy et al., 2002) to create pCBR012. In order to allow substitution of the gene 
and/or promoter the pCBR001 plasmid was modified by the introduction of an 
EcoRI site 10 bp upstream of the RBS using primers NF812 and NF813 to create 
pCBR003.  
 
The gusA reporter plasmid pTUM177 (Mani and Dupuy, 2001), containing a 
promoterless gusA gene and the toxB ribosome-binding site, was mutated by 
deletion of the BamHI site within gusA by SDM using primers NF883 and NF884.  
The toxB ribosome-binding site and the gusA ORF were amplified with primers 
NF885 and NF886, to produce an 1860 bp EcoRI-BamHI fragment. This fragment 
was ligated to pCBR003 to produce pCBR023. An illustration of pCBR023 is 
shown in Figure 3.1.  
 
The plasmid pCBR023 was then cleaved with Acc65I-EcoRI and the Pcwp2 
fragment was replaced with one of the following fragments derived by PCR of C. 
difficile CD630 DNA from upstream of cwpV: a short fragment not including the 
putative cwpV promoter (PcwpV) and having the cwpV switch in the ON orientation 
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(primers NF814 and NF815) was used to form pCBR024; a short fragment not 
including the PcwpV and having the cwpV switch on the OFF orientation (primers 
NF814 and NF815) forming pCBR025; a long fragment including the putative 
cwpV promoter was used with primers NF855 and NF856 and the transformants 
screened by PCR with the primers followed by AseI digestion to identify a plasmid 
containing the cwpV switch in the ON orientation (pCBR026) and one in the OFF 
orientation (pCBR027).  To produce pUC19-ON LIR*-GusA and pUC19-ON RIR*-
GusA plasmids (pCBR028 and pCBR030) 2 bp deletions in the IRs of pCBR026 
were carried out by inverse PCR. For ON LIR* primers NF864 and NF865 were 
used, for ON RIR* primers NF866 and NF867 were used.  To produce pUC19-
OFF LIR*-GusA and pUC19-OFF RIR*-GusA plasmids (pCBR029 and pCBR031) 
2 bp deletions in the IRs of pCBR027 were carried out by inverse PCR.  For OFF 
LIR* deletion primers NF864 and NF866 were used, for OFF RIR* production 
primers NF865 and NF867 were used.  Inverse PCR was carried out with primers 
NF894 and NF895 to delete the entire cwpV switch from pCBR027 to form 
pCBR032.  
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Figure 3.1 pCBR023 
The plasmid pCBR023 has a pUC19 backbone. The Acc65I-BamHI fragment 
contains the Cwp2 promoter and the gusA reporter gene. The EcoRI site is 
situated 10bp upstream of the ribosome binding site to enable promoters and 
genes to be switched by restriction digest using EcoRI and either BamHI (to 
switch the gene) or Acc65I (to switch the promoter). The Acc65I-BamHI fragment 
can be cloned into pMTL960 for subsequent transfer to C. difficile. pUC19-based 
plasmids were often used to plasmid mutagenesis, due to the smaller size of 
pUC19 compared to pMTL960 and also to eliminate the risk of introducing 
secondary plasmid backbone mutations in pMTL960.  
 
For plasmids pCBR023-032 the BamHI-Acc65I fragment containing the putative 
promoter sequences and the gusA gene were subcloned into pMTL960 to 
produce plasmids pCBR034-043. An illustration of pCBR034 is shown in Figure 
3.2. 
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Figure 3.2 pCBR034 
The plasmid pCBR034 has the Acc65I-BamHI fragment from pCBR024 cloned 
into pMTL960. The pMTL960 backbone encodes the functions necessary for 
conjugative transfer of the plasmid from E. coli CA434 to C. difficile. Due to the 
presence of EcoRI sites in the pMTL960 backbone promoters and genes cannot 
be simply exchanged by restriction digest, this must be done in the pUC19 
backbone plasmids and constructs subsequently subcloned into pMTL960.  
 
 
To test our model by deletion of sections of the OFF orientation of the cwpV 
switch inverse PCR was carried out with pCBR038 as template. For ∆1 primers 
NF894 and NF952 were used to create pCBR059. For ∆2 primers NF953 and 
NF954 were used to create pCBR060. For ∆4 primers NF953 and NF956 were 
used to create pCBR061. For ∆5 primers NF894 and NF954 were used to create 
pCBR062. For mutation of 5bp in the stem loop region referred to as OFF>ON, 
pCBR038 was used as template with primers NF909 and NF910 to create 
pCBR064. For ON>OFF pCBR037 was used as template with primers NF911 and 
NF912 to create pCBR063.  
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3.2 Recombinase expression in E. coli 
Genes for seven recombinase genes (CD1932, CD1905, CD2066, CD1822, 
CD1167, CD3578 and CD1222) were amplified from CD630 gDNA using specific 
primers, as detailed in Table 2.2. These PCR products were digested with BamHI 
and NotI and cloned into pACYCDuet-1 (Novagen) digested with the same enzymes 
to generate plasmids pCBR045-51, encoding N-terminally his-tagged recombinases. 
An illustration of pCBR045 is shown in Figure 3.3. 
 
Figure 3.3 pCBR045 
The plasmid pCBR045 contains the CD1932 recombinase gene in the BamHI-
NotI cloning site. This generates a construct encoding the recombinase with an N-
terminal His-tag.  
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3.3 RecV (CD1167) expression in C. difficile  
For complementation of ΔrecV the recV gene from C. difficile 630 was amplified with 
two rounds of PCR using primers NF1357 and NF1359, then NF1357 and NF1360. 
These primers were designed to add an XhoI site and a C-terminal StrepII-tag-
encoding sequence to the 5’ end of the PCR product. This amplified fragment was 
directionally cloned using SacI and BamHI into the C. difficile tetracycline-inducible 
expression vector pRPF146 to generate pCBR113 (pRecV), encoding RecV with a 
C-terminal StrepII-tag. pCBR113 is illustrated in Figure 3.4 Inverse PCR with primers 
NF1411 and NF1412, using pCBR113 as the template, was carried out to mutate the 
recV tyrosine176 codon to a phenylalanine codon. This produced the plasmid 
pCBR115 (pRecVY176F). 
 
Figure 3.4 pCBR113 
The plasmid pCBR113 encodes RecV with a C-terminal StrepII-tag under the 
control of a tetracycline inducible promoter. From this construct genes can be 
exchanged using SacI and XhoI, without affecting the C-terminal StrepII-tag.  
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3.4 Expression of CwpV repeat fragments in E.coli  
To clone fragments of CwpV for expression of recombinant proteins CwpV 
repeats from strains 630 (type I), R20352 (type II), CDKK167 (type III), M9 (type 
IV) and AY1 (type V) were amplified by PCR and primers described in Table 2.2. 
These fragments were directionally cloned using NcoI and XhoI into pET28a E. 
coli expression vector to generate plasmids pCBR068-072. pCBR068 is illustrated 
in Figure 3.5. For expression of nine type I CwpV repeats primers NF1019 and 
NF1095 were used to amplify nine repeats from 630 gDNA. This fragment was 
then cloned into pET28a to produce pCBR073. 
 
Figure 3.5 pCBR068 
The plasmid pCBR068 was constructed by insertion of sequence encoding for two 
typeI CwpV repeats into the NcoI-XhoI cloning site, yielding a plasmid encoding 
for recombinant protein with a C-terminal His-tag.  
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3.5 Expression of CwpV in C. difficile  
The full-length cwpV gene was amplified from CD630 gDNA using primers 
NF1096 and NF1097. This PCR product was digested with EcoRI and BamHI and 
cloned into pCBR023 in place of the gusA gene to create pCBR033. The Acc65I-
BamHI fragment containing PCwp2 and the cwpV gene was then subcloned into 
pMTL960 to produce pCBR044, illustrated in Figure 3.6. 
 
Figure 3.6 pCBR044 
The plasmid pCBR044 (pOECwpV) allows expression of CwpV in C. difficile. It 
utilises the Cwp2 promoter that had been assessed using GusA reporter assays. 
It was constructed from the GusA construct, by exchange of gusA for cwpV.  
 
To truncate the cwpV gene, such that it only encodes the N-terminal part of CwpV 
up to the end of the serine/gycine rich linker, inverse PCR was carried out using 
primers NF1123 and NF1124 on pCBR033 to generate pCBR065. The Acc65I-
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BamHI fragment containing PCwp2 and the truncated cwpV gene was then 
subcloned into pMTL960 to produce pCBR066.  
 
In order to add an 5’ XhoI site and a C-terminal StrepII-tag (WSHPQFEK)-
encoding sequence to cwpV the plasmid pCBR033 was used as template for 
inverse PCR with primers NF1296 and NF1297 to generate pCBR079. The 
Acc65I-BamHI fragment containing PCwp2 and the StrepII-tagged cwpV gene 
was then subcloned into pMTL960 to produce pCBR080, illustrated in Figure 3.7.  
 
Figure 3.7 pCBR080 
The plasmid pCBR080 encodes CwpV with a C-terminal StrepII-tag. The StrepII-
tag was added by inverse PCR and an XhoI site prior to the tag was included to 
allow exchange of genes without disrupting the tag or exchange of the tag without 
disrupting the gene.  
 
Cleavage domain mutants were created by inverse PCR with primers NF1308-
1317 using pCBR080 as template to create plasmids pCBR081-086. The cwpV 
genes from R20352, CDKK167, M9 and AY1 were amplified with the primers 
 141 
NF1096 and NF1298-1301 and cloned in place of the 630 gene in pCBR080 to 
create plasmids pCBR105-107 and 109 (pOE II-V).  
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4 Regulation of CwpV expression 
4.1 Introduction 
As described in the general introduction CwpV had been observed to be 
expressed in a phase variable manner, based on assays that relied upon the use 
of polyclonal antibodies raised to the CwpV N-terminus (anti-CwpVNter) and first 
C-terminal repeat (anti-CwpVrptI). In order to confirm the specificity of these 
antibodies, and therefore the reliability of the observations of CwpV phase 
variability, a CwpV knock-out strain was desired. Using the ClosTron system 
(Heap et al., 2007) Dr. Robert Fagan constructed a CwpV knock-out in C. difficile 
630∆erm and this strain, designated ∆cwpV, was therefore available for 
characterisation with anti-CwpV antibodies.  For further confirmation of CwpV 
expression observations a C. difficile plasmid was desired, conferring constitutive 
expression of CwpV in C. difficile. Prior to the start of this project complementation 
of knock-outs in C. difficile using expression from plasmids had not been 
described, although stable C. difficile plasmids were available (Purdy et al., 2002). 
In this chapter the specificity of anti-CwpV antibodies is verified using ∆cwpV and 
constitutive expression of CwpV from a plasmid. The observations of CwpV phase 
variable expression are also confirmed. 
 
In order to analyse the mechanism underlying phase variation of CwpV a reporter 
gene system for use in C. difficile was desired. Reporter gene use in C. difficile 
had been previously described; the reporter enzyme beta-glucuronidase (GusA) 
was used to investigate the C. difficile cytotoxin promoters (Mani et al., 2002). 
However, in this study the plasmids used were unstable in C. difficile. More stable 
C. difficile plasmids (Purdy et al., 2002) facilitated the development of a robust 
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reporter system for C. difficile, which is desribed in this chapter. Fluorescent 
reporters are useful for studying phase variation as they give information about 
expression at the individual cell level. Novel fluorescent proteins, which, unlike 
commonly used GFP-family proteins, are active under anaerobic conditions had 
been reported (Drepper et al., 2007a) therefore the use of these fluorescent 
proteins as reporters in C. difficile was investigated.  
 
Other inversion-based phase variation systems, where the mechanisms 
underpinning phase variation have been determined, rely upon inversion of the 
DNA sequence encoding the promoter of the gene or part of the open reading 
frame (ORF) (Wisniewski-Dye & Vial, 2008, van der Woude & Baumler, 2004). 
From the C. difficile genomic DNA sequence it can be seen that the region of 
inversion is upstream of the cwpV ORF, and therefore the ORF is not directly 
affected by DNA inversion. The location of the CwpV promoter and the effect of 
DNA inversion upon its activity were therefore investigated by use of reporter 
genes. The results presented in this chapter support the proposal of a novel 
mechanism responsible for phase variable expression of CwpV, where neither the 
orientation of the promoter nor the ORF are directly affected by DNA inversion.  
 
Inversion of a DNA sequence flanked by inverted repeats is characteristic of the 
action of site-specific recombinases. In some other systems of bacterial phase 
variation involving DNA inversion, the site-specific recombinases are encoded in 
the same genetic locus as the phase variable gene, for example the E. coli Fim 
recombinases (Klemm, 1986) and the Salmonella enterica Hin recombinase 
(Heichman & Johnson, 1990). However, in the direct vicinity of cwpV in 630 no 
obvious candidate recombinase can be found. A large number of site-specific 
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recombinases are encoded in the 630 genome in part due to the high prevalence 
of mobile genetic elements (Sebaihia et al., 2006), which carry recombinases for 
chromosome integration and excision events. Inversion of the cwpV DNA switch 
has been detected in a diverse set of C. difficile strains, therefore the 
recombinase responsible for inversion is likely to be well conserved between 
strains. Based on a microarray study (Stabler et al., 2006b) it was known which of 
the 630 site-specific recombinases were well conserved across diverse strains. 
This allowed selection of recombinase candidates for study, and the results 
presented in this chapter identify a single site-specific recombinase that is 
required for cwpV switch inversion in C. difficile. Creation of a knock out of this 
recombinase in 630 is reported in this chapter and the effects of knocking out this 
recombinase on CwpV expression are determined.  
 
4.2 Results 
4.2.1 CwpV is expressed in a phase variable manner in C. difficile 630 
The cwpV gene was targeted for disruption with a group II intron using the 
ClosTron system. Dr. Robert Fagan carried out the mutagenesis procedure and 
isolated a C. difficile clone in which the cwpV gene had been successfully 
disrupted, designated ∆cwpV (NF2015). The 630 cwpV gene was cloned into a 
stable E. coli-C. difficile shuttle plasmid pMTL960 under the control of the cwp2 
promoter, known to confer expression of Cwp2 under normal growth conditions. 
This plasmid, designed for constitutive expression of CwpV in C. difficile was 
named pOECwpV (pCBR045). This plasmid was transferred by conjugation to 
∆cwpV to yield ∆cwpV(pOEcwpV). C. difficile surface layer extracts were prepared 
from 630∆erm wild-type (WT), ∆cwpV and  ∆cwpV(pOEcwpV). These were 
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analysed for CwpV expression by SDS-PAGE followed by Coomassie staining 
and Western blotting using anti-CwpVNter and anti-CwpVrpt1 antibodies. The 
results, shown in Figure 4.1, verify the specificity of both anti-CwpV antibodies, as 
no signal is detected in ∆cwpV. Successful expression of CwpV from pOECwpV 
can be seen, with CwpV constituting a significant proportion (estimated at ~25% 
by densitometry) of the total S-layer protein in ∆cwpV(pOEcwpV). CwpV is 
expressed on the surface of C. difficile as two fragments, one `~45 kDa (open 
triangle) and one ~120 kDa (black triangle) in size. The predicted mass of CwpV 
after signal peptide cleavage is 163 kDa. Given the reactivity of the ~45 kDa 
fragment with anti-CwpVNter and the ~120 kDa fragment with anti-CwpVrpt1 it 
was therefore postulated that the mature surface-expressed form of CwpV 
consists of two fragments, the ~45 kDa N-terminal fragment and the ~120 kDa C-
terminal fragment.  
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Figure 4.1 Surface expression of CwpV.  
C. difficile strains were grown overnight in BHI broth. S-layer extracts were 
prepared and analysed by SDS-PAGE and Western blotting. A. Coomassie blue-
stained gel. B. Western blot using anti-CwpVNter (1:5000). C. Western blot using 
anti-CwpVrpt1 (1:5000). Lane 1: WT; lane 2: ∆cwpV; lane 3: ∆cwpV(pOECwpV). 
The ~43 kDa (open triangle) and ~116 kDa (closed triangle) fragments of CwpV 
are indicated. For Western blots the total protein loaded in lane 3 was fivefold less 
than in lanes 1 and 2 to allow all bands to be visualized using one exposure time. 
 
To characterize CwpV expression in these strains at the cellular level, rather than 
the average of a batch of millions of cells as seen in a surface extract, bacterial 
cells were stained with anti-CwpVrptI and anti-rabbit rhodamine red-X. Overnight 
C. difficile cultures were grown from single C. difficile colonies inoculated into 
standard BHI growth medium. As can be seen in Figure 4.2 WT cells express 
CwpV in a phase variable manner, as had been previously observed. 
Approximately 5% of cells express CwpV. This proportion of CwpV-positive cells 
was seen reproducibly in 630 cultures, with measured CwpV-positive proportions 
ranging from ~1-10%. The validity of this conclusion, based on staining with the 
anti-CwpVrptI antibody was verified by the lack of staining of all ∆cwpV cells. 
Expression of CwpV from the pOECwpV plasmids resulted in all cells expressing 
CwpV. This was as expected based on the usage of the cwp2 promoter in this 
plasmid, as Cwp2 is known to be expressed in all cells of a clonal population 
(data not shown). 
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Figure 4.2 Expression of CwpV at the cellular level.  
C. difficile strains; top to bottom: WT, ∆cwpV, ∆cwpV(pOECwpV), were grown 
overnight in BHI broth. Cells were harvested and stained for CwpV expression 
using anti-CwpVrpt1 and anti-rabbit rhodamine red-X antibodies. CwpV 
expression was detected by fluorescence microscopy. Images shown are (left to 
right) phase contrast, fluorescence, merged. 
 
4.2.2 Development of a C. difficile reporter assay 
Having confirmed and validated the observations of CwpV phase variability, the 
next aim was to investigate the molecular mechanism underpinning this phase 
variation. This required the development of a robust reporter system for use in C. 
difficile. FbFP is a flavin-based fluorescent protein developed from photoreceptors 
(Drepper et al., 2007a). Unlike the GFP family of fluorescent proteins it is active 
under both aerobic and anaerobic conditions, and therefore seemed a good 
candidate for use as a reporter gene in C. difficile. The fbfp gene was synthesized 
commercially according to the published sequence (Drepper et al., 2007a) in a C. 
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difficile codon-optimised form. This fbfp gene was then cloned into the pMTL960 
C. difficile expression vector under the control of the cwp2 promoter, in the same 
position as the cwpV gene in the previously described pOECwpV to produce 
pCBR012, which was transferred from E. coli to C. difficile by conjugation.  For 
robust, reliable reporter assays it is important that the reporter plasmid is well 
tolerated by the bacterium, which can be assessed by determining the stability of 
the plasmid. The stability of the pCBR012 plasmid in C. difficile was assessed by 
serially subculturing cells containing the plasmid in the absence of thiamphenicol 
selection, then plating the resultant cells onto plates with and without 
thiamphenicol, allowing determination of the proportion of cells still containing the 
plasmid. In  Figure 4.3A it can be seen that the plasmid is gradually lost over the 7 
serial subcultures carried out, as expected due to plasmid segregation during 
replication. However, there is no sudden loss of the plasmid once selection is 
removed, indicative of a well-tolerated stable reporter plasmid.  
 
In order to assess the usefulness of FbFP as a reporter the fluorescence of WT 
cells (no plasmid) was compared to cells containing pCBR012. FbFP expression 
was measured using a fluorescent spectrophotometer, exciting at 450nm and 
recording the emission at 495nm. In Figure 4.3B it can be seen that pCBR012 
does increase the fluorescence of C. difficile compared to WT cells. However with 
the cwp2 promoter, known to be a relatively strong promoter from the pOECwpV 
work, the fluorescence conferred by pCBR012 is only ~2.5-fold that of WT cells. 
This is in part due to relatively high intrinsic fluorescence of C. difficile cells, which 
has been documented and sometimes used to aid in C. difficile identification in a 
medical microbiology setting. A greater degree of sensitivity was desired for a 
 149 
reporter to use for investigation into the mechanisms underpinning CwpV phase 
variation. Therefore the use of FbFP was not pursued further. 
 
As mentioned in the introduction the enzyme beta-glucuronidase (GusA) has 
previously been used successfully in C. difficile (Mani et al., 2002), therefore the 
fbfp gene in pCBR012 was substituted for the gusA gene, producing pCBR035. 
GusA activity of WT 630 and 630(pCBR034) cell lysates was measured using a 
colorimetric GusA substrate as previously described (Mani & Dupuy, 2001). As 
can be seen in Figure 4.3C GusA expression driven from the cwp2 promoter in 
pCBR034 can be detected and the signal:background ratio is much higher than 
for FbFP. This reporter therefore exhibits the sensitivity desired for investigating 
the molecular mechanism of CwpV phase variation. However it cannot easily give 
information at the cellular level, as the activity is measured on a batch culture. 
This is a drawback for studying phase variation, but due to the paucity of options 
for fluorescent reporters in anaerobes it was decided to use GusA.  
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Figure 4.3 Development of a robust C. difficile reporter assay.  
A. Stability of pCBR012 in 630. Seven successive overnight cultures of 
630(pCBR012) were carried out without thiamphenicol selection. Viable counts 
were then carried out on BHI and BHI + thiamphenicol plates to determine the 
proportion of bacteria containing the plasmid. B. FbFP expression in 630 driven 
by the Cwp2 promoter. Cultures of 630 and 630(pCBR012) were grown in liquid 
culture to an OD of 0.4-0.8. The fluorescence at 495nm of the bacteria was 
measured. Three individual cultures were measured and the mean values are 
shown with standard deviation error bars. C. GusA expression in 630 driven by 
the Cwp2 promoter. Cultures of 630 and 630(pCBR034) were grown in liquid 
culture to an OD of 0.4-0.8. Bacteria were lysed and the GusA activity determined 
using a colorimetric assay as previously described (Mani & Dupuy, 2001). 
 151 
4.2.3 Using the GusA reporter system to investigate the mechanism 
underlying phase variation of CwpV 
Concomitant with development of the GusA reporter assay, some properties of 
the cwpV transcript were investigated in the laboratory. I will briefly summarise 
these findings as they were not my own work but contributed to the subsequent 
design of reporter constructs enabling elucidation of the phase variation 
mechanism. In order to locate the start site of transcription of cwpV 5′ RACE 
(Rapid Amplification of cDNA Ends) analysis on mRNA isolated from strain 630 
was carried out. The 5′ end of the transcript was found to be localized 36 or 37 
bases upstream of the left inverted repeat (LIR). Putative -10 and -35 sequences, 
closely matching those recognized by the major bacterial sigma factor σ70 in 
other Gram-positive promoters were identified appropriately positioned upstream 
of the site of transcript initiation. Interestingly, all RACE clones sequenced were 
observed to be in one orientation, termed the ON orientation. PCR-RFLP analysis 
was carried out with primers specific for the inversion region, and also clearly 
showed that the cwpV mRNA is present in the ON orientation. In contrast, the 
majority of the genomic DNA is present in the other orientation, termed the OFF 
orientation. It therefore appears that stable full-length transcripts can only be 
produced from genomic DNA in the ON orientation. This is consistent with the 
detection of CwpV expression in only around 5% of cells, possibly corresponding 
to those few cells with genomic DNA in the ON orientation.  
 
To study the ability of the cwpV DNA switch to control transcription, a series of 
gusA transcriptional reporter constructs was created in E. coli. GusA expression 
driven by the cwp2 promoter could act as a positive control for the reporter assay. 
DNA fragments located upstream of cwpV were amplified from 630 genomic DNA 
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and cloned upstream of gusA in order to assay their ability to drive expression. 
Two different lengths of fragment were used: (i) long fragments containing DNA 
extending 432 bp upstream of the start codon of cwpV, which contain the 
experimentally determined transcriptional start site and predicted promoter; and 
(ii) short fragments which extended 273 bp upstream of the start codon of cwpV 
and did not include the LIR. Plasmids with the long upstream sequence were also 
constructed containing a 2 bp deletion in the LIR (LIR*) or right IR (RIR*). This 
mutation is naturally found in the LIR of C. difficile strain R8366, which had been 
observed to not undergo DNA inversion (Emerson et al., 2009). All plasmids were 
generated such that the cwpV switch was in each of the two orientations, termed 
ON and OFF. Construction of these single orientation plasmids was possible 
because the cwpV switch does not invert in E. coli (see below). A diagrammatic 
representation of the different sequences tested for promoter activity is shown in 
Figure 4.4A.  
 
These plasmids were transferred to C. difficile 630 by conjugation. Exponential 
cultures were analysed for GusA activity (Figure 4.4B) and for the plasmids 
containing long sequences the cwpV switch orientation was assayed by PCR 
(Figure 4.4C). The plasmid containing the long upstream sequence in the ON 
orientation (pCBR037) was able to drive expression of GusA (Figure 4.4B). 
Expression was also observed from the long OFF plasmid (pCBR038). PCR 
analysis of the plasmids with long upstream sequences after growth in C. difficile 
confirmed that both originally ON and originally OFF plasmids contained DNA in 
both the ON and OFF orientations (Figure 4.4C). This suggests that in C. difficile 
the cwpV switch on this plasmid can undergo inversion, resulting in sufficient 
levels of the switch in the ON orientation to allow expression of gusA. Strains 
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containing LIR* or RIR* mutant derivatives of the ON plasmids (pCBR039 and 
pCBR041) also expressed GusA, whereas those in the OFF orientation 
(pCBR040 and pCBR042) did not. PCR analysis showed that OFF plasmids with 
the LIR* and RIR* mutations contained DNA only in the OFF orientation, 
confirming that the 2 bp deletion did indeed lock the DNA in one orientation and 
prevent switching. This is consistent with a complete lack of GusA activity 
detected in these strains and a lack of expression of CwpV in strain R8366, which 
contains the same upstream sequence as OFF LIR*. DNA in the ON orientation 
and containing the 2 bp deletion in either IR drove expression of GusA, indicating 
that the deletion itself does not prevent expression. Therefore it is the inability to 
switch that causes the OFF phenotype of strain R8366. PCR analysis of ON LIR* 
detected some of the cwpV switch in the OFF orientation showing that the 
orientation of ON LIR* does not remain fully locked ON (Figure 4.4C), suggesting 
that this 2 bp deletion inhibits the OFF to ON inversion more effectively than ON 
to OFF. Plasmids containing the short fragment of DNA upstream of cwpV 
(pCBR035 and pCBR036) did not drive the expression of gusA, regardless of the 
orientation of the cwpV switch, consistent with the promoter being located 
upstream of the LIR. Interestingly, deletion of the entire cwpV switch region 
(pCBR043) resulted in expression of gusA, demonstrating that the cwpV promoter 
functions in the absence of the cwpV switch. This indicates that the cwpV switch 
is a negative regulator of expression when present in the OFF orientation. 
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Figure 4.4 Analysis of transcription from the CwpV promoter in C. difficile 
using a GusA reporter.  
C. difficile 630 containing plasmids with different components of the cwpV switch 
upstream of gusA were grown in liquid medium, harvested and the β-
glucoronidase activity measured. A. Diagrammatic representation of the promoter 
regions present in the plasmids used in this experiment. Plasmids used were: 
Pcwp2, pCBR034; short ON, pCBR035; ON, pCBR037; ON LIR*, pCBR039; ON 
RIR*, pCBR041; short OFF, pCBR036; OFF, pCBR038; OFF LIR*, pCBR040; 
OFF RIR*, pCBR042; ∆IR, pCBR043. B. Enzyme activities of cell lysates. Error 
bars represent the standard deviations of independent cell lysates (n = 3). C. PCR 
analysis of DNA isolated from cultures using primers to detect the ON (left) 
(NF793 and 826) and OFF (NF793 and 825) orientations of the cwpV switch. 
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4.2.4 A model for the cwpV switch mechanism 
Considering the mechanisms whereby DNA inversion could act as a negative 
regulator of cwpV expression, two possibilities seem likely. First, one or more 
proteins could bind to the DNA or RNA in the OFF orientation and prevent 
transcription or translation. Second, intrinsic properties of the DNA or RNA in the 
OFF orientation could prevent transcription or translation. These two mechanisms 
are not mutually exclusive as there may be a specific structure in the OFF 
DNA/RNA to which protein binding could mediate the negative regulation. To 
explore the second hypothesis and search for the presence of intrinsic 
terminators, the RNA structure of transcripts from the two orientations were 
predicted using mfold, a program that predicts the structure and free energies of 
RNA sequences (Zuker, 2003). A stable stem loop structure consisting of a 9 bp 
stem containing four G-C bp was predicted to form in the OFF orientation at the 
junction between the LIR and the region of inversion. This stem loop structure is 
followed by a poly-U tract, as illustrated diagrammatically in Figure 4.5A. In the 
ON orientation the sequence of this region is altered by a number of base pairs 
(coloured red in Figure 4.5A) due to inversion of the cwpV switch and the 
predicted RNA structure is therefore different. A model for predicting intrinsic 
terminators in E. coli has been developed (Lesnik et al., 2001) and has been used 
to predict intrinsic terminators in a number of bacterial species including 
Clostridium acetobutylicum (Paredes et al., 2004). This model is built from 
sequence constraints based on known terminator sequences from E. coli. Briefly 
there must be a stem of 4–18 bp, containing at least four G-C bp, a loop of 3–10 
nt and following the stem a poly-U tract with sufficient U-content. Quantitative 
models explaining how such structures destabilize the transcription complex have 
been reported (Yager & von Hippel, 1991). The structure predicted for the OFF 
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orientation fulfils all the criteria for an intrinsic terminator, whereas the ON stem 
only contains two G-C bp and has a large internal loop and therefore does not 
fulfil the criteria.  
 
Figure 4.5 RNA structure and free energy predictions of the cwpV switch.  
A. Predicted RNA structures found at the junction between the LIR and the region 
of inversion. Nucleotides that differ between the two orientations are shown in red. 
GC base pairing is shown in green and AU base pairing in blue. Numbering is 
from the predicted transcriptional start site. B. Free energy predictions for the two 
orientations, measuring the ∆G of 60 nt regions and sequentially moving along the 
sequence in 10 nt segments. Data were obtained using the on-line program mfold 
(Zuker, 2003). The free energy peak seen at 50 nt in the OFF orientation 
corresponds to the predicted RNA structure shown in A. 
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To further compare the stability of predicted RNA structures of the ON and OFF 
transcripts, quantitative predictions of free energy of RNA folding for the transcript 
in the two orientations were calculated for 60 nt long stretches of sequence, 
systematically moving along the transcript in 10 nt jumps. A peak in free energy, 
characteristic of an intrinsic terminator (Washio et al., 1998), is seen in the OFF 
orientation at the junction between the LIR and the inversion region; this peak is 
not present in the ON orientation (Figure 4.5B). 
 
Based on these predictions our model for the mechanism underlying phase 
variation of cwpV is that transcription initiates upstream of the LIR regardless of 
the orientation of the cwpV switch, but in the OFF orientation transcription is 
terminated upon reaching the region of inversion due to an intrinsic terminator. In 
the ON orientation, transcription can continue through the inversion region to the 
ORF and produce a full-length transcript. Based on these predictions a set of six 
new mutants was made in the cwpV switch, these are depicted in Figure 4.6A. 
Four deletions were made to test whether the repression of expression could be 
attributed to a specific region of the switch. The other two new mutants were 
designed to change only the five base pairs that differ in the predicted stem loop 
region between the OFF and ON orientation (coloured red in Figure 4.5A). For ON 
these 5 base pairs were changed to those present in the OFF orientation and this 
mutant designated ON>OFF. For OFF these 5 base pairs were changed to those 
present in ON and this mutant designated OFF>ON. These mutants were then 
tested for GusA activity. 
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Figure 4.6 Testing the model of the cwpV switch mechanism.  
A. Six cwpV switch mutants are depicted. Δ1, Δ2, Δ4 and Δ5 are deletions of 
specific lengths of the region of inversion. ON>OFF and OFF>ON differ from ON 
and OFF respectively by 5bp changes in the predicted stem loop region. B. The 
mean GusA activity of C. difficile strains containing these reporter plasmids was 
determined by colormetric assay. Three independent cultures of each strain were 
tested. The mean GusA activity is plotted with standard deviation error bars. 
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From the GusA activities shown in Figure 4.6B it can be seen that, as predicted 
from the stem loop terminator model, Δ2 and Δ4 exhibit the OFF phenotype. This 
indicates that the 5’ end of the inversion region is sufficient for repression of 
protein expression. However, Δ1 and Δ5, where the 5’ region is deleted only show 
a low level of GusA expression, much less than the full ΔIR phenotype. This 
suggests that the 3’ end of the inversion region can also somehow inhibit protein 
expression, although it is not necessary for the OFF phenotype. Thus, there 
seems to be some redundancy in the system. The OFF>ON phenotype does not 
show GusA activity, again suggesting that there is redundancy in the mechanism, 
such that mutation of 5bp alone is not sufficient to lead to an ON phenotype. 
However, the ON>OFF does display the expected OFF phenotype, again 
suggesting that the predicted stem loop sequence alone is sufficient for inhibition 
of transcription. Therefore, overall the activity of these mutants is consistent with 
our model, but there appears to be redundancy in the mechanism by which the 
OFF orientation of the cwpV switch prevents expression from the cwpV promoter.  
 
To further test the validity of the proposed model it was decided to test the activity 
of the described GusA reporter plasmids in Clostridium perfringens. The rationale 
behind this was that a mechanism relying on specialist protein factors would be 
unlikely to function in the same way in a different species, whereas the 
mechanism we propose relies upon intrinsic properties of RNA transcripts, and 
therefore would exhibit the same activity in different species. Clostridium 
perfringens was chosen, as being another member of the Clostridia has a very 
similar G:C content to C. difficile and it therefore seems reasonable that sensitivity 
of the transcriptional apparatus to RNA secondary structure would be similar 
between the two species. The reporter plasmids illustrated in Figure 3.4A were 
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transferred by conjugation to C. perfringens and the resulting strains tested for 
GusA activity. The results shown in Figure 4.7 indicate that the activity of the 
strains mirrors that seen for C. difficile in Figure 4.4B, with the exception of OFF, 
which does not exhibit any activity in C. perfringens. This is due to a lack of cwpV 
switch inversion of OFF in C. perfringens, meaning that the OFF strain does not 
contain any cwpV switch in the ON orientation, in contrast to what is seen in C. 
difficile. Switch inversion is investigated further below. The fact that these GusA 
constructs in C. perfringens exhibit the same pattern of activity as seen in C. 
difficile supports the model we propose for the phase variation mechanism, as it 
does not rely on any specialist factors, and stem loop terminators are expected to 
function across species boundaries.   
 
Figure 4.7 Analysis of transcription from the CwpV promoter in Clostridium 
perfringens. 
C. perfringens containing plasmids with different components of the cwpV switch 
upstream of gusA (as illustrated in Figure 3.4A) were grown in liquid medium, 
harvested and the β-glucoronidase activity of cell lysates measured. Error bars 
represent the standard deviations of independent cell lysates (n = 3). 
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4.2.5 Inversion of the cwpV switch does not occur in E. coli or C. 
perfringens 
During cloning of the cwpV switch region in E .coli and transfer of cwpV switch-
containing plasmids to C. perfringens it was apparent that inversion was not 
occurring in these species. These observations suggest that one or more site-
specific recombinases in C. difficile mediate DNA inversion to control expression 
of CwpV. The ability of different species to mediate inversion of the cwpV switch 
was further assessed by orientation PCR analysis of plasmids pCBR037 and 
pCBR038. These plasmids contain the cwpV switch in the ON and OFF 
orientations respectively. The orientation of the cwpV switch can be determined 
by PCR using primers which anneal to opposite strands within the region of 
inversion, paired with a primer outside the region of inversion, as illustrated in 
Figure 4.8A. In C. difficile, inversion of the cwpV switch occurred in both the ON 
and OFF plasmids, as shown by the appearance of PCR products using either 
primer NF825 or NF826 (Figure 4.8B). In contrast, in E. coli (Figure 4.8C) or C. 
perfringens (Figure 4.8D), no inversion was seen in four independent isolates 
containing either plasmid. Therefore it is likely that C. difficile encodes one or 
more specific recombinases which catalyse the inversion of the cwpV switch and 
that these enzymes are not present in C. perfringens or E. coli. 
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Figure 4.8 DNA inversion is specific to C. difficile and does not occur in C. 
perfringens or E. coli.  
Orientation-specific PCRs were carried out to determine whether DNA inversion of 
the cwpV switch occurs in E. coli or C. perfringens. A. Diagrammatic 
representation of the cwpV switch region in the ON and OFF orientations, in 
pCRB037 and pCRB038, respectively, showing the position of the primers used to 
assay switch orientation. B. PCR products of the ON and OFF plasmids after 
introduction into C. difficile. DNA inversion occurs in each case as seen by 
amplification of both PCR products. C and D. The plasmids were introduced into 
E. coli (C) and C. perfringens (D). Four independent transformants or 
transconjugants were picked and in each case no DNA inversion is seen. 
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4.2.6 Identification of a C. difficile site-specific recombinase 
mediating inversion of the cwpV switch 
A search of the C. difficile 630 genome (Sebaihia et al., 2006) identified 22 
putative recombinases. However, 16 of these are associated with the many 
mobile genetic elements (MGEs) in this strain, and are largely absent from other 
strains as determined by microarray analysis (Stabler et al., 2006b). All C. difficile 
strains analysed to date exhibit cwpV switch inversion (except R8366), making it 
likely that the site-specific recombinase(s) responsible for inversion are well 
conserved across strains. A total of seven putative site-specific recombinase 
genes were chosen for analysis: three of the best conserved MGE-associated 
recombinases, one putative housekeeping recombinase and all three non-MGE 
associated recombinase genes. The genes were amplified from C. difficile 630 
genomic DNA (Figure 3.9A) and each cloned into pACYCDuet-1 to allow their 
expression as His-tagged proteins. These recombinase-encoding plasmids were 
co-transformed into E. coli BL21(DE3) with pUC19-based plasmids containing the 
cwpV switch in either the ON or OFF orientation (pCBR026 or pCBR027). In 
Figure 3.9B/C it can be seen that orientation-specific PCR showed that only one 
recombinase, CD1167, mediated DNA inversion. This gene, which we designate 
recV, is a tyrosine recombinase of the XerC/XerD family of DNA recombinases. It 
can catalyse inversion of the cwpV switch in both the ON to OFF and OFF to ON 
directions. None of the other recombinases tested catalysed DNA inversion in E. 
coli. Western blotting using anti-His tag antibodies verified that all recombinases 
were expressed in E. coli, producing bands of the expected size (data not shown). 
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Figure 4.9 Identification of a C. difficile site-specific recombinase mediating 
DNA inversion of the cwpV switch.  
A. Genes for seven recombinases (1; CD1932, 2; CD1905, 3; CD2066, 4; 
CD1822, 5; CD1167, 6; CD3578 and 7; CD1222) were   amplified from C. difficile 
630 genomic DNA. These genes were cloned into pACYCDuet-1 and co-
transformed into E. coli BL21(DE3) with pUC19 plasmids carrying the cwpV 
switch in either the ON or OFF orientations (pCBR026 or pCBR027). PCR 
reactions with primer pairs B. NF838 and NF825 and C. NF828 and NF826 were 
then carried out to assay cwpV switch orientation. Recombinase 5 (CD1167) 
mediated inversion in both the ON to OFF and OFF to ON directions. 
 
To definitively determine the role of recV in inversion of the cwpV switch, this 
gene was targeted for disruption in C. difficile with a group II intron, using 
ClosTron technology (Heap et al., 2010) by Dr. Lucia de la Riva-Perez. Primers 
flanking the desired insertion site were designed that would amplify a 665bp 
product from the WT copy of recV. A product of 2839bp was expected following 
successful disruption of recV. WT and four erythromycin resistant clones were 
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tested by PCR. Figure 4.10A shows that a 2839bp fragment was amplified from all 
four erythromycin resistant clones, indicative of successful recV disruption. These 
clones were therefore designated ΔrecV 1-4. In order to assay inversion of the 
cwpV switch, orientation-specific PCR was carried out. As expected orientation 
PCR with four clones of WT indicated inversion of the cwpV switch was occurring 
as expected, shown by products from both primer pairs in Figure 4.10Bi. All four 
ΔrecV clones only amplified an OFF product (Figure 4.10Bii) and were therefore 
designated ΔrecVOFF. The lack of inversion in these strains confirmed the 
necessary role of RecV in cwpV DNA switch inversion, and suggests that this is 
the only C. difficile recombinase responsible for inversion.  
 
The recV gene was cloned into the C. difficile expression plasmid pRPF146 to 
yield pRecV (pCBR113). This plasmid was introduced into ΔrecVOFF by 
conjugation. Four ΔrecV(pRecV) transconjugants were tested by orientation PCR 
for inversion of the cwpV switch. In Figure 4.10Biii it can be seen that plasmid-
encoded recV successfully complemented the ΔrecVOFF mutation resulting in 
detection of cwpV switch inversion in all four transconjugants.  
 
Bioinformatic analysis of RecV indicates that it is a member of the phage 
integrase family of tyrosine recombinases, and allows prediction of active site 
residues by comparison to characterized members of this family (for example P1 
bacteriophage Cre recombinase). CwpV tyrosine-176 was identified as a putative 
catalytic residue by sequence alignment. To confirm the key role of this residue, 
site-directed mutagenesis by inverse PCR was carried out to produce pRecVY176F 
(pCBR115).  This plasmid was introduced to ΔrecVOFF by conjugation and 
transconjugants selected by growth on thiamphenicol. In Figure 4.10Biv it can be 
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seen that all four ΔrecV(pRecVY176F) transconjugants tested only had the OFF 
orientation of the cwpV switch. Therefore RecVY176F could not complement the 
ΔrecVOFF phenotype confirming the key role of tyrosine-176 in recV-mediated 
inversion of the cwpV switch.  
 
In order to isolate ΔrecVON mutants, ΔrecV(pRecV) was serially subcultured 
without thiamphenicol selection to allow loss of the pRecV plasmid. 
Thiamphenicol-sensitive colonies were isolated and tested for cwpV switch 
orientation. All were found to contain a single orientation of the cwpV switch, as 
the plasmid-encoded copy of recV had been lost (data not shown). Four clones 
were isolated from which only the ON orientation of the cwpV switch could be 
amplified, as shown in Figure 4.10 Cv, and are referred to as ΔrecVON.  
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Figure 4.10 Isolation of ΔrecV mutants.  
A. PCR confirmation of recV (CD1167) gene disruption using ClosTron. Primers 
NF1215+1356 flanking the ClosTron target site in recV give a 665bp product in 
630Δerm (WT). After the ClosTron procedure four erythromycin resistant colonies 
were tested with these primers and a 2839bp product was amplified, indicative of 
insertion of the group II intron into recV. These clones were designated ΔrecV. B. 
Analysis of the orientation of the cwpV DNA switch in C. difficile clones by 
orientation PCR. i. Products for the ON and OFF orientations are amplified from 
WT.  ii. All four isolated ΔrecV mutants contain only the OFF orientation of the 
cwpV DNA switch, therefore these strains are referred to as ΔrecVOFF. iii. 
Complementation of ΔrecVOFF using a plasmid encoding RecV reconstituted the 
switching phenotype (ΔrecV(pRecV)). iv. Alignment of RecV with other tyrosine 
recombinases identified Y176 as the catalytic tyrosine. A RecVY176F mutant was 
unable to complement ΔrecVOFF confirming the key role of this tyrosine residue 
in RecV activity. v. ΔrecV(pRecV) was serially subcultured without thiamphenicol 
selection. Four thiamphenicol sensitive colonies were isolated from which only the 
ON orientation of the cwpV DNA switch could be amplified. These strains were 
therefore referred to as ΔrecVON. 
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4.2.7 CwpV expression in ΔrecV mutants 
Overnight cultures of WT, ΔrecV(pRecV), ΔrecV(pRecVY176F), ΔrecVOFF (x4) and 
ΔrecVON (x4) were grown. Samples were taken for cwpV switch orientation-
specific PCR to confirm orientation of the cwpV switch in each culture. All cultures 
gave the orientation results expected; WT - ON/OFF, ΔrecV(pRecV) - ON/OFF, 
ΔrecV OFF(pRecVY176F) - OFF, ΔrecVOFF (x4) - OFF and ΔrecVON (x4) – ON, as 
shown in Figure 4.11A and B.  
 
In Figure 4.11C C. difficile S-layer extracts from each culture are visualized by 
SDS-PAGE and Coomassie staining. The two major bands seen in each lane at 
~40 kDa and ~35 kDa are the HMW SLP and LMW SLP, derived from post-
translational cleavage of SlpA by the cysteine protease Cwp84. In 630 and 
ΔrecV(pRecV) extracts a low level of CwpV expression can be seen with the N-
terminal fragment running at ~ 42kDa (open triangle) and the C-terminal fragment 
running at ~ 116kDa (closed triangle), reflecting the average level of CwpV 
expression in the cells of the culture, where some cells are ON and others are 
OFF. No expression of CwpV is seen in ΔrecV(pRecVY176F) or ΔrecVOFF strains, 
as the cwpV switch is only present in the OFF orientation, and therefore full-length 
cwpV transcripts cannot be produced. Compared to WT cultures, ΔrecVON strains 
express a high amount of CwpV, suggesting that in these cells CwpV constitutes 
a relatively high proportion of protein present in the S-layer. These findings are 
confirmed by Western blot using anti-CwpVrpt1 (detects the ~116 kDa CwpV 
protein) and anti-CwpVNter (detects the ~42 kDa CwpV protein) antibodies, as 
shown in Figure 4.11 D and E respectively.  
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Figure 4.11 CwpV expression in ΔrecV mutants.  
Overnight C. difficile cultures of WT, ΔrecV(pRecV), ΔrecV(pRecVY176F), 
ΔrecVOFF (x4) and ΔrecVON (x4) were grown and analysed in the following 
ways: A. NF823+825 orientation-specific PCR amplifying the ON orientation of the 
cwpV DNA switch. B. NF823 + 826 orientation-specific PCR amplifying the OFF 
orientation of the cwpV DNA switch. C. C. difficile S-layer extracts analysed by 
SDS-PAGE and Coomassie staining. D. Western blot of S-layer extracts using 
anti-CwpVrpt1 antibody (1:5000). E. Western blot of S-layer extracts using anti-
CwpVNter antibody (1:5000). The N-terminal (open triangle) and C-terminal (black 
triangle) fragments of CwpV are indicated.  
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In order to assess CwpV expression at the individual cell level, cultures were 
stained using CwpVrpt1 antibody and a fluorescent secondary antibody, then 
analysed by fluorescent microscopy. Representative fields of view for each strain 
are shown in Figure 4.12. In the WT culture ~5% of cells are ON, as previously 
observed. In ΔrecVOFF expression cannot be detected in any cells.  In 
ΔrecV(pRecV) phase variable expression of CwpV can be seen with 
approximately 15% of cells expressing CwpV.  The higher proportion of CwpV-
positive cells compared to the WT is possibly due to a different level of RecV 
expression driven from the multi-copy expression plasmid compared to the single 
genomic copy of recV in the WT strain. In ΔrecV(pRecVY176F) no CwpV 
expression can be detected, as expected due to a lack of switch inversion from 
OFF. In ΔrecVON, CwpV expression can be detected in all cells. This suggests 
that cwpV switch orientation is the primary determinant of CwpV expression; 
provided the switch is in the ON orientation, CwpV is expressed.  
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Figure 4.12 CwpV expression at the cellular level in ΔrecV mutants. 
Immunofluorescent analysis of expression of CwpV using anti-CwpVrpt1 antibody. 
Phase and fluorescence images of a representative field of view are shown. 
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4.3 Discussion 
Phase variation mediated by DNA inversion has been described in a small 
number of bacterial systems (Wisniewski-Dye & Vial, 2008). The best-
characterized systems involve inversion of a promoter or part of the ORF. In the 
former, a promoter in one orientation actively transcribes a gene whereas in the 
opposite orientation either no gene transcription occurs or an alternative gene is 
transcribed. For example, in the E. coli fim system, the fimA gene product is either 
expressed or not, depending on the promoter orientation (Abraham et al., 1985). 
In the Salmonella hin system, in one orientation the promoter directs expression 
of the H1 flagellin, whereas in the opposite orientation it directs expression of H2 
flagellin (Zieg et al., 1977).  
 
We have established that the CwpV promoter and transcriptional initiation site are 
situated upstream of the cwpV switch and that DNA inversion controls the 
expression of cwpV. The production of stable full-length cwpV transcripts is only 
possible from template genomic DNA with the cwpV switch in the ON orientation. 
This mechanism for controlling phase variable gene expression involving DNA 
inversion encompassing neither the promoter nor the ORF is to our knowledge 
completely novel. By using a gusA transcriptional reporter in C. difficile, we have 
shown that the cwpV switch region is not required for expression from the cwpV 
promoter, and that the cwpV switch must therefore act in cis to negatively regulate 
expression. We propose a model to account for these observations based on 
predicted secondary structures of the mRNA transcripts from the two orientations. 
This mechanism involving transcriptional termination modulated by DNA inversion 
has not been reported for any other system. Transcripts in the OFF orientation are 
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predicted to form a stable stem loop structure followed by a poly-U tract, which 
induces transcriptional termination at some 60–70 nucleotides downstream of the 
transcript initiation site. In the ON orientation the predicted structure does not fulfil 
the criteria for an intrinsic terminator and transcription can proceed unhindered. 
Further mutagenesis studies support the key role of the stem-loop terminator in 
conferring the OFF phenotype of the OFF orientation. This is particularly clear 
from the ON>OFF mutation that was made, where changing just 5 bp of ON to 
confer the properties of the stem-loop completely abrogated expression. 
However, these mutants also suggest that there is some redundancy in the 
system, because other regions of the OFF orientation of the cwpV switch also 
hinder expression. We acknowledge the possibility that, in the OFF orientation, 
transcription could also be affected by binding a repressor molecule or that control 
could be mediated by a combination of these mechanisms. However, the similar 
functioning of the cwpV switch in C. perfringens suggests that there are not 
specialist factors involved, as these would be unlikely to be present in C. 
perfringens. Our model predicts function of the cwpV switch across species 
boundaries, as stem-loop termintors are ubiquitous in bacterial species. The 
observations from C. perfringens therefore support our model.  
 
Interestingly modulation of transcription termination is also seen in the E. coli fim 
system, where a Rho-dependent transcriptional terminator is present downstream 
of the fimE recombinase gene in phase OFF cells ((Joyce & Dorman, 2002, Hinde 
et al., 2005). In phase ON bacteria, termination of the fimE transcript does not 
occur and the mRNA transcript is longer and more stable, leading to increased 
levels of FimE recombinase and biasing the switch to the phase OFF. However, in 
the fim switch, the primary level of control of fimA expression is inversion of the 
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promoter, whereas in the cwpV switch described here, transcription termination is 
the key event determining expression of cwpV. 
 
The recombinase RecV was able to mediate DNA inversion in both the ON to 
OFF and OFF to ON orientations when expressed in E. coli, suggesting that if 
other protein factors are necessary for cwpV switch DNA inversion they are highly 
conserved across the bacterial kingdom. Using targeted gene knock-out we have 
shown that in C. difficile 630 the tyrosine recombinase RecV is essential for cwpV 
DNA switch inversion.  This suggests that there are no other site-specific 
recombinases expressed in 630 that can mediate cwpV DNA switch inversion. In 
well-characterised phase variation systems employing DNA inversion the 
recombinase(s) involved in DNA inversion are located either within the inverted 
DNA (S. typhimurium hin) or within the immediate vicinity of the switch (E. coli fim) 
(Wisniewski-Dye & Vial, 2008). It is interesting that recV is not located in the 
vicinity of cwpV. This fact, along with the presence of the cwpV switch and recV in 
all C. difficile strains analysed within a diverse set of isolates, suggests that this 
switch and recV have not been recently acquired by C. difficile via horizontal gene 
transfer. Rather it appears that recV is a member of the relatively small core set of 
genes common to all C. difficile strains, and has been part of the evolution of C. 
difficile over a long timescale. 
 
Analysis of CwpV expression in ΔrecV mutants showed that the cwpV switch 
orientation is the primary determinant of CwpV expression. If the switch is in the 
ON orientation CwpV expression will proceed, and if the switch is in the OFF 
orientation CwpV is not expressed. Analysis of CwpV expression in the ΔrecVON 
and ΔrecVOFF mutants throughout the growth phase gave no indication of further 
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levels of CwpV expression regulation, as expression levels were constant 
throughout (data not shown). Complementation of ΔrecV with a plasmid-encoded 
copy of recV restored cwpV switch inversion, and in fact led to a higher proportion 
of cells expressing CwpV (~15%) than in the WT (~5%). The is likely due to 
differences in RecV expression levels between ΔrecV(pRecV+) and WT. The 
relationship between RecV expression level and cwpV switch orientation has not 
yet been investigated. In the well-characterised E. coli fim switch, inherent 
differences in affinity of site-specific recombinases for different orientations of the 
switch determine the relative kinetics of switching in either direction and therefore 
determine the overall proportion of switch orientations (Gally et al., 1996). Having 
definitively determined the role of RecV in cwpV switch inversion the mechanistic 
details of this switch system can be investigated.  
 
A common theory to account for phase variation in bacterial pathogens is that 
alteration of surface structures allows evasion of the immune responses. Other 
explanations include modulation of adhesin expression that could facilitate 
detachment of bacteria from host substrates, resulting in dissemination of the 
bacteria from the host, or modulation of factors involved in biofilm formation. 
However, in many cases the biological significance of phase variation remains a 
mystery (van der Woude, 2006). Investigation into the function of CwpV is the 
focus of chapter 6.  
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5 CwpV post-translational processing and expression in 
the C. difficile S-layer: Conservation and Diversity 
across strains 
5.1 Introduction 
As shown in Chapter 4 CwpV is expressed on the C. difficile surface as two 
fragments; the N-terminal fragment (~42 kDa) and the C-terminal fragment (~116 
kDa). The implications of this finding are unclear. The N-terminal fragment 
contains the putative cell wall binding domains, and is therefore presumed to bind 
to the cell wall. The function of these PF04122 domains has however never been 
addressed experimentally. The ability to express CwpV family from a plasmid-
encoded copy of the gene in C. difficile allows investigation into the role of 
different CwpV domains by mutagenesis, and the results of such a mutagenesis 
are shown in this chapter.  
 
The mechanism of CwpV cleavage is also unknown. SlpA is cleaved into the 
HMW and LMW SLP fragments by the cysteine protease Cwp84 (Kirby et al., 
2009, Dang et al., 2010). Cwp84 and another protease of the CWP family Cwp13 
are therefore candidates for carrying out CwpV cleavage. The location of the 
CwpV cleavage site may provide insight into the mechanism of cleavage. The 
experimentally determined sequence of the CwpV cleavage site is reported in this 
chapter.  
 
Following cleavage of CwpV it is known that both fragments are expressed 
anchored to the cell surface (Emerson et al., 2009). The C-terminal fragment does 
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not contain any known cell wall binding domains, and therefore the mechanism by 
which it is anchored to the cell surface required investigation. The LMW SLP is 
thought to be anchored to the cell surface due to the complex that it forms with 
the HMW SLP, which contains the putative cell wall binding domains (Fagan et 
al., 2009). It therefore seemed possible that the C-terminal domain of CwpV may 
form a complex with proteins containing cell wall binding domains in order to 
remain anchored to the cell wall after CwpV cleavage. The results of an 
investigation into this hypothesis are presented in this chapter.  
 
Given the known diversity of the CwpV C-terminus across different C. difficile 
strains, the significance of this variation was investigated. Bacterial cell surface 
proteins are under significant immune pressure, and this can lead to diversifying 
selection based on differing antigenicities of proteins with sequence variability. 
For example, the LMW SLP exhibits a high degree of sequence variation, which is 
thought to affect its antigenicity (Karjalainen et al., 2002b). Therefore the 
antigenicity of the different CwpV repeat types was investigated, and the results 
are presented in this chapter. 
 
Although the C-terminal repeat domains are highly variable across diverse C. 
difficile strains, the N-terminal sequences are well-conserved. Therefore the level 
of conservation of mechanisms underpinning CwpV post-translational processing 
and expression in the S-layer was investigated for CwpV proteins of different 
types.  
 
As discussed in Chapter 4, CwpV is expressed in a phase variable manner in 
630. The cwpV switch and recV appear well conserved across C. difficile strains, 
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therefore it was postulated that CwpV is likely to be expressed in a phase variable 
manner in a diverse set of C. difficile strains. Strains encoding all types of CwpV 
repeat were therefore investigated for regulation of CwpV expression at the 
cellular level.  
 
 An understanding of the differences and similarities between strains with respect 
to CwpV expression informed subsequent investigations into the function of 
CwpV, which is the focus of Chapter 6.  
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5.2 Results 
5.2.1 CwpV protein domains in C. difficile 630 
The sequence of cwpV in C. difficile 630 encodes the largest protein of the CWP 
family. Three copies of the putative cell wall binding domain PF04122 are 
encoded at the N-terminus of the protein. There is a domain of unknown function 
downstream of the cell wall binding domains, followed by a 30 amino acid 
serine/glycine rich linker (S/G linker) containing 18 serine residues and 9 glycine 
residues.  This is presumed to function as a flexible linker. Then at the C-terminal 
end of the protein nine 120 amino acid repeats are encoded. A diagrammatic 
representation of the 630 CwpV protein is shown in Figure 5.1A with the amino 
acid sequence colour coded in the same manner shown in Figure 5.1B. An 
alignment of the nine repeat sequences against each other is shown in Figure 
5.1C. It can be seen that the degree of homology between the repeats is very 
high, with the first repeat being slightly more divergent that the other repeats.  
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Figure 5.1 The CwpV protein from 630.  
A. Diagrammatic representation of the CwpV protein from 630. B. Amino acid 
sequence of the CwpV protein from 630 colour coded in the same way as the 
diagram in A. Predicted PF04122 domains are underlined. C. Multiple sequence 
alignment (ClustalW2) of the nine 120 amino acid repeats from 630 CwpV. 
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5.2.2 Determination of the 630 CwpV cleavage site 
Analysis of cell surface expression of CwpV indicates that CwpV is cleaved. This 
was shown in the previous chapter and is clear from analysis of surface extracts 
analysed by SDS-PAGE followed by Coomassie staining and Western blotting, as 
shown in Figure 5.2A-C. In order to determine the CwpV cleavage site, a C. 
difficile surface extract from ∆cwpV(pOECwpV) was transferred to PVDF 
membrane and visualized via Coomassie staining. The C-terminal fragment (~116 
kDa) of CwpV was identified and this membrane sent to the PNAC at the 
University of Cambridge for N-terminal sequencing by Edman degradation. This 
yielded the sequence TFVNY, unambiguously locating the CwpV cleavage site in 
the domain of unknown function, between the cell wall binding domains and the 
S/G linker, as depicted in Figure 5.2D diagrammatically.  
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Figure 5.2 Determination of the 630 CwpV cleavage site.  
C. difficile strains were grown overnight in BHI broth. S-layer extracts were 
prepared and analysed by SDS-PAGE and Western blotting. A. Coomassie blue-
stained gel. B. Western blot using anti-CwpVNter (1:5000). C. Western blot using 
anti-CwpVrpt1 (1:5000). Lane 1: WT; lane 2: ∆cwpV; lane 3: ∆cwpV(pOECwpV). 
The ~42 kDa (open triangle) and ~116 kDa (black triangle) fragments of CwpV are 
indicated. For Western blots the total protein loaded in lane 3 was fivefold less 
than in lanes 1 and 2 to allow all bands to be visualized using one exposure time. 
D. N-terminal sequencing of the CwpV C-terminal fragment (black triangle) 
yielded the amino acid sequence TFVNY. This unambiguously locates the 
cleavage site in the middle of the domain of unknown function, between the cell 
wall binding domains and the S/G linker, as depicted here diagrammatically. 
 
5.2.3 The N-terminal fragment of CwpV mediates cell wall binding 
In order to experimentally address the function of the N-terminal fragment of 
CwpV containing the putative cell wall binding domains, the cwpV gene in the 
plasmid pOECwpV was mutated by inverse PCR to produce a truncated version 
of the cwpV gene in a new plasmid pOECwpVNter. This truncation is depicted in 
Figure 5.3A. Analysis of surface layer extracts from WT, ∆cwpV, 
∆cwpV(pOECwpV) and ∆cwpV(pOECwpVNter) by SDS-PAGE followed by 
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Coomassie staining and anti-CwpVNter Western blot was carried out, and the 
results are shown in Figure 5.3B and C. The truncated CwpV is processed to form 
the same N-terminal fragment as the full-length CwpV, which is expressed in the 
C. difficile S-layer. This suggests that the N-terminal fragment of CwpV alone is 
sufficient for stable association with the cell wall. The same amount of the N-
terminal CwpV fragment appears to be present in surface extracts from 
ΔcwpV(pOECwpV) and ΔcwpV(pOECwpVNter) surface extracts, showing that the 
truncated version of CwpV is equally well expressed on the cell surface as the full-
length CwpV protein. The N-terminal fragment of CwpV has therefore been 
named the cell wall anchoring (CWA) fragment, and this is the first reported 
experimental evidence that PF04122 motifs are responsible for cell wall 
anchoring. 
 
Figure 5.3 The CwpV N-terminal fragment mediates cell wall binding.  
A. Illustration of the truncated version of CwpV expressed by 
ΔcwpV(pOECwpVNter). B. Expression of truncated CwpV in ΔcwpV visualized by 
SDS-PAGE and Coomassie staining, compared to WT, ΔcwpV and 
ΔcwpV(pOECwpV). Truncation of CwpV does not affect the expression of the 
CwpV N-terminal fragment in the C. difficile S-layer. C. Western blot analysis of 
the S-layer extracts from WT, ΔcwpV, ΔcwpV(pOECwpV) and 
ΔcwpV(pOECwpVNter) using anti-CwpVNter antibody. 
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5.2.4 The CwpV N-terminal (CWA) fragment and C-terminal fragment 
form a complex 
Having determined the CwpV cleavage site and that the N-terminal fragment is 
sufficient for cell wall binding of CwpV it was postulated that the two CwpV 
fragments form a complex to allow anchoring of the C-terminal domain to the cell 
wall. In order to test this, an immunoprecipitation reaction using anti-CwpVrptI was 
carried out with a surface extract from C. difficile ΔcwpV(pOECwpV). This 
antibody only recognises the C-terminal fragment of CwpV, as shown in Figure 
5.2C. However, as can be seen in  
Figure 5.4 both the CWA and C-terminal fragments of CwpV are 
immunoprecipitated from the surface layer extract using this antibody.  
 
 
Figure 5.4 The two CwpV fragments form a complex.  
Immunoprecpitation on a surface extract from ∆cwpV(pOECwpV) using anti-
CwpVrptI antibody was carried out. A. SDS-PAGE gel of immunoprecipitation 
samples visualized by Coomassie staining. Lane 1: ∆cwpV(pOECwpV) surface 
extract; 2: antibody column flow through; 3: first column wash; 4: final column  
wash; 5-7: First three column elutions. B. ∆cwpV(pOECwpV) surface extract (1) 
and immunoprecipitation elutions (5-7) were analysed by anti-cwpVrptI Western 
blot. C. ∆cwpV(pOECwpV) surface extract (1) and immunoprecipitation elutions 
(5-7) were analysed by anti-cwpVNter Western blot. The CwpV C-terminal 
fragment is indicated by a black triangle, and the N-terminal fragment by an open 
triangle. 
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This suggests that the two fragments do form a complex. No other proteins were 
immunoprecipitated from the surface layer extract using this antibody, as can be 
seen from the Coomassie stained SDS-PAGE gel in  
Figure 5.4A, and probing with anti-HMW SLP and anti-LMW SLP antibodies also 
did not detect immunoprecipitation of these proteins (data not shown). The two 
CwpV fragments are co-immunoprecipitated with a 1:1 ratio of  fragments. This 
suggests that the two CwpV fragments form a stable 1:1 complex, with no 
interactions between CwpV and any other S-layer proteins detected. 
5.2.5 Expression and purification of StrepII-tagged CwpV from C. 
difficile surface extracts 
The cwpV gene from the plasmid pOECwpV was modified to encode a C-terminal 
StrepII-tag  (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys), resulting in the plasmid pOEI, 
illustrated in Figure 5.5A. This plasmid was introduced to ∆cwpV by conjugation 
and the resulting strain ∆cwpV(pOEI) used to produce StrepII-tagged CwpV. 
Surface extracts were prepared from ΔcwpV and ΔcwpV(pOEI) and analysed by 
SDS-PAGE and Coomassie staining as shown in Figure 5.5B. These extracts 
were further analysed by Western blotting with a commercial anti-StrepII tag 
antibody, which detected the ~116 kDa C-terminal CwpV fragment (Figure 5.5C). 
Western blotting with anti-CwpVNter detected the CwpV CWA fragment at ~42 
kDa (Figure 5.5D). Having validated the expression of StrepII-tagged CwpV in C. 
difficile surface extract from ΔcwpV(pOEI) was incubated with Streptactin resin to 
bind the StrepII-tagged C-terminal fragment of CwpV. The resin was washed and 
then the StrepII-tagged protein eluted by addition of desthiobiotin. The proteins 
yielded from a Streptactin binding/elution assay of a ΔcwpV(pOEI) glycine extract 
are shown in Figure 5.5E, visualized by SDS-PAGE and Coomassie staining. It 
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can been seen that the ~42 kDa and ~116 kDa fragments of CwpV are co-eluted 
(lanes 8-11), despite the presence of the strep-tag only in the larger fragment. 
This provides further evidence that the two CwpV fragments form a complex. 
 
Figure 5.5 Expression and purification of StrepII-tagged CwpV from C. 
difficile surface extracts.  
A. The cwpV gene in pOECwpV was modified to contain a C-terminal StrepII-tag. 
The StrepII-tag is illustrated here by a turquoise box at the C-terminus of CwpV 
highlighted with an arrow. The resulting plasmid was named pOEI. B-D Surface 
extracts from ∆cwpV (lane 1) and ∆cwpV(pOEI) (lane 2) were analysed by SDS-
PAGE followed by Coomassie staining (B), anti-StrepII tag Western blot (C), and  
anti-CwpVNer Western blot (D). The CwpV C-terminal fragment is indicated with a 
black triangle, and the N-terminal fragment with an open triangle. E. A streptactin 
purification from a ∆cwpV(pOEI) surface extract was carried out. Samples were 
analysed by SDS-PAGE followed by Coomassue staining. Lane 1: ∆cwpV(pOEI) 
surface extract; 2: Streptactin column flow through; 3-7: Column washes; 8-11: 
Column elutions.  
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5.2.6 Mutagenesis of the CwpV cleavage region 
To further investigate the CwpV cleavage region six deletion mutants were 
designed. Cleavage Domain Mutants (CDMs) were created by inverse PCR with 
pOEI as the template. I acknowledge that this was carried out by Marcin Dembek 
under my supervision. CDM1-5 each have a ten amino acid deletion extending 
upstream and downstream of the cleavage site and CDM6 has a 50 amino acid 
deletion encompassing the entire region as illustrated in Figure 5.6. The plasmids 
containing these deletions (pOEI CDM1-6) were then transferred to ∆cwpV.  
 
Figure 5.6 Production of CwpV Cleavage Domain Mutants.  
A. The region surrounding the cleavage site (*) of CwpV was mutated by inverse 
PCR. The plasmid pOEI was used as a template and the primers F1-F5 and R1-
R5 used to create mutants. F1+R1 were used to create CDM1, F2+R2 - CDM2. 
F3+R3 - CDM3, F4+R4 - CDM4, F5+R5 - CDM5 and finally F1+R5 - CDM6. B. 
The amino acids deleted in CDM1-5 are indicated. The cleavage site is 
designated by * at the TFNVY sequence determined by N-terminal sequencing. C. 
Cartoon representation of the six mutants made.   
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Strains ∆cwpV(pOEI CDM1-6) were grown overnight in BHI and analysed for 
CwpV expression in the surface extracts and supernatants. The results of this 
analysis are shown in Figure 5.7. In Figure 5.7A and B surface extracts are 
analysed by Coomassie staining and anti-CwpVrptI Western blotting, 
respecitively. It can be seen that the CwpV C-terminal fragment is not present in 
any of the mutant samples (Figure 5.7A/B lanes 6-11). This suggests that 
complex formation between the CWA and C-terminal fragments is abrogated by 
these mutations, and therefore the C-terminal fragment is not anchored to the cell 
surface. Large amounts of the C-terminal fragment can be seen in Figure 5.7C 
and D lanes 6-11, which contain supernatants of the C. difficile cultures (from 
which surface extracts were prepared for Figure 5.7A and B) analysed by 
Coomassie staining and anti-CwpVrptI Western blotting respectively. This further 
suggests that the CwpV C-terminal fragments from CDM1-6 are expressed but 
not anchored to the cell surface and therefore lost into the supernatant. The CWA 
fragment of CwpV is only seen in surface extracts from ∆cwpV(pOEI CDM1-3), 
suggesting that the CDM4-6 mutations affect the stability of the CwpV CWA 
fragment in the S-layer, and therefore neither CwpV fragment is detected in 
surface extracts from  ∆cwpV(pOEI CDM4-6). The CwpV N-terminal fragment 
present in the surface extract from ∆cwpV(pOEI CDM1) (Figure 5.7A lane 6) 
appears larger than the normal CwpV N-terminal size (Figure 5.7A lanes 3-5). 
This suggests that cleavage is not occurring at the native site in this mutated 
CwpV protein. Similarly the N-terminal fragment from ∆cwpV(pOEI CDM3) (Figure 
5.7A lane 8) appears smaller than the normal CwpV N-terminal size (Figure 
5.7Alanes 3-5). This also suggests that the cleavage is not occurring at the native 
site. Taken together the data from these experiments suggest that a CwpV 
cleavage domain, consisting of at least 50 residues, is required for correct 
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cleavage and complex formation of CwpV, and that 10 amino acid deletion 
mutations are not tolerated at any point in this domain. This suggests that the 
intact domain is required for native processing and expression of CwpV. 
 
Figure 5.7 Analysis of CwpV Cleavage Domain Mutants.  
Samples from C. difficile cultures 1 - WT, 2 - ∆cwpV, 3 - ∆cwpV(pOECwpV), 4 - 
∆cwpV(pOECwpVNter), 5 - ∆cwpV(pOEI), 6-11 - ∆cwpV(pOEI CDM1-6). A. 
Surface extracts analysed by SDS-PAGE and Coomassie staining.  B. Surface 
extracts analysed by anti-CwpVrptI Western blotting. C. Culture supernatants 
analysed by SDS-PAGE and Coomassie staining. D. Culture supernatants 
analysed by anti-CwpVrptI Western blotting.  The CwpV C-terminal fragment is 
indicated by an open triangle. The N-terminal fragment is indicated by a black 
triangle.  
 
None of these CwpV cleavage domain mutants led to the detection of full-length 
CwpV; even if the native cleavage site is deleted the CwpV protein still fragments. 
A panel of protease inhibitors, including inhibitors against all major classes of 
protease, was tested for activity in preventing CwpV cleavage, but none were 
found to have any effect (data not shown). Cwp84, the cysteine protease 
responsible for SlpA cleavage is not responsible for CwpV cleavage, as CwpV is 
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still cleaved in a C. difficile ∆cwp84 background (Kirby et al., 2009). There is 
another protease member of the Cwp family, Cwp13. CwpV is still cleaved in a C. 
difficile ∆cwp13 background, indicating that this is also not responsible for CwpV 
cleavage (Lucia de la Riva, personal communication). Therefore the mechanism 
responsible for CwpV cleavage remains uncharacterized, but it is clear that 
cleavage and complex formation between the CWA and C-terminal fragments of 
CwpV is necessary for stable expression of CwpV on the C. difficile surface. 
 
5.2.7 Overall Model for CwpV processing and expression 
Having characterised the CwpV cleavage site and complex formation between the 
two CwpV fragments, a model for CwpV processing and expression of the C. 
difficile cell surface could be presented. Given what is known about SlpA 
processing and expression on the C. difficile cell surface an analogy between the 
two proteins could be made. The proposed model is illustrated in  
Figure 5.8. For both SlpA and CwpV the proteins are exported across the cell 
membrane due to the presence of a signal peptide at the N-terminus of the 
protein, which is removed by signal peptidase cleavage (step 1). Following export 
to the C. difficile cell surface both SlpA and CwpV are cleaved (step 2). In the 
case of SlpA, it is known that the protease Cwp84 is required for cleavage. For 
CwpV the mechanism of cleavage has not yet been characterised. Following 
cleavage the two fragments (for SlpA HMW and LMW SLP, for CwpV the N- and 
C-terminal fragments) associate to form a complex (step 3). This allows the 
fragment containing the cell wall binding domains (HMW SLP or CwpV N-terminal 
fragment) to anchor the other fragment to the cell surface. It is clear that the C. 
difficile S-layer, although composed primarily of SlpA, can accommodate a large 
amount of CwpV, as seen in ∆recVON cells (likely to reflect the natural expression 
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level of CwpV in WT C. difficile phase ON cells). This suggests that SlpA and 
CwpV must interact in such a way that maintains the integrity of the S-layer. Other 
members of the Cwp family are also likely to be involved in these S-layer 
interactions. Such interactions merit further investigation, and are likely to rely on 
the correct functioning of the three-step processing pathway of these proteins that 
has been outlined in this chapter.  
 
 
Figure 5.8 Overall Model for CwpV processing and expression.  
A three-step model is proposed for CwpV processing, in a manner analogous to 
SlpA processing. SlpA is shown in red and grey. CwpV is shown in dark grey, 
white, pink and blue. Cleavage sites are indicated by *. Pfam04122 domains are 
indicated by hactching. Step 1: Export of the proteins across the cell membrane, 
accompanied by signal peptide cleavage. Step 2: Cleavage of the protein to yield 
two fragments. In the case of SlpA the protease Cwp84 is responsible, in the case 
of CwpV the cleavage mechanism is unknown. Step 3: Formation of a complex of 
the two fragments, which allows anchoring of both fragments to the cell surface 
via the cell wall binding domains of the HMW SLP or the CwpV N-terminal 
fragment.  
 
5.2.8 CwpV C-terminal repeat diversity across strains 
As mentioned in the introduction, prior to the start of this project a number of 
different CwpV C-terminal repeat types had been identified and their DNA 
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sequences determined by Dr. Jenny Emerson. However, the consequences of 
this sequence diversity had not been investigated. In order to investigate the five 
different known CwpV repeat types one representative C. difficile strain of each 
type was chosen for further study. The 630 CwpV repeats were termed type I, and 
this is the CwpV protein that has been characterised and discussed so far. A 
ribotype 027 strain isolated from an outbreak in Canada named R20352 encodes 
CwpV with the N-terminus up to the S/G region highly conserved compared to 630 
CwpV, but containing eight 78-79 amino acid repeats at the C-terminus, termed 
type II repeats. The sequences of these repeats and their ClustalW2 alignment, 
accompanied by a cartoon illustration of the protein is shown in Figure 5.9A. As 
can be seen from this alignment the different repeats are virtually identical, with 
the first repeat exhibiting slightly more divergence from the consensus than the 
other repeats.  
 
C. difficile strain CDKK167 was found to encode a CwpV protein with the N-
terminal domain up to the S/G linker well-conserved compared to both 630 and 
R20352, with six copies of third type of repeat, termed type III, at the C-terminus. 
A cartoon representation of this protein is shown in Figure 5.9B accompanied by 
an alignment of the six ~94 amino acid type III repeats. All six repeats align well, 
however the first two repeats are slightly more divergent from the last four repeats 
than they are from each other. This is reflected in the shading of the repeats.  
 
C. difficile strains M9 and AY1 encode the conserved CwpV N-terminus followed 
by mosaics of type III then type IV and V repeats respectively. This is illustrated in 
the diagram in Figure 5.9C, accompanied by an alignment of all the type III 
repeats from all three strains (CDKK167, M9, AY1). All the type III repeats show a 
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high degree of conservation, with the repeats from M9 and AY1 aligning best with 
the first two repeats from CDKK167. This is reflected in the colouring of the 
diagrams. The seven 98-100 amino acid type IV repeats from M9 are very well 
conserved, with very few divergent residues between repeats, as shown in the 
alignment in Figure 5.9D. Similarly, the five type V repeats from AY1 are all very 
similar in sequence, as the alignment in Figure 5.9E illustrates.  
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Figure 5.9 CwpV C-terminal repeat types II-V.   
A. C. difficile strain R20352 encodes CwpV with type II repeats. Cartoon 
representation and ClustalW2 mutliple sequence alignment of repeats is shown. 
B. C. difficile strain CDKK167 encodes CwpV with type III repeats. Cartoon 
representation and ClustalW2 mutliple sequence alignment of repeats is shown. 
C. C. difficile strains M9 and AY1 encode CwpV with mosaics of type III and Type 
IV or V repeats. Cartoon representations of these mosaic CwpV proteins and 
ClustalW2 mutliple sequence alignment of all type III repeats is shown. D. 
ClustalW2 mulitple sequence alignment of M9 type IV repeats. E. ClustalW2 
multiple sequence alignment of AY1 type V repeats is shown.  
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Given the similarity of amino acid sequence of repeats from within a specific type 
it is likely that each repeat is antigenically very similar to another repeat of its type. 
However, a key question is whether or not there is any sequence similarity 
between different CwpV repeat types. One repeat of each type was selected 
based on having the amino acid sequence closest to the repeat-type consensus 
sequence, indicated in Figure 5.10A. These five different CwpV repeat amino acid 
sequences were aligned in a ClustalW2 multiple sequence alignment and it can 
be seen in Figure 5.10B that there is no significant alignment to a consensus 
sequence of amino acids between different CwpV repeat types.  
 
 
Figure 5.10 Different CwpV types have distinct amino acid sequences 
 A. Cartoon representation of the CwpV proteins from each type-representative 
strain chosen for further study. One repeat of each  type, indicated by a black line 
above the cartoon, was selected and amino acid sequences from each type 
aligned by ClustalW2 sequence alignment. B. The ClustalW2 multiple sequence 
alignment of all CwpV repeat types indicates that there is no significant amino 
acid conservation between CwpV repeat types.  
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5.2.9 Different CwpV repeat types are antigenically distinct 
Given the completely different amino acid sequences for each repeat type we 
hypothesized that the repeats may be antigenically distinct. Investigation into this 
hypothesis was desired in order to understand the significance of CwpV repeat 
type diversity. In order to test this hypothesis antibodies against each repeat type 
were required. Antibodies against the 630 CwpV N-terminus (anti-CwpVNter) and 
the first 630 C-terminal repeat (anti-CwpVrpt1) had been raised prior to the start of 
this project and have been used extensively in experiments reported so far.  
Rabbit antibodies against repeat types II-V were obtained commercially by 
immunization with one or two recombinant His-tagged CwpV repeat domains of a 
specific type purified from E. coli. The recombinant CwpV domains used as 
antigens are indicated by black lines above the CwpV protein cartoons in Figure 
5.11A.  An example of the affinity purification carried out for each of the 
recombinant proteins is shown in Figure 5.11B, where CwpV type V repeat 
purification is shown. CwpV repeat domains of types II-IV were purified in the 
same way (data not shown).  
 
I acknowledge the technical assistance of Allie Shaw in carrying out this work.  
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Figure 5.11 Raising CwpV repeat-specific antibodies.  
A. Diagrammatic representation of the CwpV domains used to raise anti-CwpV 
antibodies. The domains used as antigens are indicated by black lines above the 
cartoons. Anti-CwpVNter and anti-CwpVrpt1 antibodies were raised prior to this 
study, but are included in this diagram for completeness. The type II-V repeat 
domains indicated were cloned into pET28a to encode a C-terminal his-tag. 
Proteins were then expressed in Rosetta E. coli and purified by Nickel affinity 
chromatography. B. Analysis of CwpV type V repeat recombinant expression and 
purification by SDS-PAGE and Coomassie staining. Lanes contain the following 
samples: 1; Whole cell lysate of uninduced Rosetta E. coli, 2; Whole cell lysate of 
induced cells, 3; Soluble fraction of induced cells, 4; Nickel column flow through, 
5; First column wash, 6; Final column wash, 7-11 Column elution fractions. This 
analysis is shown as an example, the same process was carried out for CwpV 
repeat types II-IV. 
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In order to test the resultant antibodies for reactivity against CwpV proteins of all 
five types, S-layer extracts were prepared for the representative strain of each 
type; 630 – type I, R20352 – type II, CDKK167 – type III, M9 – type III/IV, and 
AY1 – type III/V. S-layer extracts were normalized to contain the same level of 
HMW SLP, and were visualized by SDS-PAGE and Coomassie staining shown in 
Figure 5.12A. The significant variation in SlpA across these strains can be seen, 
as has been described across C. difficile strains previously (Calabi & Fairweather, 
2002a). The S-layer extracts were then analysed by Western blotting with anti-
CwpVNter antibody. A single band at ~42 KDa was seen in each strain, shown in 
Figure 5.12B, confirming that antibodies raised against the 630 CwpV N-terminal 
domain recognized this domain in all the other strains, as would be expected by 
the high level of conservation of the CwpV N-terminus across strains. This also 
confirmed that CwpV is present in all these C. difficile S-layer extracts, and 
therefore CwpV is expressed by all these strains.  
 
S-layer extracts were then analysed by Western blotting using antibodies raised 
against the specific repeat types I-V. It is clear from Figure 5.12C that anti-
CwpVrptI detects only type I CwpV repeats in strain 630. Anti-CwpVrptII detects 
only type II CwpV repeats in strain R20352. Anti-CwpVrptIII detects CwpV repeats 
in CDKK167, M9 and AY1, and all these three strains contain at least one type III 
repeat. Detection of M9 CwpV with anti-CwpVrptIII is weak, this may be due to the 
presence of only one type III repeat in this CwpV protein. Anti-CwpVrptIV only 
detects CwpV in M9, the only strain with type IV repeats. Finally, anti-CwpVrptV 
only detects CwpV from AY1. These results demonstrate that, as expected based 
on distinct amino acid sequences, the CwpV repeat types are antigenically 
distinct.  
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Figure 5.12 Different CwpV repeat types are antigenically distinct.  
A. S-layer extracts from C. difficile strains analysed by SDS-PAGE and 
Coomassie staining illustrates the variability of S-layer proteins across strains, as 
previously described (Calabi & Fairweather, 2002a). B. Western blot analyis of S-
layer extracts using anti-CwpVNter shows that the CwpV N-terminus from all 
strains is recognized, as expected due to highly conserved N-terminal sequences. 
C. Western blot analysis of S-layer extracts using anti-CwpVrptI-V shows that 
each repeat-specific antibody only detects CwpV proteins containing at least one 
repeat of its own repeat type. 
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5.2.10 The post-translational cleavage site is conserved for all 
CwpV proteins 
In order to further characterize the four distinct CwpV proteins expressed by 
R20352, CDKK167, M9 and AY1 the cwpV genes from these strains were 
amplified by PCR and cloned into a C. difficile expression vector encoding a C-
terminal StrepII-tag. The resulting plasmids pOEII-V were introduced by 
conjugation to ΔcwpV. Transconjugants were single colony purified and the 
resultant strains designated ΔcwpV(pOEII-V), for strains over-expressing CwpV 
types II-V respectively. C. difficile surface extracts were prepared from ΔcwpV and 
ΔcwpV(pOEI-V) and analysed as shown in Figure 4.13A. A high level of CwpV 
expression can be seen for each CwpV protein, with CwpV constituting a 
significant proportion of the total S-layer extract. All 5 proteins are cleaved into a 
~42 kDa N-terminal fragment and C-terminal fragments of ~90-120 kDa. These 
extracts were further analysed by Western blotting with a commercial anti-StrepII 
tag antibody, which detected the ~90-120 kDa C-terminal CwpV fragments 
(Figure 4.13B). Western blotting with anti-CwpVNter detected the CwpV N-
terminal fragment in each extract at ~42 kDa (Figure 4.13C). In order to determine 
the cleavage site for each CwpV protein, each StrepII-tagged C-terminal fragment 
was transferred to PVDF membrane and subjected to N-terminal sequencing by 
Edman degradation. This identified the first 5 amino acids of all the C-terminal 
CwpV fragments as TFVNY, unambiguously locating the cleavage site in the 
domain of CwpV between the CWA domains and the serine/glycine rich region, as 
depicted in Figure 4.13D. This domain is well-conserved between CwpV proteins 
of different types, and suggests that the CwpV post-translational cleavage 
mechanism is conserved across CwpV types.  
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Figure 5.13. There is a conserved post-translational cleavage site for all 
CwpV proteins.  
A. S-layer extracts from ΔcwpV and ΔcwpV overexpressing CwpV types I-V with a 
C-terminal strep-tag (ΔcwpV(pOEI-V)) analysed by SDS-PAGE gel and 
Coomassie staining. Open triangle, CwpV N-terminus. Black triangle, CwpV C-
terminus B. Western blot analysis of S-layer extracts using anti-Strep tag antibody 
detects the strep-tagged CwpV C-termini. C. Western blot analyis of S-layer 
extracts using anti-CwpVNter antibody detects the CwpV N-termini. D. N-terminal 
sequencing of all StrepII-tagged CwpV C-termini yielded the sequence TFVNYG, 
revealing the conserved cleavage site for all CwpV types located between the cell 
wall anchoring domains (grey) and the serine/glycine-rich region (pink). 
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5.2.11 All CwpV types form a CWA/C-terminal fragment complex 
Considering that the cleavage site of CwpV was conserved across CwpV proteins 
of different types, and that the cleavage domain thought to be involved in CwpV 
complex formation is also conserved, it seemed likely that CwpV proteins of all 
repeat types form complexes of CWA and C-terminal fragments. To test this 
hypothesis glycine extracts from ΔcwpV(pOEI-V) strains were incubated with 
Streptactin resin to bind the StrepII-tagged C-terminal fragment of CwpV. The 
resin was washed and then the StrepII-tagged protein eluted. This Streptactin 
binding/elution assay was described in detail earlier (see Figure 5.5). The 
complete S-layer extracts (S) and first elutions (E) from each assay are visualized 
in Figure 5.14. Both CwpV fragments co-eluted from S-layer extracts containing 
CwpV of all repeat types. This suggests that all types of CwpV form a complex of 
the two CwpV cleavage products.  
 
Figure 5.14 All CwpV proteins form a complex of N- and C-terminal 
fragments.  
S-layer extracts (S) and first elutions (E) from ΔcwpV(pOEI-V) Streptactin 
binding/elution assays. In each E lane the CwpV N-terminal fragments (open 
triangle) and CwpV C-terminal fragments (closed triangle) can be seen, indicative 
of complex formation by the two fragments. 
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5.2.12 Phase variable regulation of CwpV expression by C. 
difficile strains of all CwpV repeat type 
Given the known conservation of recV and the cwpV switch across C. difficile 
strains it seemed possible that CwpV would be expressed in a phase variable 
manner in strains expressing all types of CwpV. Overnight C. difficile cultures of 
representative strains for each type were analysed by cwpV switch orientation 
PCR. It can be seen in Figure 5.15A that all strains exhibited cwpV switch 
inversion. The same cultures were stained using the appropriate anti-CwpVrpt 
antibody for analysis by immunofluorescent microscopy. As can be seen in Figure 
5.15B all strains were shown to express CwpV in a subset of cells, indicative of 
phase variable expression.  In all strains CwpV was expressed in a minority of 
cells, ranging from 0.1 - 10% of cells being CwpV-positive. The factors 
determining the proportion of CwpV-positive cells are yet to be determined, but it 
is clear that under standard laboratory culture conditions it is a minority of cells 
that are CwpV-positive in all strains tested.  
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Figure 5.15 Phase variable regulation of CwpV expression by C. difficile 
strains of all CwpV repeat type.  
A. Orientation PCRs amplified from overnight cultures of C. difficile strains 630, 
R20352, CDKK167, M9 and AY1 indicating that all strains exhibit cwpV switch 
inversion. B. Overnight C. difficile cultures for each strain were stained with the 
appropriate anti-CwpVrpt antibody (630 – rptI, R20352 – rptII, CDKK167 – rptIII, 
M9 – rptIV, AY1 – rptV), then with anti-rabbit rhodamine red. From left to right – 
Phase image, fluorescent image, overlay. 
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5.3 Discussion 
 
The high degree of sequence conservation within repeats of a specific type, 
exhibited for all repeat types, suggests that the repetitive repeat domain structure 
may have arisen by genetic duplication events. Without knowing the function of 
CwpV it is unclear why a repetitive repeat domain structure would be maintained, 
however one obvious explanation is that if these repeats are involved in a ligand 
binding event then by increasing the number of repeats present in each CwpV 
protein the avidity of the interaction would be increased. This is discussed further 
in Chapter 6, which focuses on the function of CwpV 
 
C-terminal variation of CwpV across different C. difficile strains, with antigenically 
distinct types encoded by unrelated sequences, suggests that these sequences 
have been acquired by horizontal gene transfer, rather than having diverged from 
a common genetic ancestor. Any known mechanism of chromosomal sequence 
acquisition; homologous recombination, illegitimate recombination or additive 
integration could account for introduction of these sequences to the C. difficile. 
chromosome (Thomas & Nielsen, 2005). Without knowing the origin of these 
sequences, the mechanism of transfer into C. difficile cells and incorporation into 
the C. difficile genome is not clear. Searching of current nucleotide databases 
does not provide any clear evidence as to the origin of these sequences. Much of 
the human microbiome remains uncharaterised, but is currently targeted for high-
throughput sequencing (Peterson et al., 2009), which may shed light on the 
origins of CwpV sequences. However, if acquisition of these sequences by C. 
difficile occurred a long time ago, sequence divergence may hide links between 
CwpV sequences and the sources. The presence of mosaic gene structure in M9 
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and AY1 strains, where they have type III repeats combined with type IV and V 
repeats respectively, suggests that there have been at least two independent 
horizontal cwpV repeat acquistition events in these strains, unless the source of 
the repeats already contained a mosaic. Our current knowledge of the repeat 
types found in different C. difficile  strains is shown in  Table 5.1. Typing of the C. 
difficile strains listed here was carried out by Dr. Jenny Emerson, Zoe Seager and 
Stina Linden.  
 
This is by no means an exhaustive examination of C. difficile strains, and it seems 
likely that as more strains are investigated further novel CwpV repeat types will be 
discovered. Based on the strains analysed so far it seems that CwpV type 
exchange is not occurring at a very high frequency, as all strains tested from 
within one ribotype contain the same CwpV type. For example, all 078 strains 
tested, despite diverse geographic sources and different animal hosts, all have 
type I CwpV repeats. Current understanding of the phylogeny of the diversity of C. 
difficile strains is limited, with the most detailed study only including 5 different 
ribotypes (He et al., 2010). However, we can say that current data suggests a 
single CwpV type is associated with each clade; the HY (027) clade identified 
appears to all have type II CwpV, the A-B+ clade type IV CwpV, the HA2 (078) 
clade type I CwpV, and the HA1 clade type I CwpV. The locations of type III and V 
CwpV strains within this phylogenetic tree of C. difficile are not yet known. As 
more C. difficile strains are sequenced and our understanding of evolutionary 
relationships between strains improves it will become more clear as to when 
different CwpV types were acquired, and whether single or multiple independent 
acqusition events for each type have occurred.  
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Whatever the mechanism for CwpV type acquisition, it seems likely there is 
positive selection pressure for CwpV variablilty, as genetic changes are only 
maintained in a population if they produce successful genomes. Host immune 
pressure is one possible selection pressure that could promote CwpV variability. 
This selection pressure seems to have been at work promoting variability in other 
C. difficile surface proteins SlpA and Cwp66 (Lemee et al., 2005) and from this 
study it is clear that one key difference between CwpV types is their antigenicity. 
Variation in surface proteins may be involved in competition between different C. 
diffiicle strains. It has been reported that 60-70% of healthy infants are colonized 
by C. difficile and that there is an immune response to infection that can be 
protective in later life (Jangi & Lamont, 2010). This implies that there may be 
inherent differences in susceptibility of individuals to different strains depending 
on their histories of C. difficile infection and resulting immune memory. 
Interestingly, Type II CwpV has thus far only been found in ribotype 027 strains, 
which have exhibited recent worldwide spread and caused multiple hospital 
outbreaks (McDonald et al., 2005). It is possible that the susceptibility of 
individuals to 027 strains, that were previously rarely isolated, may be higher than 
to other antigenically different C. difficile strains that were more likely to have 
colonized individuals as infants. Further work is required to understand the 
relationships between prior C. difficile exposure and susceptibility. If susceptibility 
differences do exist CwpV may play a role. 
 
Conserved post-translational processing of CwpV across different CwpV types 
suggests that this process is important for optimal CwpV expression and function. 
We have shown that cell wall proteases Cwp84 and Cwp13 are not responsible 
for CwpV cleavage (data not shown) and therefore the mechanism of CwpV 
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cleavage is not known. It is possible that CwpV undergoes protein 
autoprocessing, which has been reported for a number of families of proteins 
(Paulus, 2000, Tajima et al., 2010, Dautin et al., 2007). Given that we show a 
threonine residue to be directly downstream of the cleavage site CwpV, a 
plausible mechanism of autocleavage is N, O-acyl migration with the oxygen of 
the hydroxy group of threonine acting as the nucleophile. Such a reaction requires 
extreme chemical conditions (Crawhall & Elliott, 1955), unless catalysed by the 
tertiary structural organisation of the protein. This mechanism of peptide bond 
cleavage is deployed by a number of different protein families, which undergo 
autocleavage, for example the N-terminal nucleophile hydrolases (Brannigan et 
al., 1995), glycosylasparginases (Xu et al., 1999) and SEA proteins (Johansson et 
al., 2008). Targeted mutagenesis of specific residues at the CwpV cleavage site is 
likely to provide evidence for or against an autocleavage mechanism. Mutation of 
the threonine residue at the cleavage site to a serine or a cysteine may still allow 
cleavage to proceed due to the presence of a nucleophilic side chain, although 
cleavage may be less efficient. However, mutation to an alanine residue would 
abolish cleavage if it does rely on this autocleavage mechanism. The cleavage 
domain should also cleave in a heterologous system, for example in E. coli, if no 
exogenous protease is required for cleavage. Further experiments are required to 
test this hypothesis. The functional importance of this CwpV cleavage is currently 
unclear. If the two CwpV fragments do not disassociate after cleavage, there may 
be no real consequence to cleavage compared to if CwpV remained a single 
protein. There may however be conditions were the two fragments disassociate, 
which may have functional importance.  
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It has been shown that inhibition of SlpA cleavage leads to shedding of uncleaved 
SlpA into a C. difficile culture supernatent, suggesting that this unprocessed form 
of SlpA is not stable in the S-layer (Dang et al., 2010). By analogy it seems likely 
based on the mutagenesis study reported in this chapter that cleavage of CwpV is 
important for stable incorporation of CwpV into the C. difficile S-layer. This 
domain, the cleavage site and subsequent complex formation between the CWA 
and C-terminal domains are conserved in all CwpV proteins, again indicating the 
importance of this processing for optimal CwpV expression and function. Given 
the high proportion of the total S-layer that CwpV constitutes in ΔrecVON cells it 
seems likely that CwpV interacts positively with other S-layer proteins to maintain 
the integrity of S-layer packing. The loss of the CwpV CWA domain from the cell 
surface in the CDM4-6 mutants suggests that this domain could no longer be 
anchored in the S-layer. This may be due to loss of cell wall anchoring, although 
the PF04122 domains were not directly affected by the mutation. Interactions 
between the CwpV CWA domain and the HMW SLP may have been affected. 
Whether or not such interactions are important for C. difficile S-layer integrity is an 
interesting area for future investigation. If found to be important, such interactions 
may rely on the mature cleaved forms of these proteins. 
 
The experimental demonstration that the CwpV CWA domain alone can anchor to 
the cell wall is the first direct evidence of the function of PF04122 domains. For S-
layer proteins from some other bacterial species the mechanism of surface 
anchoring has been characterised (Sara, 2001), however the mechanism 
underpinning cell wall anchoring via PF04122 domains has not been 
characterised. It should be noted that such studies with SlpA have not been 
possible as it has not been possible to create an slpA knock-out mutant, perhaps 
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suggesting that slpA is an essential gene. The experimental setup developed in 
this study, expressing the CwpV CWA domain in C. difficile from a plasmid, will 
facilitate investigation into the details of the PF04122 cell wall anchoring 
mechanism, which will improve our understanding of the whole CWP family of 
proteins.  
 
All types of CwpV being phase variable, suggests that this complex regulatory 
mechanism is important for optimal function of CwpV. Phase variation of bacterial 
surface proteins has been reported to be involved in a number of processes 
including immune evasion and colonization (van der Woude, 2006). Many such 
explanations behind CwpV phase variable regulation can be suggested, and this 
will be discussed further in Chapter 6, which focuses on CwpV function.  
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 Table 5.1 CwpV characteristics of C. difficile strains examined 
Strain CwpV architecture Other characteristics Reference or source 
 Type No. of repeats 
Ribo-
type 
Toxin 
status  
CDKK371 I  6 b 001 +ve (Calabi & Fairweather, 2002b) 
R8366 I  4 b 001 A+, B+ (Calabi et al., 2001a) 
R13537 I  6a 001 +ve (Eidhin et al., 2006) 
R12879 I  6 a 001 +ve (Eidhin et al., 2006) 
R14628 I  6 a 001 +ve 
 
(Eidhin et al., 2006) 
Y I  4 b 010 A-, B- (Calabi & Fairweather, 2002b) 
630 I  9 b, c 012 A+, B+ (Calabi et al., 2001a)  
CDKK959 I  4 b 053 +ve (Calabi & Fairweather, 2002b) 
CDKK101 I  4 b 053 +ve (Calabi & Fairweather, 2002b) 
CDKK291 I  4 b 053 +ve (Calabi & Fairweather, 2002b) 
M120 I 4 a 078 A+, B+ B. Wren 
C22 I 4 a 078 A+, B+ S. d’Arc 
C36 I 4 a 078 A+, B+ S. d’Arc 
H57 I 4 a 078 A+, B+ S. d’Arc 
H94 I 4 a 078 A+, B+ S. d’Arc 
R20291 II  8 b, c 027 A+, B+; CDT+ (Stabler et al., 2006a) 
R20352 II  8 b 027 A+, B+; CDT+ (Stabler et al., 2006a) 
R20928 II  8 a 027 A+, B+; CDT+ (Stabler et al., 2006a) 
CD196 II  8 a 027 A+, B+; CDT+ (Popoff et al., 1988) 
R12628 II  8 a 027 +ve J. Brazier 
R16760 II  8 a 027 +ve J. Brazier 
CDKK167  III  6 b 016 +ve C. Kelly 
NF2029 III  6 a 106 A+, B+  M. Wilcox 
R7404 III/IV 1/7 a 017 A–, B+ (Calabi et al., 2001a) 
M9 III/IV 1/7 b 017 A–, B+ D. Drudy 
AY1 III/V 2/5 b N.D. A–, B- D. Gerding 
AY2 III/V 2/5 b N.D. A–, B- D. Gerding 
AY3 III/V 2/5 b N.D. A–, B- D. Gerding 
AY4 III/V 2/5 b N.D. A–, B- D. Gerding 
AY5 III/V 2/2 b N.D. A–, B- D. Gerding 
B-one (B1) I  9 a N.D. A+, B+ Gill Douce; (Merrigan et al., 2003a) 
 
The types of repeats and their number were determined by aPCR (this study), bDNA sequencing 
(this study) or c genome sequencing studies 
http://www.sanger.aC.uk/resources/downloads/bacteria/Clostridium-difficile.html; N.D., not 
determined; +ve, toxin A+ve but toxin B unknown.  
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6 Investigating the Function of CwpV  
6.1 Introduction 
Chapter 4 described the discovery of the phase variable regulation of CwpV, 
elucidation of the mechanism underpinning phase variation and determination of 
the essential role of the recombinase RecV in CwpV phase variation. Chapter 5 
concerned CwpV protein domain structure, post-translational processing and C-
terminal repeat sequence variability exhibited across C. difficile strains. So far it 
has been discussed that many aspects of CwpV are conserved across diverse 
sets of C. difficile strains; phase variable regulation, the CWA domain, the 
cleavage domain, formation of a CWA/C-terminal fragment complex and repetitive 
C-terminal structure. However, we have shown that there are distinct types of 
CwpV repeat, which appear to have been acquired by independent horizontal 
gene transfer events. These repeats are antigenically distinct. All this information 
hints at a complex evolutionary history for CwpV but does not provide any direct 
information as to the function of CwpV in the C. difficile life cycle. The previous 
chapters also describe the production of mutant C. difficile strains that are ideal 
for subjecting to functional assays in order to investigate the function of CwpV, 
which is the focus of this final results chapter.  
 
Clues as to protein function can be gained from searching the databases of 
known proteins. Bioinformatic analysis of CwpV identifies the presence of the 
PF04122 domains in the CWA domain, shown in the previous chapter to be 
responsible for cell wall anchoring. The cleavage domain does not contain any 
Pfam domains and using BLASTP does not show significant homology to any 
well-characterised proteins in the protein database. The repeat domains have 
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also been analysed by bioinformatics searches. Type I repeats do not contain any 
Pfam motifs, nor show significant sequence homology to any well-characterised 
proteins. The best hit is with a hypothetical protein from the bacterium 
Shuttleworthia satelles but this only shows 29% amino acid identity with an e 
value of 2.7. Type II repeats do contain a Pfam motif, the PF07554 FIVAR motif, 
which is an uncharacterized sugar binding domain. This Pfam domain is found in 
proteins with varying functions. Of note it is present in a fibronectin-binding 
surface protein from Staphylococcus epidermis. This Pfam domain shows a lack 
of conserved catalytic residues, which can be characteristic of a ligand binding 
domain. However this Pfam family is not characterised to the extent that the 
binding ligand can be identified by sequence analysis. The best match from a 
BLASTP search for a type II repeat is a putative surface expressed glycosyl 
hydrolase from Clostridium beijerinckii which shows 49% sequence identity, with 
an e value of 8e-9. This protein is however not well characterised, so little can be 
said about the relevance of this homology to type II repeat function. Type III 
repeats do not contain any Pfam motifs. The most significant homology match 
found by BLASTP is a predicted alpha-L-fucosidase S-layer protein (containing an 
SLH domain) from Paenibacillus sp., which is predicted to have sugar binding 
function. This shows 52% sequence identity with a type III repeat, with an e value 
of 2e-14. This protein and none of the other significant matches by BLASTP have 
been well-characterised though, therefore direct interpretation of the homology to 
type III repeat function is not possible. Similarly the CwpV type IV repeat contains 
no Pfam motifs, with the best BLASTP hit being a hypothetical putative S-layer 
protein from Syntrophomonas wolfei which shows 44% sequence identity with an 
e value of 5e-10. Finally the type V CwpV repeat contains no Pfam motifs, and its 
closest homolog in the database is a hypothetical protein from Clostridium 
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carboxidivorans with a predicted signal peptide, which has 53% sequence identity 
to type V repeat and gives an e value of 3e-8. Therefore bioinformatic analysis of 
the CwpV repeats does not give any clear indication as to their likely function.  
 
Most of these proteins to which the repeats show a level of homology do not 
themselves contain repeats of the region of homology. This was determined by 
analysis of the homologous sequences using RADAR (Rapid Automatic Detection 
and Alignment of Repeats) (Heger & Holm, 2000). An interesting exception to this 
is a predicted S-layer domain protein from Paenibacillus sp., which contains a 
repetitive domain with 54% sequence identity to the six type III repeats found in 
CDKK167, with an e value of 1e-59. The function of this homologous protein has 
not been investigated, therefore little can be said about the significance of this 
homology. Overall, the evidence suggests that the generation of repeats has 
occurred since the sequences have been acquired by C. difficile. This is further 
supported by the discovery that different numbers of repeats of a given type have 
been found in different strains, for example 630 contains 9 type I repeats, whilst 
CDKK371 contains contains only six. This is indicative of the numbers of CwpV 
repeats increasing or decreasing since the introduction of the sequence to the 
species. 
  
It has been reported that in prokaryotes for proteins of >1000 amino acids in 
length ~ 20% contain repeats (Marcotte et al., 1999). Therefore repetition of 
domains appears to be a successful way of generating large proteins in 
prokaryotes. This high prevalence of repeating proteins is thought to be due to the 
fact that repetition of protein domains is a good way to generate proteins of novel 
function, in a similar way to how gene duplication and genome duplication have 
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been thought to allow diversification of genes and genomes (Wolfe, 2001). In 
proteins where the repeats can be clearly identified it is likely that repeat 
generation is a relatively recent evolutionary event. This is further confirmed in the 
case of CwpV, as C. difficile is known to be an ancient species with an estimated 
age of 1.1-85 billion years (He et al., 2010), but the existence of these distinct 
repetitive cwpV genes in different strains suggests recent evolutionary change. 
 
Generation of repeats can occur during DNA replication via recombination events 
or slip-strand mispairing. For long repeats, as seen in CwpV, recombination is the 
more likely mechanism for generation of repeats (Marcotte et al., 1999). Whatever 
the mechanism of repeat generation, a selective advantage conferred by domain 
repetition is required to maintain the repetitive sequence. One obvious such 
advantage conferred by repetition is increased avidity to ligands via multiple 
copies of the binding domain. This avidity is conferred by a much reduced overall 
dissociation rate when multiple interactions rather than a single interaction must 
dissociate simultaneously in order for two molecules to dissociate fully, which has 
been shown experimentally using engineered antibody molecules (Zhou, 2003). 
 
Given the surface expression of CwpV, its repetitiveness and homology of repeat 
domains with various ligand-binding proteins, it seemed plausible that CwpV may 
have a ligand binding function. In other pathogenic bacteria repetitive surface 
proteins are known to function as adhesins, for example the MSCRAMM family of 
extracellular matrix binding proteins (Schwarz-Linek et al., 2004) and therefore it 
seemed possible that CwpV may also act as an adhesin. However, as previously 
mentioned, large bacterial proteins are often repetitive and therefore this 
characteristic in itself is not indicative of a specific functional role.  
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In this chapter the role of CwpV in the C. difficile life cycle is investigated using 
available in vitro assays. CwpV is shown to be an aggregation-promoting factor, 
and exhibits fibronectin binding activity but does not appear to directly affect 
adhesion of C. difficile to Caco-2 cells. The expression level of CwpV under 
different conditions is also investigated, as this may provide insight into its 
function. No conditions have been identified where expression of CwpV is 
specifically switched ON or OFF. The implications of these findings for future 
investigations into CwpV function, including in vivo experiments, are discussed.  
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6.2 Results 
For clarity a table of the strains used in this chapter is shown in Table 6.1. 
Table 6.1 C. difficile strains used in Chapter 6 
NF 
strain 
name 
Descriptive Strain 
name 
Strain genotype Plasmid 
CwpV 
repeat 
type 
% cells 
expressing 
CwpV 
2147 WT 630Δerm pMTL960* I 1-10 
2166 ΔcwpV 630ΔermΔcwpV pMTL960* I 0 
2151 ΔcwpV(pOENter) 630ΔermΔcwpV 
pCBR067 
pOENter 
- 100 
2167 ΔcwpV(pOEI) 630ΔermΔcwpV 
pCBR080 
pOEI 
I 100 
2176 ΔcwpV(pOEII) 630ΔermΔcwpV 
pCBR105 
pOEII 
II 100 
2177 ΔcwpV(pOEIII) 630ΔermΔcwpV 
pCBR106 
pOEIII 
III 100 
2178 ΔcwpV(pOEIV) 630ΔermΔcwpV 
pCBR107 
pOEIV 
III/IV 100 
2179 ΔcwpV(pOEV) 630ΔermΔcwpV 
pCBR109 
pOEV 
III/V 100 
2225 ΔrecVON 630ΔermΔrecV 
pMTL960* 
 
I 100 
2226 ΔrecVOFF 630ΔermΔrecV 
pMTL960* 
 
I 0 
 
* For all experiments comparing the full panel of strains, inclusion of empty vector 
pMTL960 allowed all strains to be under thiamphenicol selection. For sporulation 
and germination experiments WT, ∆cwpV, ∆recVON and ∆recVOFF without 
plasmids are used.  
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6.2.1 All C. difficile strains have the same exponential growth rates 
The growth rates for each C. difficile strain were analysed. C. difficile overnight 
cultures were grown in triplicate in TYG medium supplemented with thiamphenicol 
to select for pMTL960-based plasmids (present in all strains, see Table 6.1). 
These cultures were subcultured into fresh growth medium and the OD600nm was 
monitored. A graphical representation of the results is shown in Figure 6.1. As can 
be seen the exponential growth rates, represented by the gradient of the growth 
curves between OD600nm of 1.5 - 2.5, of all strains are equal. This suggests that 
under standard laboratory conditions the level of CwpV expression and the type of 
CwpV expressed does not affect growth rate.  
 
Figure 6.1 Growth curves of C. difficile strains.  
C. difficile cultures in TYG medium supplemented with thiamphenicol were 
monitored for growth by OD600nm. Cultures were grown in triplicate with shaking 
under standard anaerobic conditions. The mean OD600nm value at each timepoint 
is plotted against time. Error bars represent the standard deviation of the triplicate 
measurements. 
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6.2.2 C. difficile strains exhibit colony morphology differences  
The colony morphology of C. difficile strains was assessed by growth of C. difficile 
on solid BHI agar plates supplemented with thiamphenicol. Plates were inoculated 
from C. difficile overnight cultures at an appropriate dilution such that bacterial 
growth occurred as single isolated colonies. In Figure 6.2 photographic images of 
the topside of C. difficile colonies grown for 36 hours can be seen. There is a clear 
difference between the strains with high levels of CwpV expression (∆recVON, 
∆cwpV(pOEI-V)) and low or no CwpV expression (WT, ∆cwpV and ∆recVOFF). 
The strains with high levels of CwpV expression exhibit a small, round colony 
morphology, although this is less marked for ∆recVON  than for strains expressing  
each of the five CwpV types from a plasmid ∆cwpV(pOEI-V). The smaller colonies 
also appear denser and shinier. The ∆cwpV(pOENter) colonies appear similar to 
WT, ∆cwpV and ∆recVOFF colonies, suggesting that it is the repeat domains of 
CwpV that confer the morphology difference.  
 
In order to further investigate this difference in morphology strains were grown for 
6 days before analysis of colony morphology. As can be seen in Figure 6.3, after 
this extended period of growth on solid medium WT C. difficile colonies exhibit 
sprawling colony morphologies with branching edges of growth. This is observed 
for WT, ∆cwpV, ∆recVOFF and ∆cwpV(pOENter), whilst ∆recVON and 
∆cwpV(pOEI-V) have much rounder edges. The images in Figure 6.3 were taken 
by scanning through plates, and the increased density of the ∆recVON and 
∆cwpV(pOEI-V) colonies compared to the more diffuse WT, ∆cwpV, ∆recVOFF 
and ∆cwpV(pOENter) colonies can be seen. Therefore high levels of CwpV 
expression cause a dense, tight, shiny pattern of colony growth on solid medium, 
with little branching at the edge of colonies. This colony morphology phenotype is 
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conferred by the repetitive C-terminal domains of CwpV rather than the CWA 
domain. All CwpV repeat types confer this phenotype, despite their distinct 
sequences. 
 
Figure 6.2 C. difficile mutants exhibit colony morphology differences.  
Photographic images of the top-side of C. difficile colonies grown on BHI agar 
supplemented with thiamphenicol for 36 hours under standard anaerobic 
conditions. 
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Figure 6.3 C. difficile strains exhibit colony morphology differences.  
Scanned images of C. difficile colonies grown on BHI agar supplemented with 
thiamphenicol for 6 days under standard anaerobic conditions.  
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6.2.3 Microscopic analysis of C. difficile growth solid medium 
To understand the basis of these colony morphology differences at the cellular 
level, colonies were grown in glass-bottomed Petri dishes, between the glass and 
the solid growth medium, to allow microscopic analysis of the edges of colony 
growth. Images of the edges of growth at 40x and 63x magnification are shown in 
Figure 6.4. In WT, ∆cwpV, ∆recVOFF and ∆cwpV(pOENter) images the growth 
can be seen to be quite diffuse at the edges of colonies, with a clear single layer 
of cells visualized. These cells appear to grow with a certain level of cellular 
alignment, forming directional protrusions that appear as flare-like patterns of 
growth. In contrast ∆recVON and strains expressing each of the five CwpV types 
from a plasmid ∆cwpV(pOEI-V) exhibit a more densely packed edge of growth, 
with a more randomly arranged packing of cells. This seems to correlate with the 
morphology seen macroscopically with WT, ∆cwpV, ∆recVOFF and 
∆cwpV(pOENter) having directional protrusions leading to ruffled edges, whilst 
∆recVON and ∆cwpV(pOEI-V) have no directional protrusions leading to smooth 
edges. 
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Figure 6.4 Microscopic images of the edges of C. difficile colony growth.  
C. difficile strains were grown between glass and solid growth medium to allow 
analysis of growth by microscopy. Images of the edges of colony growth at 40X 
and 63X magnification are shown. Differences in cellular packing between strains, 
attributable to CwpV expression, can be seen. 
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6.2.4 CwpV is an Aggregation Promoting Factor 
Such a colony morphology change caused by CwpV over-expression could be 
explained by an aggregation-promoting function of CwpV. Therefore the 
propensity of C. difficile to aggregate from an even cellular suspension was 
assessed. Initial assessment was carried out with 630 CwpV (type I) over-
expression in ∆cwpV(pOEI) compared to WT, ∆cwpV and ∆cwpV (pOE Nter). 
Bacteria were grown overnight under standard conditions, harvested by 
centrifugation and resuspended to an OD600nm of ~3 in round bottomed glass 
tubes. After 7 hours the appearance of the tubes was photographed. As can be 
seen from Figure 6.5A, CwpV expression did cause aggregation of cells. This was 
dependent on the repetitive domain, as expression of the N-terminal CWA domain 
alone did not cause aggregation. To assess this aggregation as a function of time, 
the meniscus OD600nm of C. difficile suspensions was monitored over time. In 
Figure 6.5B the decreasing OD600nm over time at the meniscus of the suspension 
is caused by Type I CwpV over-expression and reflects the aggregation of cells. 
Having established that Type I CwpV could promote aggregation of C. difficile 
cells from a suspension, aggregation promoting function was assessed in the 
same way for all CwpV types. It can be clearly seen in Figure 6.5C that over-
expression of all CwpV types, except type IV, can induce aggregation of C. 
difficile from a suspension with a starting OD600nm of 10. Aggregation was followed 
in real time, and could be detected in tubes where aggregation was occurring 
from as soon as 1 hour after suspension of bacteria. Tubes were left for 16 hours 
and photographed as shown in Figure 6.5C. No further aggregation was observed 
if tubes were left for 48 hours.  
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Figure 6.5 CwpV is an Aggregation Promoting Factor.  
A. C. difficile strains were grown overnight under standard conditions. Cells were 
harvested by centrifugation then resuspended to an OD600nm of ~3 in round 
bottomed glass tubes. After 7 hours the appearance of the tubes was 
photographed. Type I CwpV expression promoted cellular aggregation, 
dependent on the repetitive domain. B. The meniscus OD600nm of C. difficile 
suspensions was monitored over time and the decreasing OD600nm at the 
meniscus caused by Type I CwpV overexpression reflects the aggregation of 
cells. C. A large panel of C. difficile strains were resupended to an OD600nm of 10 
and after 16 hours the tubes were photographed. All CwpV types except type IV 
promoted aggregation of cells. 
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It was found that only 630 CwpV (type I) induced aggregation of C. difficile from 
suspensions with an OD600nm of 3, while 630 CwpV and R20352 CwpV (type II) 
induced aggregation from an OD600nm of 6 (data not shown). An OD600nm as high 
as 40 did not lead to type IV-mediated aggregation, nor aggregation of WT, 
ΔcwpV or ΔcwpV(pOENter) (data not shown). Therefore it appears that ability to 
induce aggregation is highest for 630 CwpV, followed by R20352 CwpV, then 
CDKK167 and AY1 CwpV, with no observed propensity of M9 CwpV or the CwpV 
CWA fragment to induce aggregation of C. difficile from suspension.  
 
6.2.5 CwpV expression in C. difficile does not affect FliC expression 
or swimming motility 
Functional interaction between bacterial autoaggregation and motility has been 
reported in E. coli, with the autoaggregative protein antigen 43 (Ag43) and flagella 
having opposing functional roles (Ulett et al., 2006). C. difficile is known to exhibit 
flagellar-mediated motility (Twine et al., 2009), therefore the effect of CwpV 
expression on C. difficile swimming motility and flagellar expression was 
investigated. C. difficile cultures were analysed for flagella expression based on  
the release of FliC from intact cells after vigorous vortexing (Twine et al., 2009). 
Figure 6.6A shows the analysis of C. difficile flagella expression by SDS-PAGE 
and Coomassie staining, with 630 FliC running at ~33 kDa. No significant 
differences in FliC expression are caused by different levels of CwpV expression. 
In order to assess the swimming motility of C. difficile strain BHI 0.175% agar was 
poured into sterile tubes and allowed to cool to room temperature. Tubes were 
then transferred to the anaerobic cabinet and left for 4 hours to equilibrate under 
anaerobic conditions. Tubes were inoculated to a defined depth with the straight 
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end of sterile inoculation loops that had been dipped into C. difficile overnight 
liquid cultures. Tubes were incubated overnight then photographed to document 
motility. Images of C. difficile strains with varying levels of CwpV expression are 
shown in Figure 6.6B. No significant differences in C. difficile swimming motility 
were observed due to CwpV expression.  
 
Figure 6.6 CwpV expression does not affect FliC expression or swimming 
motility. 
A. C. difficile strains were analysed for FliC expression based on a published 
protocol (Twine et al., 2009). C. difficile FliC expression from the panel of strains 
with varying levels of CwpV expression was assessed by SDS-PAGE and 
Coomassie staining, with 630 FliC running at ~33 kDa. Lanes 1: WT, 2: ∆cwpV, 3: 
pOENter, 4-8: pOEI-V, 9: ∆recVON, 10: ∆recVOFF. B. To assess swimming 
motility of C. difficile strains BHI 0.175% agar was inoculated to a defined depth 
with C. difficile from overnight liquid cultures. Tubes were incubated overnight 
then photographed to document motility. Tubes are numbered in the same way as 
the lanes in A.  
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6.2.6 CwpV exhibits fibronectin binding activity 
Given the recognition that CwpV may act as an adhesin, as well as promoting C. 
difficile aggregation, purified repeats of CwpV were tested for binding to 
commercially available extracellular matrix proteins. DNA fragments encoding  
one or two CwpV repeats were cloned as indicated in Figure 6.7A and were 
expressed and purified via a C-terminal His-tag. Seven commercially available 
mammalian extracellular matrix proteins were tested for interaction with these 
CwpV repeats by ELISA. 96-well plates were coated with the extracellular matrix 
proteins, which were then incubated with four different concentrations of CwpV 
repeat proteins. Detection of CwpV repeat binding to the immobilized extracellular 
matrix protein was achieved using an anti-His tag-HRP conjugate antibody and a 
colorimetric HRP substrate. The results of these seven ELISAs are shown in 
Figure 6.7A-H. The only interaction detected was between plasma fibronectin and 
CwpV repeat types I and IV.  To follow up this result, a more stringent ELISA was 
set up to assess plasma fibronectin binding. All repeat types were tested in 
triplicate against plasma fibronectin and BSA (as a control), using a range of 
concentrations of CwpV repeats. Purified recombinant LMW SLP was also 
assayed to act as a further negative control. The results of these assays (Figure 
6.8A and B) indicate that CwpV repeats types I and IV interact with plasma 
fibronectin in a concentration dependent manner, but do not interact with BSA. In 
order to study this interaction further it was decided to focus on CwpV type I 
repeats. A final ELISA with 6 replicate wells per concentration of repeat was 
carried out to compare CwpV type I binding to plasma fibronectin and BSA, which 
further confirmed this interaction (Figure 6.8C). 
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Figure 6.7 Screening for interactions between CwpV repeats and 
extracellular matrix proteins by ELISA. 
A. Diagrammatic representation of repeat fragments cloned and purified from E. 
coli for use in ELISAs with extracellular matrix proteins. The legend for all ELISA 
graphs is also shown. B-H. ELISAs using four different concentrations of CwpV 
repeats binding to collagen III, collagen, IV, vitronectin, fibrinogen, fibronectin, 
laminin, elastin respectively. Binding was detected using an anti-his-HRP antibody 
conjugate with a colorimetric HRP substrate. A492 represents the amount of 
CwpV repeat binding detected. 
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Figure 6.8 Confirmation of interaction between CwpV repeats types I and IV 
with fibronectin. 
A. CwpV repeats ELISA assaying binding to immobilized plasma fibronectin. 
Concentrations of CwpV repeats were assayed in triplicate. Mean values are 
plotted with standard deviation error bars. B. CwpV repeats ELISA assaying 
binding to immobilized BSA. Concentrations of CwpV repeats were assayed in 
triplicate. Mean values are plotted with standard deviation error bars. C. Direct 
comparison of CwpV type I repeats binding to fibronectin and BSA. 
Concentrations of CwpV repeats were assayed with six replicates. Mean values 
are plotted with standard deviation error bars. 
 
Fibronectin purified from plasma or from cells is commercially available. These 
two sources of fibronectin differ in size, with cellular fibronectin being larger due to 
the presence of additional polypeptide segments, accounted for by alternative 
splicing of fibronectin mRNA (Kornblihtt et al., 1985). Thus far CwpV binding had 
only been assessed using plasma fibronectin, therefore levels of binding to 
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plasma fibronectin and cellular fibronectin were directly compared. Purified CwpV 
repeats were assayed for cellular and plasma fibronectin binding activity by ELISA 
and the results are shown in Figure 6.9A and B respectively. Binding activity is 
exhibited for type I and type IV repeats with both forms of fibronectin, but there is 
increased binding activity with cellular fibronectin. Therefore for all future assays 
cellular fibronectin was chosen for use.  
 
Figure 6.9 Comparison of cellular and plasma fibronectin interactions with 
CwpV repeats. 
A. CwpV repeats ELISA assaying binding to immobilized cellular fibronectin. B. 
CwpV repeats ELISA assaying binding to immobilized plasma fibronectin. 
Concentrations of CwpV repeats were assayed in triplicate. Mean values are 
plotted with standard deviation error bars. 
 
In order to assess the avidity effect due to increasing numbers of CwpV repeats a 
recombinant protein containing nine type I repeats was expressed and purified, 
and its binding affinity for cellular fibronectin compared to protein containing only 
two type I repeats (used in previous fibronectin-binding experiments). The two 
different recombinant proteins are shown diagrammatically in Figure 6.10A. An 
ELISA was carried out to assess the relative binding activity of the two proteins. 
As can be seen in Figure 6.10B increasing the number of CwpV type I repeats 
does increase the binding activity. However, there is only ~ 2-fold increase in the 
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signal detected by ELISA, reflecting a modest increase in binding activity with the 
increase from two repeats to nine repeats.  
 
Figure 6.10 Cellular fibronectin binding activity of 2 and 9 CwpV type I 
repeat domains. 
A. Diagrammatic representation of the two recombinant proteins compared, 
containing 2 and 9 CwpV type I repeat domains. B. ELISA assaying binding of 
recombinant protein to immobilized cellular fibronectin. 
 
Having assayed fibronectin binding activity of purified recombinant protein 
containing CwpV repeats, the cellular fibronectin binding activity of C. difficile cells 
expressing high levels of CwpV on the surface was investigated. C. difficile 
overnight cultures were harvested by centrifugation then resuspended to an OD600 
of 10. A two-fold dilution series of the bacterial suspension was carried out in 
PBS. Samples of bacterial suspensions of the appropriate OD600 were then added 
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to fibronectin-coated wells and incubated for 1 h at 37ºC. Following incubation 
wells were washed and bound cells detected using anti-HMW SLP and anti-LMW 
SLP antibodies. The results of an assay using WT, ∆cwpV, ∆cwpV(pOENter) and 
∆cwpV(pOEI) are shown in Figure 6.11A. It can be seen that the cells from ∆cwpV 
(pOEI), which express high levels of CwpV, exhibit increased cellular fibronectin 
binding activity compared to WT, ∆cwpV and ∆cwpV(pOENter) cells. This 
suggests that the CwpV repeats expressed on the surface of C. difficile cells 
confer cellular fibronectin binding activity. C. difficile strains expressing the 
different types of CwpV repeats were then assessed for cellular fibronectin 
binding activity. The results of an assay using ∆cwpV and ∆cwpV(pOEI-V) C. 
difficile cells is shown in Figure 6.11B. It can be seen that all CwpV types appear 
to confer some cellular fibronectin binding activity. However, the binding activity 
conferred by CwpV over-expression was less than two-fold that exhibited by 
∆cwpV suggesting that CwpV does not confer a high affinity interaction between 
C. difficile cells and immobilized fibronectin. A number of different variations to 
this assay format were tried, including shorter and longer incubations with cells, 
cross-linking of cells to the plate after incubation, and increasing the bacterial 
densities used. However, none of these assays increased the sensitivity of the 
assay without specificity being compromised. Thus a greater difference between 
the binding activities of ∆cwpV and ∆cwpV(pOEI-V) than shown in Figure 6.11 
was not observed (data not shown). Therefore, it appears that CwpV expression 
on the C. difficile surface confers a low affinity fibronectin binding activity.  
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Figure 6.11 C. difficile binding to cellular fibronectin. 
A. WT, ∆cwpV, ∆cwpV(pOENter) and ∆cwpV(pOEI) bacteria were harvested by 
centrifugation then resuspended to an OD600 of 10. A two-fold dilution series of 
the bacterial suspension was carried out in PBS. 50 µl samples of bacterial 
suspensions of the appropriate OD600 were then added to fibronectin-coated wells 
and incubated for 1 h at 37ºC. Following incubation wells were washed, then anti-
HMW SLP (1:15,000 dilution) and anti-LMW SLP (1:30,000 dilution) antibodies, 
followed by anti-rabbit HRP and colorimetric HRP substrate, were used to detect 
bacteria bound to the plate. B. ∆cwpV and ∆cwpV(pOEI-V) C. difficile cells were 
harvested by centrifugation and assayed for cellular fibronectin binding as 
described for A.  
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6.2.7 CwpV (type I) expression does not affect C. difficile binding to 
Caco-2 BBE1 cells 
Having found that CwpV confers fibronectin binding activity it was postulated that 
CwpV may facilitate adhesion of C. difficile to host cells. C. difficile binding to cells 
in vitro has been reported in a number of studies, with Caco-2 cells (Cerquetti et 
al., 2002, Drudy et al., 2001, Eveillard et al., 1993, Dingle et al., 2010, Schwan et 
al., 2009), Vero cells (Waligora et al., 1999), HT-29 cells (Eveillard et al., 1993, 
Drudy et al., 2001) and primary cells isolated from biopsies (Drudy et al., 2001) 
having been used. The Caco-2 cell line is derived from human epithelial colorectal 
adenocarcinoma cells, and differentiates in vitro into a polarized monolayer 
mimicking the in vivo morphology and functionality of the intestinal epithelium 
(Hidalgo et al., 1989). The most recent C. difficile in vitro adhesion studies have 
employed Caco-2 cells (Schwan et al., 2009, Dingle et al., 2010), which are 
known to express fibronectin (Levy et al., 1994). It was therefore decided to test 
the effect of CwpV on C. difficile Caco-2 cell adhesion.  
 
In Figure 6.12A it can be seen that CwpV expression does not affect C. difficile 
binding to Caco-2 cells as WT, ∆cwpV and ∆cwpV(pOEI) bacteria are all 
recovered to the same level. To validate the numbers of bacteria found to be 
adherent, the assay was repeated and the cells fixed prior to analysis by 
immunofluorescent microscopy. Low levels of adhesion were observed, with 
approximately one bacterium present per 200 Caco-2 cells. An example of a field 
of view showing two individual C. difficile cells adhered to the Caco-2 monolayer 
is shown in Figure 6.12B. This level of adhesion observed corresponds well to the 
number of bacteria determined by viable counts: It was determined that there are 
5x105 Caco-2 cells per well of a 12-well plate (data not shown), therefore binding 
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of 1 bacterium per 200 cells would mean a total of 2500 counts per well, which is 
the approximate number of counts recovered per well as shown in Figure 6.12A. 
This level of adhesion observed can be compared to a recently published paper 
describing a Caco-2 adhesion assay where levels of adhesion are measured by 
qPCR (Dingle et al., 2010). In this assay an MOI of 1:1 is used, which for a 12-
well plate would equate to 5 x 105 bacterium added per well. Adhesion is reported 
to be ~ 0.7% of the total innoculum, which would equate to 3500 counts per well. 
The adhesion assay we used was adapted from (Schwan et al., 2009), and the 
levels we observed are comparable to the levels observed in this study (C. 
Schwan, personal communication). Therefore the levels of adhesion observed in 
my assay are comparable to those observed in published studies. A number of 
variations to the Caco-2 binding assay were carried out, including wounding the 
monolayer prior to incubation, use of different incubation media, longer and 
shorted incubation times, but no significant differences in adhesion level were 
observed (data not shown). As no difference in Caco-2 adhesion was conferred 
by type I CwpV, the effect of expression of the other types of CwpV on adhesion 
was not tested. It remains possible that these other CwpV types affect C. difficile 
adhesion to Caco-2 cells.  
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Figure 6.12 Effect of CwpV expression on C. difficile binding to Caco-2 
BBE1 cells. 
A. WT, ∆cwpV and ∆cwpV(pOEI) bacteria were incubated with Caco-2 BBE1 cells 
and the number of adherent bacteria determined by plating onto BHI plates and 
determining the C. difficile colony forming units (c.f.u.) recovered per well. B. 
Visualization of WT C. difficile adherence to Caco-2 cells. Images shown from left 
to right: Phase contrast image, Hoechst DNA staining (bacterial cells and Caco-2 
cell nuclei) and rhodamine-red stained C. difficile cells. Locations of bacterial cells 
are indicated by arrows.  
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6.2.8 CwpV expression and C. difficile sporulation  
Sporulation is a key stage in the C. difficile life cycle and comparative genomics to 
the well-characterised sporulation process of Bacillus subtilis and other Clostridial 
sp. has allowed identification of putative factors involved in C. difficile sporulation 
(Paredes et al., 2005). Sporulation has not been studied intensively in C. difficile, 
but links between sporulation and toxin production have been shown (Underwood 
et al., 2009). This suggests interlinking of sporulation and virulence signaling 
networks, which has been observed in other spore-forming bacterial species 
(Perego & Hoch, 2008). Given the importance of sporulation in the C. difficile life 
cycle, and links between regulatory networks governing sporulation and other 
pathways, it seemed possible that CwpV expression may be regulated during 
sporulation. The spore proteome has recently been described (Lawley et al., 
2009b) and the data showed CwpV is present in the spore. One main question to 
address was whether the proportion of cells expressing CwpV alters during 
sporulation. In order to do this sporulation was induced using a protocol kindly 
provided by Simon Cutting at Royal Holloway London, an expert in Bacillus 
subtilis sporulation. Six timepoints from the sporulation protocol are documented 
in Figure 6.13A by phase microscopy images. The formation of spores (dark blue 
under our microscopy conditions) can be seen to occur once on the SMC plates, 
with many spores present after 24 h and maximum numbers of spores after 48 h, 
with no increase in spore numbers after 72 h. These observations were validated 
by counting numbers of heat resistant colony forming units present over time 
(data not shown).  Samples from four time points during the sporulation protocol 
were taken and cells assayed for CwpV expression by staining with anti-CwpVrptI 
and anti-rabbit rhodamine red-X followed by immunofluorescent microscopy. As 
can be seen from Figure 6.13B CwpV is expressed in ~ 5% of cells at all stages of 
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the sporulation process. This suggests that CwpV expression is not specifically 
turned ON or OFF during sporulation. Some staining of spores was observed 
using anti-CwpVrpt1, however this was shown to be non-specific as the pre-
immune serum also stained spores and this staining was observed in ∆cwpV 
(data not shown). 
  
It is possible that CwpV and/or RecV expression level affects C. difficile 
sporulation directly. Therefore sporulation efficiency in the available mutant strains 
(WT vs. ∆cwpV, ∆recVON and ∆recVOFF) was investigated.  Spores were 
produced using the same protocol and once harvested from the SMC plates they 
were washed and purified by density centrifugation. This purification method 
removed the vast majority of vegetative cell debris, as can be observed in the 
phase contrast images shown in Figure 6.13C. The percentage of material 
recovered by density centrifugation as determined by OD600 was used as a 
measure of sporulation efficiency. In Figure 6.13D it can be seen that there is no 
significant difference in sporulation efficiency between WT, ∆cwpV, ∆recVON and 
∆recVOFF, with approximately 70% of material recovered by density 
centrifugation for all strains. This suggests that CwpV and RecV do not play key 
roles in the sporulation process.  
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Figure 6.13 CwpV and C. difficile sporulation. 
A. Phase contrast images of WT C. difficile samples taken at timepoints during 
the sporulation process. Spores can be identified by their dark blue appearance. 
B. Assessment of CwpV expression level in WT C. difficile at various sporulation 
timepoints by immunofluorescent staining. Images shown are (left to right) phase 
contrast, red fluorescence, overlay. % cells CwpV positive was calculated by 
counting 5 fields containing a total of at least 500 cells. C. Purification of spores 
by density centrifugation was followed for WT, ∆cwpV, ∆recVON and ∆recVOFF 
by phase contrast microscopy. D. Sporulation efficiency measured as % material 
recovered by density centrifugation for WT, ∆cwpV, ∆recVON and ∆recVOFF. 
Values shown are mean values from three independent sporulation preparations 
and purifications, with standard deviation error bars. 
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6.2.9 CwpV expression and C. difficile germination  
Ingestion of C. difficile spores leads to germination of spores and subsequent 
vegetative proliferation of C. difficile. This is the necessary first stage of C. difficile 
infection of the enteric system. Bile salts sodium taurocholate and sodium cholate 
stimulate spore germination (Wilson et al., 1982, Wilson, 1983) and more recently 
glycine was shown to act as a co-germinant (Wheeldon et al., 2008a, Sorg & 
Sonenshein, 2008). Given the key importance of germination to the C. difficile life 
cycle, I investigated whether or not CwpV expression was regulated during 
germination, and if CwpV expression affected germination efficiency. Inoculation 
of BHIS medium containing the germinant sodium taurocholate (0.1%) with either 
spores (purified by Histodenz) or vegetative cells allowed determination of the 
growth kinetics of WT C. difficile directly after germination, compared to vegetative 
cells. As can be seen in Figure 5.14A inoculation with spores follows the same 
growth kinetics as inoculation with vegetative cells, but growth from spores 
exhibits a lag of ~ 60 minutes. This germination growth curve was also followed 
by phase microscopy of samples taken at timepoints during growth from spores, 
as shown in Figure 5.14B. It can be seen that as the growth progresses the 
proportion of vegetative cells, but not spores (dark blue) increases. The time-point 
410 minutes after inoculation was chosen for assessment of CwpV expression 
level by immunofluorescence, as at this time-point cells have divided 5-6 times 
following initital germination. Therefore the majority of material is in vegetative cell 
form but represents a stage of growth likely to mimic the early colonization phase. 
In Figure 5.14C it can be seen that at this time-point 5.9% of cells are CwpV-
positive. This level of CwpV expression is similar to that seen during normal 
vegetative cell growth, and therefore suggests that CwpV expression at this point 
shortly after germination is not switched ON or OFF. Earlier time-points were also 
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analysed in this way, but were complicated by non-specific binding of the anti-
CwpVrptI antibody to spores. It seems unlikely that CwpV expression would 
recover to 5% after 5-6 cell divisions if its expression was specifically switched ON 
or OFF during germination, however without further investigation into S-layer 
protein expression during germination this cannot be conclusively ruled out. 
  
To assess the role of CwpV and/or RecV in sporulation efficiency the number of 
c.f.u/ml of a purified spore preparation with an OD600 of 1.0 was measured for WT, 
∆cwpV, ∆recVON and ∆recVOFF. Counts were measured for three independent 
spore preparations of each strain. As shown in Figure 5.14D all four strains gave 
values of ~ 1 x 108 c.f.u./ml(OD600 = 1.0). This suggests that CwpV and RecV 
expression do not affect germination efficiency in vitro.  
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Figure 6.14 CwpV and C. difficile spore germination. 
A. Comparison of the growth kinetics of WT C. difficile cultures in BHIS 0.1% 
sodium taurocholate inoculated with vegetative cells or spores to a starting OD600 
of 0.05. B. Phase contrast images of samples taken at various timepoints (given 
in minutes) throughout germination. C. Assessment of CwpV expression level in 
WT C. difficile at 410 minutes after germination by immunofluorescent staining. 
Images shown are (left to right) phase contrast, red fluorescence, overlay. % cells 
CwpV positive was calculated by counting 5 fields containing a total of at least 
500 cells. D. Germination efficiency of purified spore preparations of WT, ∆cwpV, 
∆recVON and ∆recVOFF C. difficile strains measured as C.f.u./ml(OD600=1) 
grown on BHIS 0.1% sodium taurocholate plates. Values are means calculated 
from counts of three independent spore preparations. Error bars represent the 
standard deviation. 
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6.3 Discussion 
A high level of expression of all known CwpV types was found to alter colony 
morphology. This effect of CwpV expression is conferred by the repetitive domain, 
as high level of expression of the CwpV N-terminal CWA domain does not affect 
colony morphology. This suggests that, despite being entirely distinct at the amino 
acid sequence level, the different types of CwpV repeat exhibit a functionally 
conserved activity. Although single species colony growth in vitro is somewhat 
removed from natural growth conditions, in vitro colonies are organized 
populations of bacteria and differences in colony morphology reflect differences in 
the cellular organization of a population (Shapiro, 1995) that can translate to 
important differences affecting natural growth dynamics. The difference in the 
cellular organization of colonies can be seen clearly in the microscopic images in 
Figure 5.4, with high levels of CwpV expression causing denser more randomly 
packed cellular organization than the diffuse, directional patterns of cellular 
packing seen at the edge of WT colonies. Such differences can be explained by 
an aggregative function for CwpV, but could also be caused by a decrease in 
cellular motility.  
 
The CwpV-mediated aggregation of C. difficile cells from suspension suggests 
that CwpV does have a direct aggregation-promoting function. All CwpV types, 
apart from type IV, were shown to cause aggregation from cellular suspensions of 
C. difficile. Propensities of different CwpV types to cause aggregation differed, 
observed by the different starting densities of cellular suspensions required in 
order to lead to aggregation. This is likely to reflect different affinities of the 
different CwpV proteins for their ligand(s). Type IV CwpV does confer the same 
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colony morphology phenotype as all the other CwpV types, but perhaps the 
affinity of type IV CwpV for its aggregating ligand(s) is lower than for the other 
CwpV types, which could explain why aggregation from suspension was not 
observed for this type of CwpV. The colony morphology phenotype observed for 
type IV CwpV does however suggest that it carries out the same general function 
as the other types.  
 
Functional interaction between bacterial autoaggregation and motility has been 
reported in E. coli, with the autoaggregative protein antigen 43 (Ag43) and flagella 
having opposing functional roles (Ulett et al., 2006), but in the case of C. difficile 
CwpV expression does not appear to affect swimming motility. The diffuse 
directional organization of WT colony edges seen in this study is reminiscent of 
twitching motility mediated by type IV pili in Clostridium perfrigens (Varga et al., 
2006). C. difficile does have type IV pili clusters, which are conserved across 
strains (Janvilisri et al., 2009). Type IV pili may therefore be responsible for the 
cellular organization of WT colonies grown on solid surfaces observed here. 
CwpV may interact with motility factors such as type IV pili to alter the cellular 
organisation of colonies, but as the factors responsible for this motility are yet to 
be definitively characterised it was not possible for us to investigate direct 
interactions between CwpV expression and these factors.  
 
Identification of the CwpV ligand(s) responsible for its aggregative function is a 
future research priority. CwpV may interact with itself or with other C. difficile 
surface components. Whether or not different CwpV types recognize the same 
ligand(s) is another interesting question to be investigated. Fluorescent labeling of 
C. difficile expressing CwpV would be a useful tool, as this would allow cells with 
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and without CwpV expression to be mixed, and aggregates analysed for levels of 
CwpV expression. If CwpV interacts with itself you would expect aggregates to 
contain a majority of cells expressing CwpV, which could be identified by their 
fluorescence. As discussed in Chapter 4, there is a paucity of fluorescent 
reporters available for use under anaerobic conditions, and the FbFP protein 
(Drepper et al., 2007a) does not exhibit high sensitivity compared to background 
fluorescence of C. difficile. However, one possibility for the future is the use of 
FlAsH tags in proteins of interest, which can be irreversibly fluorescently labelled 
under aerobic or anaerobic conditions (Machleidt et al., 2007), and would allow 
identification of sub-populations of C. difficile that did, or did not, express the 
FlAsH tag, which could be engineered to correlate with CwpV expression. 
Alternatively, his-tagged purified CwpV repeats could be incubated with C. difficile 
cells that do, or do not, express CwpV to determine if they associate with the C. 
difficile cells, and if so whether this is dependent on CwpV expression. A similar 
experiment was used to demonstrate that the Staphylococcus aureus 
autoaggregative protein SasG binds to itself rather than any other surface 
component, mediating its biofilm-promoting function (Geoghegan et al., 2010). 
The effect of varying numbers of CwpV repeats on the affinity of the interaction 
can be investigated once the ligand has been identified.  
 
Aggregation-promoting proteins have been described in a number of other 
bacterial species. In species where biofilm assays are available, autoaggregative 
proteins have often been shown to play roles in biofilm formation (Kuboniwa et al., 
2009, Corrigan et al., 2007, Huang et al., 2009). There have been no studies on 
C. difficile biofilms reported, and in our experience C. difficile does not exhibit 
significant biofilm formation on abiotic surfaces (data not shown). However, in C. 
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difficile-infected mice large aggregates of C. difficile cells, described as 
exaggerated mats, were reported to be associated with regions of severe 
inflammation (Lawley et al., 2009a). This description is indicative of a biofilm-like 
growth of C. difficile during infection. Multispecies biofilms in the human GI tract 
have been observed (Macfarlane & Dillon, 2007) and C. difficile is likely to require 
factors that promote appropriate intra- and inter-species interactions to colonise 
the gut. CwpV may play important roles in this process. An in vitro biofilm model 
would be useful for assessing the function of CwpV and other cell surface proteins 
in C. difficile growth on surfaces.  
 
Aside from its aggregation-promoting function CwpV may have other functions. 
The fibronectin binding activity observed was of low affinity. Also, an increase 
from 2 to 9 repeats in purified protein did not lead to a significant increase in the 
binding affinity detected. If the repeat domains mediated a specific interaction with 
fibronectin, a more marked increase in affinity upon such an increase in the 
number of domains would be expected. It is therefore unclear as to the relevance 
of this interaction detected. No significant difference in adhesion to Caco-2 cells 
caused by CwpV expression was observed, which does not support an adhesive 
role for CwpV. This adhesion assay does rely upon low levels of C. difficile 
adhesion, and as yet has not been directly compared to adhesion levels of C. 
difficile to primary tissue or cells. This would give an indication as to how 
physiologically relevant such adhesion assays are, and therefore how well-suited 
they are to assessment of adhesive functions of surface proteins. CwpV was 
annotated as a putative hemagglutinin/adhesin in the 630 genome, reflecting its 
similarity to proteins known to have such functions. Purified CwpV type I repeats 
and WT, ∆cwpV, ∆cwpV(pOEI) C. difficile strains were tested for hemagglutination 
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activity but no such activity was observed, suggesting that type I CwpV does not 
act as a hemagglutinin (data not shown). An obvious important question for future 
work is whether CwpV expression affects colonization level in vivo, and if so 
whether this is due to its aggregation-promoting function or whether it does confer 
any other properties to C. difficile.  
 
A variety of in vitro conditions have been investigated for their effect on CwpV 
expression, including addition of salts, taurocholic acid, glucose and serum (data 
not shown), as well as sporulation-inducing conditions and germination of spores. 
However, none yet have significantly affected CwpV expression level, with 
reproducible levels of ~5% of cells being CwpV-positive under all conditions. 
Therefore it is not known whether there are any environmental signals that affect 
CwpV expression levels. Given the relatively constant CwpV expression level 
observed in strain 630, it appears that under all conditions tested cwpV DNA 
switch inversion occurs at high frequency leading to an equilibrium of switch 
orientation, conferring the stable average CwpV expression level seen in large 
populations of cells such as colonies or cultures.  A future research priority is the 
investigation of CwpV expression levels during infection in vivo. After infection of 
mice or hamsters, sections of gut tissue could be analysed for the presence of  
CwpV-positive C. difficile cells present using antibody staining and appropriate 
microscopic techniques.  
 
Understanding the roles of CwpV during in vivo infection is a future research 
priority and will be addressed using the isogenic mutants described in this study. 
The ∆recVON and ∆recVOFF strains constructed and characterised in this study 
are ideal for assessing the effects of CwpV expression level on colonization, as 
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they are genetically identical aside from the orientation of the cwpV switch, 
determining fixed high or absence of CwpV expression respectively. It is of course 
possible that both these mutants are less well suited to host colonization than the 
WT strain with its ability to switch CwpV expression ON or OFF. Established 
animal models of infection focus more on the acute stage of C. difficile infection, 
rather than colonization (Douce & Goulding, 2010). However, recent 
developments of animal models better suited to studying the roles of C. difficile 
genes likely to be involved in colonization, such as CwpV, have been described 
(Lawley et al., 2009a, Steele et al., 2010) that will facilitate future investigations.  
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7 Discussion 
 
C. difficile is a bacterial pathogen, which causes significant morbidity and mortality 
worldwide. There are shortcomings in the current therapeutic options available for 
treatment of C. difficile and there is no vaccine available for prevention of CDAD. 
Rational design of novel therapeutics and vaccines is limited by our lack of 
understanding of the molecular mechanisms underpinning colonisation of the host 
by C. difficile. This study has focused on the cell surface protein CwpV. A number 
of interesting properties and characteristics of CwpV have been determined, 
which shed light on the roles this protein may play during infection. These findings 
have generated new questions, both with regard to CwpV itself and to the 
molecular basis of C. difficile pathogenesis in general. A summary of the most 
important findings of this study, the questions that these findings raise and some 
suggestions as to how to address them are discussed in this final chapter. 
 
7.1 CwpV phase variation 
 
Discovery of the phase variable expression of CwpV is the first reported discovery 
of phase variable regulation of protein expression in C. difficile. It is also the first 
report of phase variation mediated by site-specific recombination in any gram-
positive bacterial species (Wisniewski-Dye & Vial, 2008). It therefore represents 
an important finding, indicating that mechanisms of phase variation previously 
characterised in other bacterial species are also utilized by C. difficile. It is 
possible that other phase variable proteins will be discovered in C. difficile, and 
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the tools for studying phase variation mechanisms developed in this study would 
be useful for future studies.  
 
The formation of a transcription-terminating stem loop at the boundary of the 
cwpV switch region in the OFF orientation, which is disrupted upon cwpV switch 
inversion to ON, confers the ON and OFF CwpV expression phenotypes. This 
represents a novel and elegant mechanism of phase variable regulation of protein 
expression.  There are, however, still many aspects of the cwpV switch that merit 
further study. For example, determination of the affinity of the recombinase RecV 
for the two orientations of the cwpV switch would inform us how the relative 
proportions of the ON and OFF orientations of the cwpV switch are established 
and maintained. This has relevance to how RecV expression level could control 
the proportion of cells expressing CwpV. No conditions have yet been identified in 
which CwpV expression is specifically switched towards ON or OFF. A research 
priority is to study the proportion of CwpV-positive cells present during infection in 
vivo. This could be done by fluorescent microscopy analysis of gut tissue from 
patients or animals colonized by C. difficile stained with the relevant antibodies. If 
it does appear that CwpV is switched ON or OFF in vivo, the environmental 
signals responsible for this regulation can be investigated in vitro. Such work may 
lead to an improvement in the understanding of C. difficile regulatory networks, 
which are key to the C. difficile life-cycle. 
 
7.2 C. difficile strain diversity 
The diversity of CwpV C-terminal repeat sequences reflects the considerable 
sequence diversity found across C. difficile strains, as assessed by microarray 
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studies (Marsden et al., 2010, Stabler et al., 2006b, Janvilisri et al., 2009) and 
genomic sequencing (He et al., 2010). The five distinct repeat types identified so 
far have been discovered from a relatively limited survey of strains, and it is 
therefore likely that further repeat types, and/or mosaics of types exist. It will be 
interesting to determine the cwpV sequence of more strains and, if further CwpV 
types exist, their antigenicity, post-translational processing and aggregation-
promoting activity should be tested to see if they fit the same patterns of 
conservation and variation as has been observed so far.  
 
Recently, there has been much emphasis on the characterisation of so-called 
hypervirulent strains of C. difficile, such as the ribotype 027 strains, that have 
caused a number of nosocomial outbreaks of infection worldwide and appeared to 
be associated with increased incidence of infection (Stabler et al., 2009, Cartman 
et al., 2010). However, the prevalence of different C. difficile strain types causing 
disease is dynamic, both temporally and geographically (Cheknis et al., 2009, 
Brazier et al., 2008). It is clear that common virulent strains have arisen from 
multiple lineages, and therefore research should not focus too closely on any one 
strain type or lineage, as virulent strains emerge independently from across the 
diversity of C. difficile strains (He et al., 2010). This is of particular importance for 
vaccine and antimicrobial development, where understanding of the total species 
genome or the pan-genome, is highly desirable in order to ensure that any 
vaccine developed has suitable strain coverage (Muzzi et al., 2007). Future 
genome sequencing projects will dramatically increase our understanding of the 
full diversity of C. difficile and of the phylogenetic relationships between strains. 
As already discussed this will be of general use to the selection of well-conserved 
vaccine targets, but will also allow us to understand better how CwpV has 
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evolved, ascertaining when and how many times different CwpV repeat types 
have been acquired. This may shed light onto the mechanisms involved in the 
acquisition and the functional importance of this variability.  
 
7.3 CwpV and the C. difficile S-layer 
This study represents the first detailed molecular study of a CWP family member 
via expression of mutated proteins in C. difficile. The cell wall anchoring function 
of the PF04122 domains has been demonstrated experimentally for the first time. 
The tools developed here to express CwpV from a plasmid copy amenable to 
mutagenesis, could be used in future to further characterize the mechanism of cell 
wall anchoring employed by this family of proteins. As this mechanism is likely to 
be conserved across the whole CWP family, including SlpA, it could represent a 
useful target for therapeutic intervention.  
 
It is clear from this study that CwpV is post-translationally processed in a manner 
analogous to SlpA. High levels of CwpV can be tolerated in the C. difficile S-layer, 
with CwpV constituting a major component of the total S-layer protein in 
∆cwpVON cells. It seems likely that this family of CWPs has evolved to allow C. 
difficile to have an S-layer of dynamic composition, allowing its functionalities to 
vary in response to external conditions. In order for the S-layer to maintain its 
integrity it seems likely that all members of this family contribute interactions to the 
two-dimensional S-layer packing. Interactions between these CWP proteins 
therefore merit further investigation. Plasmids encoding tagged CWPs for 
expression in C. difficile, as developed in this study, would be valuable tools for 
such investigations. 
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7.4 CwpV and C. difficile pathogenicity 
 Given the aggregation-promoting function of CwpV it is possible that its function 
may be linked to motility and/or biofilm production. These two general areas of C. 
difficile biology, particularly during in vivo infection, are currently poorly 
understood. It is clear that C. difficile does exhibit motility in liquid (Twine et al., 
2009) and on solid surfaces in vitro. Exaggerated mats of C. difficile cells found on 
tissue from infected mice have been reported (Lawley et al., 2009a), and are 
suggestive of biofilm-like growth. Therefore these areas should be considered for 
future research prioritization, as they may be key to the C. difficile colonisation 
process. 
 
In order to determine the role of CwpV in C. difficile pathogenesis, experiments 
using animal models of infection are likely to provide the most definitive results. 
The mutants created and characterised in this study (∆cwpV, ∆recVON and 
∆recVOFF) are ideal for carrying out animal experiments to determine the role of 
CwpV during infection. The importance of such experiments using isogenic C. 
difficile mutants has been demonstrated by recent studies on toxins A and B 
(Lyras et al., 2009, Marsden et al., 2010), which have called into question the 
findings of earlier experiments addressing the contribution of the two toxins to 
virulence. Recent developments of animal models (Lawley et al., 2009a, Steele et 
al., 2010), more suitable for studying colonisation than established models of 
acute toxin-mediated disease (Goulding et al., 2009), are likely to be most useful 
for assessing the function of surface molecules such as CwpV.  
 
The tools used to genetically modify C. difficile for this study (Heap et al., 2010) 
demonstrate that the C. difficile research field is now well-positioned to create 
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isogenic mutants in putative colonisation factors and test these in animal models 
of infection. Such research is necessary to significantly improve our 
understanding of the factors key to colonisation of the host.  
7.5 Overall conclusions 
Understanding the common features of C. difficile as an ancient species is 
important, as in order for intervention strategies to be successful in the long-term 
they must target the full diversity of C. difficile strains, rather than specific 
lineages. This study of CwpV has provided a lesson in bacterial variability. CwpV 
appears to be a core component of C. difficile, including its phase variable 
regulation controlled by RecV, post-translational processing mechanism, and 
aggregation-promoting function. This suggests the importance of CwpV to C. 
difficile survival throughout the evolution of this diverse species. Despite this 
conservation CwpV appears to have been under positive selection for antigenic 
variability, hinting at a complex evolutionary history. Further investigation into the 
roles of CwpV in the C. difficile life cycle will teach us about what makes C. 
difficile a successful pathogen, providing opportunities for new rational 
intervention strategies. 
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